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Abstract 
 
Flk-1 (Foetal liver kinase-1), a receptor tyrosine kinase, and its ligand VEGF 
(vascular endothelial growth factor) are essential for vasculogenesis and 
haemopoiesis in the early embryo. Flk-1 is expressed initially on the haemangioblast, 
the common precursor of haemopoietic and endothelial cells, and on subsequent 
committed endothelial lineages. Flk-1 expression is maintained on adult endothelial 
cells and mediates angiogenesis, making it an important pharmaceutical target in the 
pathology of many human diseases including cancer and rheumatoid arthritis. 
Though involvement of Flk-1 in disease has lead to its extensive study in adult 
humans little is known about the signals it mediates during development.  
 
Using ES cells as a model of development, the aim of this investigation was to 
identify signals mediated through Flk-1 during early development and to characterise 
their relative importance in the formation of the haemopoietic, endothelial and 
cardiomyocyte lineages.  Activation of the MAPK and PLC signalling pathways 
were demonstrated following VEGF treatment of Flk-1-expressing embryoid body-
derived cells, though surprisingly activation of Flk-1 did not appear to mediate 
activation of the PI3K signalling pathway. Use of an embryoid body-based 
endothelial sprouting assay demonstrated a requirement for Flk-1 in both endothelial 
specification and angiogenic expansion. However, this activity was not mediated 
through either the MAPK or PI3K pathways. The finding that the PI3K pathway is 
not activated following VEGF stimulation nor required for early 
vasculogenesis/angiogenesis is surprising given its important role in both 
homeostatic and pathological angiogenesis in the adult. Previous work had suggested 
a role for Flk-1 in cardiac differentiation. Investigation of cardiomyocyte 
differentiation using Flk-1 null ES cells demonstrated a delay in formation of beating 
cardiomyocytes suggesting that Flk-1 may be involved in, but not required for 
cardiomyocyte specification. Finally, Flk-1-Tet-on ES cell lines were generated to 
facilitate investigation of the temporal importance of Flk-1 signalling during 
different developmental processes. Due to unforeseen difficulties in the maintenance 
of Flk-1 expression upon ES cell differentiation the full potential of this system was 
not realised in this study.  
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1.1 Stem cells 
Stem cells were first brought to prominence by the pioneering work of Till and 
McCulloch which identified for the first time the Haemopoietic Stem Cell (HSC) 
(McCulloch and Till, 1964). Stem cells can be defined as unspecialised cells which 
have the capacity to self-renew (to produce daughter stem cells) and differentiate into 
more specialised cell types. Different types of stem cells exhibit different constraints 
in their abilities to differentiate. Embryonic stem (ES) cells, derived from the inner 
cell mass of the pre-implantation blastocyst are pluripotent meaning they can 
potentially differentiate into any cell type of the adult organism. Other pools of stem 
cells in the developing fetus and the adult are multipotent, meaning they have the 
potential to differentiate into multiple organ-specific cell types. For example, 
haemopoietic stem cells found in the adult bone marrow can differentiate into any 
blood cell but are largely considered restricted to the haemopoietic lineage. The 
ability to self-renew is unusual in the adult organism as most of its constituent cells 
are terminally differentiated and lack the ability to divide. Stem cells maintain and 
replace tissues that rapidly turn over such as the gut, skin and blood.  
 
1.1.1 Therapeutic potential of stem cells 
The ability of stem cells to differentiate into specialised cells has provoked much 
research into their potential therapeutic uses in providing a source of replacement 
cells or tissues. Conditions with the potential for stem cell treatment include 
Parkinson’s disease, Alzheimer’s disease, diabetes, cardiac ischaemia, liver diseases, 
spinal cord injuries and other degenerative diseases and injuries (Bobis et al., 2006; 
De Sousa et al., 2006; Keller, 2005; Pessina and Gribaldo, 2006). Figure 1-1 
illustrates the stem cell hierarchy and potential therapeutic stem cell populations.  
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Figure 1-1 The stem cell hierarchy. Both the zygote and morula are totipotent meaning 
they can form any tissue of the aduilt organism and the extra-embryonic tissues. The inner 
cell mass (ICM) of the blastocyst forms the embryo proper and is the source of embryonic 
stem (ES) cells. Both the ICM and ES cells are pluripotent meaning they can form any tissue 
of the adult organism, but not extraembryonic tissues. Adult stem cells are multipotent as 
they have the ability to differentiate into more committed cells of a specific lineage. This 
figure illustrates some of the cells types which could be derived from both adult and 
embryonic stem cells. Diagram adapted from (Eckfeldt et al., 2005) 
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Treatment utilising some adult stem cells is already in place. Bone marrow is a 
source of haemopoietic stem cells used to treat blood disorders such as leukaemia 
(Amos and Gordon, 1995) and limbal stem cells from the eye can be used to replace 
a damaged cornea (Boulton and Albon, 2004). For most other cell and tissue types 
however this ultimate goal is still many years away. Adult stem cells are scarce, 
difficult to identify and isolate and don’t generally grow well in culture making it 
difficult to expand them into useful numbers of cells. They are also generally thought 
to be lineage restricted, though some research into adult stem cells, including 
haemopoietic and mesenchymal (the stem cells of the bone, cartilage, muscle, fat  
and fibroblasts) stem cells has indicated that they may retain plasticity and given the 
correct microenvironmental cues could differentiate into other cell types. Currently 
the incidence of this is too low to be therapeutically beneficial and a great deal of 
controversy still surrounds the mechanism of these rare events (Oreffo et al., 2005; 
Wagers and Weissman, 2004).  
 
Human embryonic stem cells (hES cells)  were isolated in the late 1990s (Thomson 
et al., 1998) and like murine embryonic stem cells appear to have to the capacity to 
differentiate into any cell type of the adult. However, as with adult stem cells, 
research into the maintenance of human ES cell self-renewal in large scale cultures 
and without feeder cells, along with the ability to derive pure populations of 
differentiated progeny, are largely unresolved and the field is still in its infancy. 
Furthermore, the use of human embryonic stem cells compared with adult stem cells 
holds greater ethical and regulatory concerns. Though the UK has a permissive 
policy regarding human embryonic stem cell research, countries such as Germany, 
Ireland and Norway have banned it and government funding is restricted in the USA 
(Check, 2005; Guenin, 2001; Munn et al., 2001).  
 
An additional hurdle to overcome in the therapeutic use of any stem cells is the state 
in which to transplant them. Undifferentiated stem cells carry with them an inherent 
risk of cancer formation when injected in vivo (Roy et al., 2006). A test of 
pluripotency of embryonic stem cells involves their injection into a mouse leading to 
formation of a teratoma, a tumour containing cells and tissues from all three germ 
layers. For the replacement of many tissues, implantation of cells alone may not be 
enough for full reconstitution. More than one cell type may be required, plus it may 
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be necessary to seed and differentiate cells on a scaffold (tissue engineering) (Polak 
and Bishop, 2006). Lastly, as with any transplanted tissue, stem cell treatment would 
provoke an immune response. Only autologous transplants, were appropriate, or 
Somatic Cell Nuclear Transfer (SCNT in which a fibroblast cell from the patient is 
fused with an enucleated donor oocyte and patient matched embryonic stem cells are 
isolated from the resulting embryo) could fully get round this problem. SCNT has 
not yet been successfully carried out in humans and could be prohibitively expensive 
(Boyd et al., 2005; Priddle et al., 2006). Providing sufficient human ES cell lines to 
provide a tissue match for any potential patient would be a huge undertaking. 
Estimates comparing blood group and HLA types of cadaveric organ donors (as a 
surrogate for donor embryos) with the UK kidney transplant waiting list concluded 
that 150 hES cell lines would provide a full match for HLA –A (Human Leukocyte 
Antigen-A), HLA-B and HLA-DR for less than 20% of patients and that increasing 
the pool further provided little additional benefit (Taylor et al., 2005). 
 
Though there is much promise for the therapeutic future of stem cells, the field is still 
in its infancy and much of the basic research has yet to be conducted. The fastest 
route to a role in therapeutics may be as models of different tissue types or disease 
states in drug discovery (McNeish, 2004). 
1.1.2 Embryonic stem cells 
Embryonic stem (ES) cells were first derived from the pre-implantation blastocyst of 
the mouse in 1981 (Evans and Kaufman, 1981; Martin, 1981) and have since also 
been derived from medaka  (kill fish) (Wakamatsu et al., 1994), rabbit (Moreadith 
and Graves, 1992), chicken (Pain et al., 1996), pig (Wheeler M B, 1994),  non-
human primate (Thomson et al., 1995) and human embryos (Thomson et al., 1998). 
ES cells possess the potential to differentiate into any cell type of the organism, a 
property known as pluripotency. This potential has been demonstrated particularly 
well in mouse and chicken where embryonic stem cells cultured in vitro have, upon 
re-implantation contributed to the whole organism including the germ line (Nagy et 
al., 1993; Pain et al., 1996). Current and potential uses of embryonic stem cells are 
illustrated in Figure 1-2. 
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Figure 1-2 Current and potential uses of embryonic stem cells. Diagram adapted from 
‘stem cell information’ available at http://stemcells.nih.gov/info/media/defaultpage accessed 
15th February 2007. 
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in vitro, or form further teratocarcinomas producing cells of each of the germ layers 
(Kleinsmith and Pierce, 1964; Martin and Evans, 1975). In some cases (albeit at low 
efficiency due to aneuploidy in most embryonal carcinoma cell lines) these cells 
Pluripotent ES cells
Tissues/Cells for therapy
Knockout mice
Models of 
development 
Model tissues in 
drug development 
Discovery of drug 
targets 
Gene therapy
Nerve cells for 
Parkinsons 
Heart 
muscle for 
heart attack 
victims 
Pancreatic 
islet cells 
for Type I 
Diabetes 
Bone and bone 
marrow for 
leukaemia and bone 
regeneration 
Chapter 1 - Introduction 
 7
could contribute to the embryo and produce chimeric offspring (Brinster, 1974). The 
finding that embryonal carcinoma cell lines were best maintained in co-culture in 
particular on mitotically-inactivated embryonic fibroblasts paved the way for the 
derivation of embryonic stem cells from the pre-implantation embryo (Martin et al., 
1977). 
1.1.2.2 Derivation of embryonic stem cells 
Figure 1-1 illustrates the derivation of mouse embryonic stem cells. A number of 
different methods have been used to derive ES cells including the use of embryos 
undergoing delayed implantation (Evans and Kaufman, 1981), immunosurgical 
isolation of inner cell masses and derivation of ES cell lines in feeder-free conditions 
(Nichols et al., 1994; Ying et al., 2003). Most commonly ES cells are isolated on a 
feeder layer of mitotically inactivated Mouse Embryonic Fibroblasts (MEFs). Day 
3.5 pre-implantation blastocysts are plated in DMEM supplemented with FCS and 
Leukaemia inhibitory factor (LIF) on MEFs. Over 2 days the embryos hatch from the 
zona pellucida and the trophoblast spreads out forming a monolayer of cells on 
which the inner cell mass can be seen. The inner cell mass is cultured for a further 2 
to 4 days (before a core of endoderm forms around it) and is then either mechanically 
disaggregated or trypsinised and replated onto fresh MEFs. The disaggregated inner 
cell mass gives rise to ES cell colonies and other cell types. Over 7-10 days the ES 
cell colonies will be apparent, as other colonies differentiate and cease to proliferate, 
and the ES cells can then be expanded in culture (Abbondanzo et al., 1993; Nagy et 
al., 1993). Curiously, it has not been possible to derived ES cells from all mouse 
strains. Most widely-used embryonic stem cell lines, including R1 and E14, have 
been derived from the 129/Sv strain. ES cell lines from other inbred strains, 
including the C57BL/6J and C3H/He have been successfully derived, though 
generally with much lower efficiency (Abbondanzo et al., 1993; Gardner and Brook, 
1997). There are many established protocols for the maintenance of ES cells in 
culture, both in the presence and absence of feeder cells. These will be discussed 
more fully in section 1.1.2.3 Maintenance of self-renewal. 
1.1.2.3 Maintenance of self-renewal 
The definition of self-renewal in stem cells is ‘the ability of a stem cell to give rise to 
a daughter cell with equivalent developmental potential’. This can be achieved by 
Chapter 1 - Introduction 
 8
either symmetric or asymmetric cell division. In the adult, asymmetric stem cell 
division enables maintenance of the stem cell pool, and simultaneous commitment of 
the second daughter cell to a more differentiated cell type required for tissue 
maintenance or repair. Symmetrical self-renewal, producing two identical daughter 
cells, is one of the defining features of embryonic stem cells. Understanding the 
mechanisms by which this is regulated is important if ES cells are to be derived and 
maintained in a defined medium in mass culture for both therapeutic and research 
purposes. Figure 1-3 gives an overview of the signals known to be involved in the 
regulation of murine ES cell self renewal which are described below. 
 
Initially ES cells were grown on mouse fibroblast feeder layers to maintain them in 
an undifferentiated state. This is still common practise but advances in our 
understanding of the control of self-renewal have enabled the culture of mouse 
embryonic stem cells in medium containing a more defined serum replacement or in 
some cases in completely chemically defined medium (Wiles and Johansson, 1999; 
Ying et al., 2003). These advances have uncovered both extrinsic and intrinsic 
mechanisms important for the maintenance of self-renewal, demonstrated some of 
the similarities and differences in these mechanisms between mouse and human ES 
cells and revealed the complexity of a system still to be fully elucidated.  
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Figure 1-3 Signalling pathways regulating murine ES cell pluripotency. Diagram 
adapted from (Boiani and Scholer, 2005; Welham, 2007) 
1.1.2.3.1 Signalling pathways with important roles in self-renewal 
The first molecular signalling pathway demonstrated to be important for the 
maintenance of mES cell self-renewal was elucidated following the discovery that 
conditioned medium from Buffalo rat liver cell feeders was able to replace the 
feeders and sustain self-renewal. This led to the purification of differentiation 
inhibitory factor (DIA) (Smith et al., 1988) which was able to maintain self-renewal 
in the presence of foetal calf serum (FCS) without the need of a feeder cell layer. 
Simultaneously the previously cloned Leukaemia Inhibitory Factor (LIF) (Gearing et 
al., 1987) was also found to maintain the developmental potential of mES cells. DIA 
and LIF were subsequently identified as one and the same (Williams et al., 1988).  
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LIF was found to bind to a heterodimeric gp130/LIFRβ receptor (Davis et al., 1993) 
causing phosphorylation and activation of  associated Jak2 kinases (Janus Kinase 2; 
illustrated in Figure 1-3) (Narazaki et al., 1994; Stahl et al., 1994). Once activated, 
Jak2 kinases phosphorylate several residues on the cytoplasmic domain of the 
gp130/LIF receptor subunits allowing SH2 (src-homology 2) domain containing 
proteins to bind. One such protein was identified as STAT 3 (signal transducer and 
activator of transcription 3) a ‘key transcriptional determinant’ (Boeuf et al., 1997; 
Niwa et al., 1998) phosphorylated by Jak2 allowing it to dimerise and translocate to 
the nucleus where it controls transcription of genes involved in self-renewal. Studies 
using constitutively active STAT3 mutants found that activation of STAT 3 
abrogated the requirement for LIF (Matsuda et al., 1999). Further analysis revealed 
that one of the mechanisms through which this was achieved was the stabilisation of 
the transcription factor c-myc (Cartwright et al., 2005). Signalling downstream of 
LIF is not limited to STAT3. The Mitogen Activated Protein Kinase (MAPK) 
pathway is activated through the SHP-2-Gab-1-Grb-2 complex. Mutation of the 
SHP-2 tyrosine binding site or inhibition of MEK, a component of the MAPK 
pathway (see Figure 1-16), with small molecule inhibitors enhances self-renewal thus 
activation of the MAPK pathway appears to promote differentiation (Burdon et al., 
1999). 
 
Although LIF is important for maintaining ES self-renewal it is unable to sustain 
self-renewal in the absence of FCS and additional extrinsic signals have recently 
been identified. These include the two serum proteins BMP2/4 (bone morphogenic 
protein 2 and 4) which are able to act in synergy with LIF in a chemically defined 
medium to maintain ES cell pluripotency, relieving the requirement for serum (Ying 
et al., 2003). BMPs activate downstream signalling molecules called Smads (Similar 
to Mothers Against Decapentaplegic). Smad-4 induces expression of Id (inhibitor of 
differentiation) transcriptional repressors which repress expression of genes required 
for neurogenesis, considered as the ‘default’ differentiation pathway for mouse 
embryonic stem cells. However, in the absence of LIF, BMP2/4 promotes 
differentiation, through activation of Smads 1, 5 and 8, towards non-neural lineages 
demonstrating the fine balancing act required to maintain ES cell self-renewal. Wnt 
signalling has also been reported to play an important role in the maintenance of self-
renewal. Experiments performed with BIO, a small molecule inhibitor of GSK-3 
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(Glycogen Synthase Kinase-3) downstream of Wnt signalling, or Wnt3a conditioned 
medium, have demonstrated that activation of the Wnt signalling pathway supports 
self-renewal and reduces (but does not abrogate) the requirement for LIF (Ogawa et 
al., 2006; Sato et al., 2004). The use of another small molecule inhibitor, this time 
LY294002, a PI3K (phosphoinositide-3-kinase) inhibitor, along with dominant 
negative approaches, has demonstrated the involvement of PI3K-dependent 
signalling in maintaining optimal self-renewal of murine ES cells (Paling et al., 
2004).  
1.1.2.3.2 Transcription factors required for maintenance of ES cell self-
renewal 
As well as the signals mediated through LIF, BMPs, Wnts and PI3Ks, self-renewal is 
also regulated by a set of transcriptional regulators. The first transcription factor for 
which a role in self-renewal was identified was the POU domain transcriptional 
regulator encoded by the Oct-3/4 gene. Oct-3/4 can activate or repress DNA 
transcription dependent on the sequences flanking its octamer repeat binding site. It 
is expressed by undifferentiated ES cells and is down-regulated upon differentiation 
(Okamoto et al., 1990; Pesce and Scholer, 2001; Rosner et al., 1990; Scholer et al., 
1989). Knockout studies have shown Oct-3/4 to be essential for derivation and 
maintenance of ES cells and for the formation of the pluripotent inner cell mass of 
the blastocyst (Nichols et al., 1998). The level of Oct-3/4 expression is a critical 
determinant of cell fate (Figure 1-4). Conditional expression of Oct-3/4 in ES cells, 
demonstrated that a two-fold increase in expression could cause differentiation 
towards primitive endoderm and mesoderm lineages. Repression of Oct-3/4 
expression meanwhile caused dedifferentiation of ES cells to the trophectodermal 
lineage  (Niwa et al., 2000). Oct-3/4 often binds in partnership with the  homeobox 
domain containing protein transcription factor Sox-2 (SRY (sex-determining region –
Y)-related high-mobility-group box protein) which binds to neighbouring sox 
elements (Pevny and Lovell-Badge, 1997).  
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Figure 1-4 Relative expression of Oct-3/4 determines pluripotent cell fate. To maintain 
pluripotency Oct-3/4 expression must remain within 50% of normal diploid expression. An 
increase above this directs differentiation towards the primitive endodermal and mesodermal 
lineages. A decrease below this causes dedifferentiation towards the trophectodermal lineage 
(reviewed(Wobus and Boheler, 2005).  
 
More recently, the homeodomain protein Nanog has been identified as another 
transcription factor critical for the establishment and propagation of pluripotency in 
both ES cells and in the epiblast (Chambers et al., 2003; Mitsui et al., 2003; Wang et 
al., 2003). Overexpression of Nanog can maintain ES cells in a pluripotent state in 
the absence of LIF and its target genes overlap substantially with those of Oct-3/4 
(Loh et al., 2006). The regulators of Nanog are not yet well characterised but recent 
work has demonstrated that PI3K-dependent signalling regulates Nanog expression 
through GSK-3 dependent mechanisms (Storm et al., 2007). 
 
Signalling pathways and transcription factor expression/localisation alone cannot 
complete the self-renewal picture. Epigenetic mechanisms including DNA 
methylation, histone modification and repression by polycomb group complexes also 
influence transcription factor mediated self-renewal mechanisms and are thus 
essential for cell fate decisions (Boyer et al., 2006; Gan et al., 2007; Hattori et al., 
2004; Tada and Tada, 2001). 
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1.1.2.4 Similarities and differences between human and murine 
embryonic stem cells 
Both mouse and human ES cells are derived from the inner cell mass of the pre-
implantation blastocyst and can be maintained on a murine embryonic fibroblast 
(MEF) feeder cell layer. Human ES cells were derived more recently and culture 
conditions are not currently as well established as for murine ES cells. This may be 
part of the reason that human ES cell lines have thus far proved less karyotypically 
stable than their murine counterparts. The most common anomalies,  trisomies of 
chromosomes 12 and 17, appear to enhance growth and self-renewal of human ES 
cells (Draper et al., 2004). Although differences between human ES cell lines have 
been reported (Abeyta et al., 2004; Allegrucci and Young, 2006), a recent 
collaborative study, in which the expression of 17 cell surface antigens and 93 genes 
was compared between 59 independently derived human ES cell lines from 17 
laboratories in 11 countries, demonstrated no significant differences between the cell 
lines themselves and postulated that reported differences may be due to differences 
in culture conditions (The International Stem Cell Initiative, 2007). 
 
Many of the well characterised mechanisms of control of self-renewal in mouse ES 
cells including Wnt signalling and Oct-3/4, Sox2 and Nanog transcription factors are 
also important in the maintenance of self-renewal in human ES cell lines (Rao, 
2004). Oct-4 and Nanog appear to have overlapping binding site in human as well as 
in mouse ES cells (Boyer et al., 2005). Direct comparison of Oct-4 and Nanog targets 
identified in human ES cells by Boyer et al., with those  identified in murine ES cells 
indicated limited between species overlap (Loh et al., 2006). Although transcriptome 
profiling of human and mouse ES cells does indicate key differences between the 
species (Wei et al., 2005), a recent comparison of the methodology used by each 
group (ChIP on CHIP analysis from Boyer et al., and ChIP-PET analysis by Loh et 
al., indicates that observed difference may at least in part be due to methodological 
differences  (Euskirchen et al., 2007). 
 
The most striking difference in regulation of self-renewal between human and mouse 
ES cells is the inability of LIF to maintain self-renewal of human ES cells. The LIF 
receptor/gp130 is present at low levels in some human ES cell lines but activation of 
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the JAK/STAT3 pathway does not appear to be required for human ES cell self-
renewal (Ginis et al., 2004; Thomson et al., 1998). A possible explanation for this is 
may be that the requirement for LIF in mouse ES cells is related to the role of LIF in 
maintaining the pluripotent state of the inner cell mass during diapause (delayed 
blastocyst implantation) of which there is no equivalent in the human. Murine LIF 
knockout embryos are unable to proceed after diapause but in the absence of 
diapause (which does not occur in the human embryo) the LIF knockout embryo 
proceeds as normal until gastrulation (Nichols et al., 2001). BMP-4 also has an 
alternate function in human ES cells, promoting trophectoderm formation rather than 
ES cell self-renewal (Xu et al., 2002).  
 
In contrast to murine ES cells, FGF signalling appears to play an important role in 
the self-renewal of human ES cell lines. In the presence of a fibroblast feeder layer or 
fibroblast conditioned medium 4ng/ml bFGF/FGF2 is sufficient to maintain 
pluripotency (Amit et al., 2000). Feeder-free ES culture as has been achieved in 
murine ES cells has not been achieved for many human ES cell lines. However, 
increased bFGF/FGF2 concentrations (of 100ng/ml) have recently been 
demonstrated to support human ES cells plated on matrigel (a complex of 
extracellular matrix proteins) when supported by knockout serum replacement 
(Levenstein et al., 2006; Xu et al., 2005a; Xu et al., 2005b). Sphingosine-1 phosphate 
(S-1-P) and Platelet derived growth factor (PDGF) have also been shown to provide 
a growth signal in serum free culture in the presence of knockout serum replacement 
(Pebay et al., 2005).  
 
There is still much work to be done in the understanding of both human and murine 
ES cell self-renewal. The study of mouse ES cells will help inform that of their 
human equivalents but an appreciation of species differences needs to be maintained. 
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1.2 Embryonic development and in vitro models               
1.2.1 Embryonic development – a general overview 
Mouse embryonic development is used as a model for the study of mammalian 
development due to the ease of manipulation of mouse embryos and the ethical-
unfeasibility of similar studies in humans. Mouse embryonic development takes 
place over 20 days, from fertilisation to birth.  Figure 1-5 shows the early 
development of the embryo from fertilisation to gastrulation during which time the 
three germ layers, mesoderm, endoderm and ectoderm, which later give rise to all 
tissues and organs of the body, are formed. An overview of early murine 
development, based upon the following sources is given below (Downs, 2002; 
Gilbert, 2003; Wild and Fleming, 2002) 
1.2.1.1 Pre-implantation development 
 The fertilised zygote divides through asynchronous rotational cleavage to form a 
loose ball of 8 cells. This continues dividing and undergoes compaction to form a 
morula in which cells are tightly packed and stabilised by tight junctions between the 
outer cells.  Cells on the periphery of the day 3 morula endocytose extraembryonic 
fluid into its centre in a process called cavitation, forming the blastocoel of the 
blastocyst at day 3.5 post-coitum (E3.5). This creates two distinct cell populations, 
the inner cell mass (ICM), which goes on the form the embryo proper, and the 
trophectoderm, which forms the embryonic contribution to the placenta, the chorion.  
 
For the first 3.5 days the conceptus is enclosed in the zona pellucida (originally the 
extracellular matrix of the egg) which prevents implantation before the conceptus has 
reached the uterus. The blastocyst now ‘hatches’ from the zona pellucida  using a 
trophoblastic protease, strypsin, to lyse a hole which the growing blastocyst then 
squeezes through. The first segregation of the inner cell mass at E4-4.5 creates the 
hypoblast, (or primitive endoderm) which delaminates to line the blastocoel cavity 
and the epiblast (or primitive ectoderm) from which the embryo proper is formed 
(see Figure1-5, E4-4.5blastocyst).  
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Figure 1-5 Mouse embryonic development.  Diagram adapted from Wild and Fleming 
2002 and Gilbert, 2003. From E5.5 onwards the yolk sac, placental trophoblastic lineages 
and parietal endoderm are excluded for clarity.  
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1.2.1.2 Implantation 
Implantation occurs at E4.5 and over the next 24 hours the polar 
trophoectoderm/trophoblast (proximal) proliferates down into the blastocyst forcing 
the epiblast into the blastocoel. The hypoblast further differentiates and migrates to 
line the blastocoel. Hypoblast still adjacent to the epiblast forms the visceral (or 
proximal) endoderm whilst the hypoblast no longer in contact with the epiblast 
becomes the parietal (or distal) endoderm. The parietal endoderm associates with the 
giant trophoblastic cells of the mural trophoblast and secretes a thick basement 
membrane converting the blastcoel into the primary yolk sac. The yolk sac becomes 
filled with maternal plasma proteins from polar trophectoderm infiltration into 
maternal capillaries. The visceral endoderm digests these proteins to provide 
nutrients for the rapidly dividing epiblast which has become organised into a 
pseudostratified epithelium and also induces apoptosis of central cells in the epiblast 
forming the proamniotic cavity. At E5.5 the conceptus is at the egg cylinder stage 
illustrated in Figure 1-5, E5.5-egg cylinder stage. 
1.2.1.3 Gastrulation 
Gastrulation begins at E6.5 with the formation of the primitive streak which begins 
as a thickening of the epiblast at the posterior end of the embryo where the epiblast 
joins the visceral endoderm. As soon as the streak is formed epiblast cells begin to 
migrate through it. Cells emerging from the primitive streak come to lie between the 
outer epiblast and the visceral endoderm. The first of these form mainly mesoderm, 
both extraembryonic and embryonic (Figure 1-5, E6.5 – egg cylinder formation). 
Mesoderm destined for extraembryonic fates migrates proximally to form the 
membranes of the allantois,  chrorion and amnion (Lawson et al., 1991). The 
amniotic folds fuse to form the exocoelomic cavity. Migrating mesodermal 
aggregates destined to differentiate into blood islands colonise the presumptive yolk 
sac and eventually mesoderm lines the cavity forming the lining of what has become 
the visceral yolk sac (Ferkowicz and Yoder, 2005). Embryonic mesoderm migrates 
distally forming structures such as the somites and lateral plate mesoderm (Lawson 
et al., 1991). As development progresses the streak extends distally, recruiting more 
delaminating epiblast cells, to the late streak stage at which it reaches the distal tip of 
the embryo. Cells emerging from the streak now form both mesoderm and endoderm 
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(Figure 1-5 E7.5 – gastrulation continues). Ectoderm forms from epiblast cells which 
do not migrate through the streak and relies upon interaction with the mesoderm for 
its further development. Lineage specification of ectoderm, mesoderm and endoderm 
is illustrated in Figure 1-6. 
 
 
Figure 1-6. Lineage specification of the primary germ layers in the mammalian 
embryo. Diagram adapted from Gilbert, 2003 
 
By E7.5 the streak has extended to the distal tip and the node forms from an area of 
cells of mesodermal origin at the end of the streak with no covering of visceral 
endoderm and from the epiblast above them. The node is the area from which the 
head is formed and it also contributes to the neural tube and axial mesoderm. 
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Definitive gut endoderm arises from the same area. The extra-embryonic mesoderm, 
which migrated through the primitive streak at the beginning of gastrulation, has 
expanded and spread posteriorly. Cavities in this extra-embryonic mesoderm have 
coalesced to form exocoelum and the allantois, amnion and chorion contributions 
have been specified. Embryonic mesodermal precursors have migrated into the yolk 
sac and formed the blood islands which will generate the first vascular endothelial 
and primitive haemopoietic cells (Kinder et al., 1999).  
1.2.2 Modelling embryonic development in vitro 
As discussed in 1.1.2 mouse ES cells have the capacity to form any cell of the three 
germ layers under appropriate conditions. This property allows their exploitation as a 
model of development to investigate lineage commitment. There are several 
advantages to this in vitro approach over studies performed in the whole embryo. In 
vitro differentiation can provide a means to gain access to large populations of 
precursor or lineage-committed cells relatively easily, providing suitable quantities 
of material for protein and RNA work. The ES cell model can also be used in gene-
targeting approaches where in vivo studies may be more difficult or not possible due 
to, for example, embryonic lethality. In addition, particularly with regard to human 
ES cells, it provides a more ethically robust mode of study.  
 
The most common method of differentiating ES cells is by removing LIF and placing 
them in an environment conducive to the formation of embryoid bodies (EBs) 
(Doetschman et al., 1985; Keller, 1995). Embryoid bodies are three dimensional 
aggregates of embryonic stem cells the development of which mimics early 
embryogenesis (see Figure 2-1 for pictures). They can be formed in one of three 
ways (Keller, 1995): 
1. Embryonic stem cells grown in methylcellulose semi-solid medium at 1x104/ml 
for at least three days prior to study. 
2. Embryonic stem cells cultured in hanging drops of media containing 400-1000 
cells for 2 days and then replated into a suspension culture. 
3. Embryonic stem cells grown on non-adhesive culture plates. 
The other main methods of ES cell differentiation are differentiation on a stromal cell 
feeder layer (e.g. OP-9) (Nakano et al., 1994) or differentiation on extracellular 
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matrix proteins such as collagen (Nishikawa et al., 1998a). The method used (and the 
growth factors added) influences the balance of cell lineages formed. Formation of 
embryoid bodies in semi-solid medium in the presence of the appropriate cytokines, 
or differentiation on a feeder layer of OP-9 cells biases differentiation towards 
mesodermal lineages including haemopoietic, endothelial and muscle (Dang et al., 
2002; Desbaillets et al., 2000). Further analysis of developing populations within 
embryoid bodies, on feeder layers or in adherent differentiation, may require 
replating of the differentiated populations into new culture conditions e.g replating 
embryoid bodies formed in hanging drops to direct cardiac differentiation (Sachinidis 
et al., 2003a) or replating embryoid bodies formed in methylcellulose into a 
haemopoietic colony assay to analyse the haemopoietic progenitors present (Keller et 
al., 1993). Additionally, analysis of differentiated ES cell populations can be 
conducted morphologically, genetically, biochemically or immunologically (Keller, 
1995). 
 
Embryoid bodies have proved good models of embryogenesis being able to 
differentiate into the three germ layers and then into more committed cell types, for 
example; cardiomyocytes, skeletal muscle, endothelial cells, neuronal cells, 
adipocytes and haematopoietic precursors, mimicking development of the embryo 
(Desbaillets et al., 2000). Study of genetic markers of embryonic differentiation and 
their appearance in EBs supports the observation that EB development mimics 
embryonic differentiation both spatially and temporally. After differentiation is 
initiated an endodermal outer layer differentiates within the embryoid body. This is 
followed by development of an ectodermal ‘rim’ and mesodermal specification 
(Wobus and Boheler, 2005). Days 3.5 to 4.5 in the EB represent the gastrulation 
stage which occurs in vivo between day 6.5 and 7.5 and after day 6 EBs are 
equivalent to the early organogenesis stage which occurs from day 7.5 onwards in 
the embryo (Leahy et al., 1999). Disruption of primary EBs allows expansion of any 
one of the three germ layers preferentially in a further culture system enabling 
dissection of the development of different systems. One example of this is the 
dissection of the development of haemopoietic and endothelial cell lineages. The BL-
CFC (Blast Colony-Forming Cell) is thought to be the in vitro equivalent of the 
haemangioblast, defined as a common precursor of haemopoietic and endothelial 
lineages (see section 1.4.2). The BL-CFC population arises at around Day 3 in 
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primary embryoid bodies. Dissociation of primary embryoid bodies at this point 
allows expansion and differentiation of this BL-CFC population in a secondary blast 
assay which allows further dissection of the formation of haemopoietic and 
endothelial progenitors (Faloon et al., 2000; Kennedy et al., 1997). Cells are plated 
into fresh methylcellulose medium containing Vascular endothelial growth factor 
(VEGF) and conditioned medium from D4T embryoid body-derived endothelial cells 
to promote formation of blast colonies which reportedly contain both haemopoietic 
and endothelial progenitors (Choi et al., 1998; Faloon et al., 2000; Kennedy et al., 
1997). 
1.2.3 Haemopoietic and vascular development 
In the adult, as well as the developing embryo, the haemopoietic and vascular 
systems play important inter-connecting roles. The importance of the circulatory 
system is demonstrated by its early requirement in the embryo. By E10 diffusion (see 
1.2.1 embryonic development – a general overview) is no longer sufficient to supply 
nutrients to or remove waste from the developing embryo and a functioning vascular 
system must be in place to ensure embryonic survival (Fujiwara et al., 1996; Porcher 
et al., 1996; Shalaby et al., 1995). The importance of vascularisation is such that that 
the earliest mesodermal derivatives to differentiate are the endothelial and 
haemopoietic precursors which form the primitive vascular system (Kinder et al., 
1999).  
1.2.3.1 Establishment of primary circulation (including primitive 
haemopoiesis) 
The first haemopoietic cells to arise are primitive erythrocytes, along with small 
numbers of megakaryocytes and macrophages, although it is unknown whether these 
cells derive from a common site within the yolk sac. Primitive erythrocytes are larger 
than foetal and adult erythrocyes and contain an embryonic form of haemoglobin (β-
H1-globin) along with the adult form (β-major-globin) (Leder et al., 1992). They are 
nucleated until between E12.5 -16.5 when enucleation, thought to be associated with 
terminal differentiation, occurs (Fraser et al., 2007; Kingsley et al., 2004). Both the 
endothelium of blood vessels and the haemopoietic cells themselves are derived from 
the blood islands which form in the proximal visceral yolk sac (furthest from the 
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embryo) when aggregates of mesodermal cells (thought to have already undergone 
lineage commitment (Huber et al., 2004; Palis et al., 1999)) colonise the presumptive 
yolk sac at around E7 to form the blood islands (Haar and Ackerman, 1971; Palis et 
al., 1995). It would be expected that the vascular endothelium and haemopoietic 
precursors would differentiate simultaneously and proximally to form a functional 
vascular system and in the 12 hours following mesodermal aggregation the inner 
cells of the blood islands differentiate into maturing primitive erythrocytes whilst the 
peripheral cells form endothelium (Haar and Ackerman, 1971). This observation of 
proximal development was first made in the chick blastodisc by Florence Sabin 
(Sabin, 1920) and gave rise to the theory that both lineages differentiate from a 
common precursor, the haemangioblast (Murray, 1932). The existence of the 
haemangioblast has been a cause of much controversy and will be discussed in more 
detail in section 1.2.3 The Haemangioblast. 
 
By E8, at which point somatogenesis begins, the endothelial cells of the blood 
islands have anastomosed to form the capillary network or vascular plexus which 
then develops asymmetrically in the visceral yolk sac whilst remaining centred round 
the blood islands. At the same stage, primitive erythrocytes remain restricted to the 
blood islands. Simultaneously, in the embryo, angioblasts (the precursors of 
endothelial cells) begin to differentiate and coalesce forming the aortae, the first 
blood vessels of the embryo proper which form initially in the absence of associated 
haemopoietic precursors (Jaffredo et al., 1998). By E8.25 the vascular plexus has 
spread throughout the yolk sac and formed vitelline connections with the vasculature 
of the embryo proper. It is around this time that small numbers of erythrocytes are 
first observed away from the blood islands in the distal yolk sac and the embryo 
proper, and that the first true contractions of the heart as an organ are observed (Ji et 
al., 2003; McGrath et al., 2003). 
 
Between E8.5 and 10.5 the numbers of primitive haemopoietic progenitors in the 
yolk sac expands exponentially (Ji et al., 2003) and continue to infiltrate the maturing 
vascular system. By E9.5 the vascular system has matured into an arborized network 
formed by both vasculogenesis and angiogenesis. A fully functional circulation is 
established by E10.5 with the vascular network fully populated with maturing 
primitive erythrocytes which now comprise 40% of the embryo (McGrath et al., 
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2003). This correlates well with the timing of fatality in mouse mutants deficient in 
formation of any part of the circulatory system (Fujiwara et al., 1996; Porcher et al., 
1996; Shalaby et al., 1995; Wakimoto et al., 2000). 
1.2.3.2 Definitive haemopoiesis 
Definitive haemopoiesis gives rise to all definitive erythroid, myeloid and lymphoid 
lineages which arise from a common haemopoietic stem cell. Until E10.5 yolk sac 
haemopoiesis is the only source of blood in the developing embryo. At this point the 
progeny of definitive haemopoiesis begins to emerge in the circulation. Definitive 
erythrocytes are fully matured before entering the circulation. They are also smaller, 
and utilise some different transcriptional machinery and growth factor signalling 
(e.g. c-kit is essential for definitive but not primitive haemopoiesis;(McGrath and 
Palis, 2005) than their primitive counterparts. The number of circulating definitive 
haemopoietic cells increases from E11.5 onwards and they become predominant 
between E13.5 and E14.5 (Kingsley et al., 2004). Sites of early haemopoiesis in both 
human and mouse are illustrated in Figure 1-7 below. 
 
 
Figure 1-7 An illustration of haemopoietic organs in (A) a mouse and (B) a human embryo, 
at 11 days and 5 weeks of gestation, respectively (yellow, yolk sac; green, dorsal aorta of the 
aorta-gonad-mesonephros (AGM) region; red, fetal liver; blue, umbilical vessels and fetal 
vasculature in the placenta). The yolk sac in the mouse embryo surrounds the embryo due to axial 
rotation, an anatomical peculiarity of mice. In humans and other mammals the yolk sac is balloon 
shaped and connected to the mid-gut via a long stalk. The hematopoietic function of the human 
placenta has not yet been experimentally proven. Diagram from Mikkola 2006. 
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The site of initiation of definitive haemopoiesis is still some-what controversial. In 
part this is due to differing definitions of the term. Some researchers define 
‘definitive haemopoiesis’ as the formation of all haemopoietic lineages,  excluding 
primitive erthrocytes and early macrophages (and megakaryocytes) (Keller et al., 
1999; McGrath and Palis, 2005). Others define it as the expansion and differentiation 
of the definitive haemopoietic stem cell (HSC), HSCs themselves being defined as 
“those cells possessing their own ability to differentiate and expand on definitive, 
adult, hematopoietic territories” (Medvinsky and Dzierzak, 1999).  
 
Using the first definition, definitive erythroid and myeloid precursors have been 
found in the yolk sac as early as E8.25. They are not thought to mature in situ, rather 
migrating to the presumptive foetal liver where they engraft and mature (Palis et al., 
1999). The second site of definitive haemopoiesis is the para-aortic splanchneopleure 
(P/Sp E8.5-9.5) /aorta-gonad-mesonephros (AGM E10.5-11.5) region which contains 
the dorsal aorta, genital ridge/gonads, and pro/mesonephros area and which gives rise 
to all haemopoietic lineages. The exact origin of haemopoietic cells in this region is 
unclear, though the close anatomical relationship between haemopoietic clusters and 
endothelial cells in the dorsal aorta has led to postulation that the blood cells of the 
AGM differentiate from a haemogenic endothelium (see section 1.2.4.4).  The AGM 
is also well established as the site of emergence of HSC capable of reconstituting an 
adult recipient (de Bruijn et al., 2000; Medvinsky and Dzierzak, 1996) with HSC 
emerging at around E10.5. HSCs with the capacity to rescue a lethally irradiated 
adult mouse have not been isolated prior to this developmental stage, although HSCs 
capable of repopulating the newborn (possibly through maturation in the foetal liver 
which is still capable of limited haemopoiesis at birth), but not the adult, are found 
much earlier at E9 both in the P/Sp and at greater frequency in the yolk sac (Yoder et 
al., 1997). More recent work using an elegant Runx1 labelling method to label 
haemopoietic cells in the yolk sac at E7.5, prior to their emergence in the embryo 
proper, has suggested at least a partial yolk sac contribution to HSCs and 
haemopoiesis in the adult mouse via colonisation of the umbilical vein, AGM and 
foetal liver (Samokhvalov et al., 2007). However, as the Cre-loxP-Runx-1 labelling 
method is reliant on expression of Runx-1 at E7.5 occuring exclusively in the yolk 
sac (which has not been proven) this work cannot be considered proof of a yolk sac 
contribution.  
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HSCs have also been located in the embryonic contribution to the placenta, which 
appears to be constitute a site of HSC origin (Ottersbach and Dzierzak, 2005; Zeigler 
et al., 2006), and in the umbilical and vitelline arteries (de Bruijn et al., 2000). By 
E10 definitive haemopoiesis in the foetal liver, which is seeded by cells from both 
the yolk sac and AGM, has begun. This becomes the major site of foetal 
haemopoiesis until just before birth when haemopoiesis in the bone marrow, the 
main site of adult haemopoiesis, becomes dominant (Baron, 2003; Mikkola and 
Orkin, 2006) as illustrated in Figure 1-8. 
 
 
Figure 1-8 Changes in the major haemopoietic sites during development. YS-yolk sac, 
P/Sp/AGM-Para-aortic-Splanchnopleure/Aorta-Gonad-Mesonephros, Diagram adapted from 
Baron, 2003.  
1.2.4 The Haemangioblast 
1.2.4.1 The origins of the haemangioblast hypothesis 
The haemangioblast can be defined as a common precursor for haemopoietic and 
endothelial cells, particularly in the early embryo. The first endothelial and 
haemopoietic cells develop in the blood islands, aggregates of mesodermal cells 
which migrate into the extra-embryonic visceral yolk sac during gastrulation (see 
also sections 1.2.1 – ‘Embryonic Development – a general overview’ and section 
1.2.3 ‘Haemopoietic and Vascular Development’). The inner cells of these blood 
islands differentiate into primitive haemopoietic cells whilst the outer cells 
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differentiate into endothelial cells which later fuse with other blood islands to begin 
to form the yolk sac blood vessels. The developmental proximity of these two 
lineages led to the first proposal of a common precursor, the haemangioblast, by 
Murray in 1932 (Murray, 1932) illustrated in Figure 1-9.   
 
 
Figure 1-9 Historical model of the haemangioblast. Mesodermal cells migrating out of the 
primitive streak colonise the yolk sac. One clonal haemangioblast forms one blood island 
proliferating to form an aggregate the inner cells of which differentiate to form the blood 
whilst the outer cells form the endothelium. 
1.2.4.2 In vitro studies support the existence of the haemangioblast 
The existence of the haemangioblast is supported by gene expression data which has 
demonstrated expression of a number of different genes to be common to both 
haemopoietc and endothelial lineages including Foetal liver kinase-1 (Flk-1) (Kabrun 
et al., 1997; Millauer et al., 1993), the stem cell leukaemia gene (Scl) (Visvader et 
al., 1998), Cd34 (Fina et al., 1990), erythropoietin (Anagnostou et al., 1994) and c-kit 
(Bernex et al., 1996). Indeed, in recent years ever more endothelial markers 
including VE-cadherin (Vascular Endothelial-cadherin) (Kim et al., 2005) and 
Pecam-1 (platelet/endothelial cell adhestion molecule-1) (Baumann et al., 2004) have 
been identified in haemopoietic populations leaving very few true endothelial-
specific markers (Fleming, 2005). A number of genes including Flk-1 (Shalaby et al., 
1995) and Tgf-b1 (Dickson et al., 1995) in the mouse and Cloche in Danio rerio 
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(zebrafish) (Stainier et al., 1995) affect both lineages when knocked-out, further 
supporting a common origin hypothesis. Though these results support the 
haemangioblast hypothesis, the existence of the haemangioblast in vivo has been 
more difficult to prove.   
 
In vitro studies, using the differentiation of mouse ES cells into embryoid bodies as a 
model of embryogenesis, have identified a transient cell population which arises after 
2.5-5 days of culture, prior to haemopoietic commitment, which is termed the Blast 
colony forming cell (BL-CFC). Upon culture in methylcellulose, with the addition of 
VEGF and conditioned medium from the D4T embryoid body-derived endothelial 
cell line, the BL-CFC gives rise to blast colonies containing both haemopoietic and 
endothelial cells and thus represents the in vitro  haemangioblast (Choi et al., 1998; 
Kennedy et al., 1997). The clonal origin of these haemopoietic and endothelial 
lineages was demonstrated using two labelled embryonic stem cell lines in mixing 
studies (Choi et al., 1998) and work by Fehling and colleagues demonstrated the 
haemangioblast to be derived from cells in the culture which co-expressed the 
tyrosine kinase receptor Flk-1 and the T-box gene, Brachyury (see section 1.3.1) 
(Fehling et al., 2003). 
1.2.4.3 The haemangioblast in vivo 
Although molecular and in vitro studies support the existence of the haemangioblast 
it has been more difficult to study in the actual embryo. Huber et. al. recently 
identified a cell in vivo which first appears in the primitive streak at the mid-streak 
stage, coexpresses Flk-1 and Brachyury and which when cultured in vitro behaves in 
the same way as BL-CFC, forming blast colonies containing both haemopoietic and 
vascular endothelial cells (Huber et al., 2004). This work, the first to identify a cell 
with haemangioblastic potential in vivo, indicates that vascular and haemopoietic 
commitment begins prior to migration of these cells into the yolk sac. Other research 
into yolk sac, definitive and adult haemopoiesis and vasculogenesis has added further 
complexity to the haemangioblast model and raised new questions.  
 
Recent research into yolk sac haemopoiesis and vasculogenesis in vivo has begun to 
cast doubt upon the haemangioblastic origin of all yolk sac vascular endothelium. 
Vascular development without associated haemopoiesis has been observed at sites 
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away from the blood islands (McGrath et al., 2003) and  recent co-culture 
experiments, using cells isolated from embryos at various stages observed 
endothelial  progenitors earlier than progenitors of the haemopoietic lineages (Furuta 
et al., 2006). Further support for the existence of a second more committed 
endothelial precursor population has been gained from recent lineage tracing 
experiments (Ueno and Weissman, 2006).  
1.2.4.4 Haemogenic endothelium 
Definitive haemopoiesis in the AGM region also develops in close association with 
endothelial cells. Molecular characterisation of AGM haemopoietic stem cells 
revealed expression of endothelial markers including VE-Cadherin (Taoudi et al., 
2005) and Flk-1 (Jaffredo et al., 1998), which are later down-regulated, supporting a 
lineage relationship. A close anatomical relationship between clusters of 
haemopoietic cells and endothelial cells lining the ventral floor of the dorsal aorta 
(reviewed (Dieterlen-Lievre et al., 2006) and the formation of the aorta and vitelline 
arteries at least one day prior to the appearance of haemopoietic progeny in the 
embryo proper, (Jaffredo et al., 1998) has led to the hypothesis that the blood cells of 
the AGM region differentiate from a ‘haemogenic endothelium’ of the dorsal aorta.  
 
Cell sorting studies have demonstrated that cells of AGM origin display a plethora of 
endothelial markers including Pecam-1, CD34, Flk-1 and VE-cadherin, have the 
ability to take up Acetylated Low Density Lipids (AcLDL) and are able to generate 
CD45 expressing haemopoietic cells including lymphocytes in vitro (Nishikawa et 
al., 1998b; Oberlin et al., 2002). In labelling studies, using intra-cardiac injection to 
label the endothelial lining of blood vessels in both chick and mouse embryos with 
either AcLDL or a non-replicative retroviral vector containing a reporter gene, both 
CD45-expressing budding cluster cells and definitive erythrocytes in the blood 
stream were found to be labelled. Dissociation of the AGM region, immediately 
following labelling, demonstrated that the labelled cells expressed other endothelial 
markers and had the ability to differentiate into haemopoietic lineages in vitro 
(Jaffredo et al., 1998; Jaffredo et al., 2000; Sugiyama et al., 2003). Further 
supporting evidence for the haemogenic endothelium came from studies in Ly6A-
GFP mice in which GFP positive cells confirmed as HSCs by adoptive transfer were 
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found in the endothelial wall of the ventral floor of the dorsal aorta (de Bruijn et al., 
2002). 
 
Haemogenic endothelium is both spatially and temporally restricted to the ventral 
floor of the dorsal aorta from around E9.5, peaking at E11.5 and declining thereafter 
(Yao et al., 2007). Studies using chick/quail chimeras have suggested that 
haemogenic endothelium lining the ventral floor of the dorsal aorta is of 
splanchnopleural origin where as the rest of the dorsal aorta at that time is of somatic 
origin. As haemogenic endothelium differentiates and migrates into the blood stream 
somatic endothelium, which is non-haemogenic, replaces it to maintain vessel 
integrity (Pouget et al., 2006). This study may explain both the temporal and spatial 
restriction of  haemogenic endothelium and is supported by further studies in both 
quail/chick and quail/mouse chimeras which suggests that vessel formation in 
splanchnopleural tissues of the embryo occurs in situ whereas vessel formation in 
somatic tissues requires immigration of angioblasts (Pardanaud et al., 1989; 
Pudliszewski and Pardanaud, 2005). 
 
The existence of haemogenic endothelium in the AGM is by no-means proven. 
Similar evidence has been interpreted as indicative of an AGM haemangioblast (Yao 
et al., 2007) (though there is no proof of balanced bipotentiality), whilst other studies 
point to sub-endothelial mesenchymal patches as the origin of the haemopoietic 
clusters (Bertrand et al., 2005; North et al., 2002). Still greater developmental 
potential has been postulated for these endothelial cells with some evidence of 
myogenic differentiation ability (Tavian et al., 2005). The endothelial lining of the 
floor of the dorsal aorta obviously has an important role to play in definitive 
haemopoiesis but little is known about the origin (haemangioblastic?) of these 
haemopoietic endothelial cells. 
1.2.4.5 The haemangioblast in the adult organism? 
Whilst endothelium appears to play an important role in definitive haemopoiesis in 
the embryo, in the adult organism there is evidence that HSCs are involved in 
neovascularisation and maintenance of the vascular system. In vitro differentiation of 
enriched populations of haemopoietic stem cells and monocytes towards the 
endothelial lineage has been demonstrated (Asahara et al., 1997; Fujiyama et al., 
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2003; Zhang et al., 2005) but phenotypic overlap between monocytes with 
angiogenic potential and vascular endothelial cells has complicated in vitro studies 
(Rohde et al., 2006; Schmeisser and Strasser, 2002). In vivo experiments in 
myeloablated mice with donor bone marrow have demonstrated engraftment of 
endothelial cells of donor origin both in response to injury and in tissue homeostasis. 
The donor cells contain no karyotypic anomalies suggesting that the cells are not the  
result of fusion of a donor haemopoietic cell with an existing host endothelial cell 
(Bailey et al., 2004; Elsheikh et al., 2005; Grant et al., 2002). Contribution of donor-
derived endothelial cells has also been observed in human patients receiving sex mis-
matched bone marrow transplants, both in vessel homeostasis and in tumour 
angiogenesis (Jiang et al., 2004; Peters et al., 2005).  Human endothelial cells have 
also been found to participate in neovascularisation of ischaemically injured retinas 
in NOD/SCID mice previously rescued with human Umbilical Cord Blood (UCB) 
after myeloablation (Cogle et al., 2004).  
 
It is well known that a single HSC has the ability to reconstitute the haemopoietic 
potential of myeloablated mice (Osawa et al., 1996) and three groups have 
demonstrated this single cell approach to also be successful in providing a donor 
contribution to the endothelium of a recipient animal (Bailey et al., 2004; Grant et 
al., 2002; Larrivee et al., 2005)  This evidence supports the haemangioblast 
hypothesis in the demonstration of a clonal origin for both haemopoietic and 
endothelial cells in the recipient animal but does not preclude the possibility that the 
cell responsible is in fact a less committed multipotent stem cell with the ability to 
differentiate into multiple tissue types (reviewed (Kucia et al., 2005). 
 
The potential therapeutic benefits of being able to stimulate neovascularisation in 
conditions such as myocardial infarction, cerebrovascular accident and wound 
healing are obvious. However, the contribution of bone marrow-derived cells to 
neovascularisation appears to constitute only a small part of the involvement of bone 
marrow in vascular growth. The paracrine stimulation of vascularisation seems of 
even greater importance and is therefore the main area of research in the application 
of bone marrow-derived cells in vascular therapy (reviewed (Cho et al., 2006; 
Schatteman et al., 2007; Werner and Nickenig, 2006).  
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1.2.4.6 The current state of the haemangioblast hypothesis 
 In recent years, extensive research into the identity and role of the haemangioblast at 
different developmental stages and in distinct tissue compartments appears to have 
further confused, rather than clarified, the field. Ueno and Weissman recently 
published work disproving the original hypothesis of a clonal haemangioblast giving 
rise to a single blood island (illustrated in Figure 1-9). Their work, using a novel 
system in which 3 ES cell lines, expressing different fluorescent markers, were 
injected into wild type embryos to create chimeras, found more than one colour 
fluoresence to be present in individual blood islands in chimeric animals proving that 
the blood islands themselves are not clonally derived from a single haemangioblastic 
cell (Ueno and Weissman, 2006). As the investigators had used three coloured ES 
cell lines to produce the chimeras the chimerism in the blood islands could provide 
more clues to the origin of its constituent cells. 
 
The possible outcomes of the experiment are illustrated in Figure 1-10. Most blood 
islands in the study belonged to type IV in which either; 
A) there were no haemopoietic cells exhibiting fluorescence of a colour which 
was not also seen in the endothelial population 
B) there were no endothelial cells exhibiting fluorescence of a colour not also 
found in the haemopoietic population  
C) Both haemopoietic and endothelial populations contain cells exhibiting 
fluorescence of more than one colour, but no haemopoietic cell is the same 
colour as an endothelial cell (and vice versa).  
The rest of the blood islands fell into type II in which any colour of fluorescence 
found in the blood island was exhibited in cells of both lineages.  
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Figure 1-10 Schematic of expected chimerism in yolk sac blood islands in the 
Ueno/Weissman study (Ueno and Weissman, 2006). Type I blood islands comprised of 
cells of a single colour would occur if one bipotential haemangioblast gave rise to each blood 
island. Type II blood islands in which both endothelial and haemopoietic cells are chimeric 
but share the same mixture of colours would occur if bipotential progenitors proliferated in 
the primitive streak and mixed during migration. If endothelial and haemopoietic progenitors 
were generated separately in the primitive streak and each blood island was formed from one 
of each progenitor blood islands in which all endothelial cells and all haemopoietic cells 
were a single colour would form giving rise to either type III or type I blood islands. Lastly if 
endothelial and haemopoietic progenitors were generated separately in the primitive streak 
and each blood island was derived from several of each progenitor type IV blood islands 
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would arise. Type IV can be sub classified into A-C. If the fluorescence of the haemopoietic 
cells in a particular blood island was a subgroup of that found in the endothelial cells, they 
are defined as A. If the endothelial cells are a subgroup of those in the hematopoietic cells, 
they are type B. If some colours do not overlap in both lineages, they are classified as type C.  
 
The investigators interpreted these results to support one of the following two 
hypotheses;  
A) the haemangioblast is the common progenitor of both haemopoietic and 
endothelial lineages but does not always divide asymmetrically. In this 
hypothesis one haemangioblast cell could form either purely haemopoietic 
progenitors, purely endothelial progenitors or both haemopoietic and 
endothelial progenitors (Figure 1-11A) 
B)  the haemangioblast constitutes some of the haemopoietic and endothelial 
capacity of the blood islands and is augmented by endothelial and/or 
haemopoietic specific progenitors not themselves derived from the 
haemangioblast (Figure 1-11B) (Ueno and Weissman, 2006).  
 
Work by Furuta et al., in the mouse and Vogeli et al., in zebrafish  also support 
hypothesis B in which endothelial and haemopoietic precursors exist in addition to 
the  bipotential haemangioblast (Furuta et al., 2006; Vogeli et al., 2006). 
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Figure 1-11 Current haemangioblast hypotheses as put forward by Ueno and 
Weissman, 2006. Model A. Bipotential haemangioblast model. One haemangioblast can 
differentiate into either endothelial, haemopoietic or both lineages. Model B. The 
haemangioblast and endothelial specific progenitor model.  Haemopoietic and endothelial 
cells are derived from the haemangioblast and endothelial cells can also be derived from an 
endothelial specific progenitor the angioblast. A progenitor specific for haemopoiesis may 
also exist. 
 
The definition of the haemangioblast appears to have broadened and has been used 
by different researchers to describe different situations. Generally, the term now 
seems to be used to describe any cell with the potential to differentiate towards a 
haemopoietic and endothelial lineage even if this potential is unbalanced, as 
described in the sections above discussing both haemogenic endothelium and the 
adult haemangioblast. The original haemangioblast theory, describing differentiation 
of a single cell to form both endothelial and haemopoietic daughter cells, has never 
been observed in vivo. A possible reason for this may be that in vivo a cell is unlikely 
to be in a situation where environmental cues would provoke such a simultaneous 
differentiation. 
 
The second recent evolution in modern haemangioblast theory is that the 
haemangioblast appears to have a greater capacity for differentiation than previously 
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thought,  encompassing smooth muscle differentiation in vitro (potentially via 
transdifferentiation of endothelial cells) (Ema and Rossant, 2003) and  possibly 
sharing a common precursor with cardiac endothelium and muscle (Kattman et al., 
2006).   
 
The available data concerning the kinetics, characterisation, definition and even 
existence of the haemangioblast in vivo are currently open to interpretation. Whilst it 
is clear that the original simple description of the haemangioblast model illustrated in 
Figure 1-9 is unlikely to exist, a clear picture is yet to emerge. What is known is that 
haemopoietic and endothelial cells share a very close developmental and functional 
relationship. Further research in vitro and in vivo into signalling pathways important 
in the expansion, migration and commitment of these lineages will help further 
clarify the haemangioblast hypothesis. 
 
1.3 Cell signalling in haemopoietic and vascular 
development 
Little is known about the molecular signalling processes which regulate the 
formation, migration and differentiation of the haemangioblast. However, the use of 
in vitro knockout approaches has enabled the detailed study of the importance of key 
signalling molecules, the most prominent of which are discussed below. Further 
research in this area would contribute to a greater understanding of the development 
of the haemopoietic and endothelial lineages and their interactions. Important 
intrinsic (of embryonic origin) and extrinsic (of extra-embryonic origin) signalling 
pathways in haemopoietic and vascular development are summarised in Figure 1-12. 
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Figure 1-12 Important signalling pathways in haemangioblast commitment and 
differentiation. Diagram illustrating signalling molecules and transcription factor required 
in the development of the haemopoietic and endothelial lineages. Red wording indicates 
expression status of the molecule by cells of the lineage indicated. For further clarification 
and references see 1.3.1.1-1.3.1.5. 
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1.3.1 Signalling intrinsic to the embryo 
1.3.1.1 Brachyury 
 Brachyury is a T box gene important in the regulation of mesodermal fate during 
gastrulation and is first detected in the primitive streak at E7 remaining until E9.5 
(Kispert and Herrmann, 1994; Wilkinson et al., 1990). Brachyury null ES cells, 
reintroduced into the embryo, are unable to migrate, and remain in the primitive 
streak (Wilson et al., 1995). Knockout and lineage tracing experiments have 
demonstrated a further requirement for Brachyury, when coexpressed with Flk-1, in 
the formation of mesoderm fated to specify the haemangioblast (Fehling et al., 2003; 
Huber et al., 2004). 
1.3.1.2 Flk-1 
Flk-1 (foetal liver kinase-1) is one of the most studied signalling molecules with 
reference to the haemangioblast. Studies into the effect of Flk-1 gene knockout, 
published in 1995, provided supporting evidence for the haemangioblast theory, 
since mice null for this receptor tyrosine kinase died by E9.5 due to a failure in the 
formation of both haemopoietic and vascular systems (Shalaby et al., 1995). This 
early embryonic lethality led to the use of embryoid bodies to further investigate the 
role of Flk-1 and its ligand vascular endothelial growth factor (VEGF). In vitro 
studies support a role for Flk-1 in the migration of the putative haemangioblast, as 
well as its specification and differentiation (Choi et al., 1998; Hidaka et al., 1999; 
Kabrun et al., 1997; Schuh et al., 1999). The role of Flk-1 signalling in the 
haemangioblast is discussed further in section 1.4.1.1, Flk-1 signalling is discussed in 
section 1.4.2. 
1.3.1.3 Vascular Endothelial Growth Factor (VEGF) 
VEGF (VEGF-A), also known as vascular permeability factor (VPF), is a member of 
the platelet derived growth factor (PDGF) supergene family. Other vascular 
endothelial growth factors include VEGF-B, VEGF-C, VEGF-D and VEGF-E. 
VEGF-C and VEGF-D bind to VEGFR-3 (fms-like tyrosine kinase-4 (Flt-4)) that is 
expressed on lymphatic endothelial cells. VEGF-A and VEGF-B bind to VEGFR-1 
(fms-like tyrosine kinase-1 (Flt-1)), a sister tyrosine kinase to Flk-1/KDR/VEGFR-2 
that is also involved in the development of the embryonic vasculature. Flk-1 binds 
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VEGF-A, VEGF-C, VEGF-D and VEGF-E. VEGF-A is usually referred to simply as 
VEGF and is encoded by an eight exon gene on the short arm of chromosome 6. 
Alternative splicing of VEGF-A mRNA in humans gives rise to five different 
isoforms of the gene. The most abundant and biologically active of which, VEGF165, 
forms a 46kDa disulphide linked homodimer (Zachary, 2001). 
 
Mice with a heterozygous knockout of VEGF die at E10.5, seemingly due to delayed 
endothelial development, indicating either that VEGF action is dose-dependent or 
that there is a critical VEGF threshold required for endothelial development 
(Carmeliet et al., 1996; Ferrara et al., 1996). This view is supported by in vitro 
observations in which VEGF supports a dose-dependent differentiation of endothelial 
cells from embryonic stem cell-derived mesodermal cells (Hirashima et al., 2003) 
The VEGFR-1 knockout is also embryonic lethal, due to a severe disorganisation of 
the vasculature (Fong et al., 1995). However, a truncated form of VEGFR-1, lacking 
the tyrosine kinase domain, can rescue the knockout phenotype suggesting that its 
role is not in mediating signalling but rather in sequestering VEGF, for which it has a 
10-fold higher affinity than Flk-1 (Waltenberger et al., 1994), in order to negatively 
modulate Flk-1 signalling (Hiratsuka et al., 1998). The transmembrane domain of 
VEGFR-1 appears to be important in this role allowing direct regulation of VEGF 
levels at the cell surface (Hiratsuka et al., 2005b).  This negative modulatory role of 
VEGFR-1 is further supported by partial rescue of the VEGFR-1 knockout 
phenotype by addition of soluble VEGFR-1 (Kearney et al., 2004), or partial 
inhibition of Flk-1 (Roberts et al., 2004).  
 
VEGF also binds to Neuropilins 1 and 2 which also play a role in vasculogenesis. 
Neuropilin-1 binds VEGF-A165 , VEGF-B, VEGF-E and the related placental growth 
factor-2 (PIGF-2). The Neuropilin-1 knockout phenotype includes impaired yolk sac 
vascularisation (Klagsbrun et al., 2002) and when Neuropilins-1 and 2 are knocked 
out together death occurs at E8.5 due to a severe failure in vascularisation 
(Takashima et al., 2002). When co-expressed with Flk-1, neuropilin-1 increased 
VEGF binding to Flk-1 and associated mitogenic effects (Soker et al., 1998). 
Modelling suggests this effect may be explained by binding of VEGF-A165 to both 
neuropilin-1 and Flk-1 causing formation of a heterodimer (Mac Gabhann and Popel, 
2005). The cytoplasmic domain of both neuropilins is small, indicating that 
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signalling is not transduced through them but rather that they act as co-receptors.  
The mechanism of their action is not yet fully elucidated. Other co-receptors include 
the Heparin sulphate proteoglycans which also enhance VEGF-A165 mediated Flk-1 
signalling (Ashikari-Hada et al., 2005). 
1.3.1.4 Stem Cell Leukaemia factor 
Scl or Tal1 is a basic helix-loop-helix transcription factor first identified in T cell 
acute lymphoblastic leukaemia. The Scl knockout mouse, like the Flk-1 knockout 
mouse dies between E9 and E10.5 due to anaemia (Shivdasani et al., 1995). In the 
absence of Scl haemopoiesis is undetectable, suggesting an early role in the 
specification of the primitive haemopoietic system (see Figure 1-12) (Porcher et al., 
1996). Selective rescue of the Scl knockout in which the GATA-1 promotor was 
used to target Scl expression to the haemopoietic system, revealed a later, endothelial 
defect in the remodelling of the primitive vascular plexus to form a complex 
capillary system (Visvader et al., 1998). Many workers initially placed Scl as 
important in the formation of the haemangioblast, as in its absence blast colonies, 
indicative of formation of the Blast colony forming cell (BL-CFC), the in vitro 
equivalent of the haemangioblast, failed to form (Faloon et al., 2000; Robertson et 
al., 2000). However, further work demonstrated that cells from Scl null embryoid 
bodies, dissociated during the temporal window in which BL-CFC in wild-type 
embryoid bodies would be expected, were able to form secondary blast colonies, 
when a viral Scl vector rescue strategy was employed upon plating of cells into the 
secondary blast assay. Furthermore, genetic analysis found no Scl gene expression 
until day 1 of blast colony formation (D'Souza et al., 2005). This suggests that the 
BL-CFC can form in Scl null embryoid bodies but is unable to expand. 
1.3.1.5 Other signalling factors 
The complexity of signalling surrounding early patterning of the haemopoietic and 
vascular systems in the embryo is becoming ever more apparent with many recent 
publications revealing the involvement of novel molecules. Table 1-1 briefly 
summarises the signalling and transcription factors included in Figure 1-12. 
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Table 1-1 Signalling factors involved in haemopoietic and endothelial development 
Signalling 
molecules 
Role in haemopoietic and/or vascular endothelial 
development 
References 
Hex Hex is a homeobox gene which appears to negatively 
regulate the haemangioblast and endothelial lineages 
(Kubo et al., 
2005) 
Endoglin 
(CD105) and 
TGFβ 
Endoglin is a TGFβ receptor. Expression is comparable 
to that of Flk-1 and the knockout is embryonic lethal due 
to vascular and cardiac defects. The TGFβ knockout is 
embryonic lethal in 50% of animals due to defective 
yolk sac haemopoiesis and vasculogenesis. Defective 
endothelial differentiation results in weak vessels with 
reduced cellular adhesion. Park et. al. reported inhibition 
of VEGF induced vascular and haemopoietic expansion 
by TGFβ. 
(Dickson et 
al., 1995; Li et 
al., 1999; Park 
et al., 2004; 
Perlingeiro, 
2004) 
puromycin 
insensitive 
leucine specific 
amino peptidase 
(PILSAP) also 
known as Arts1 
A leucine and methionine specific metalloproteinase 
upregulated during endothelial differentiation. Inhibition 
of PILSAP using a dominant negative approach or 
siRNA inhibited growth and differentiation of 
haemopoietic, endothelial and vascular smooth muscle 
lineages. 
(Abe and 
Sato, 2006) 
Runt-related 
Transcription 
Factor-1 (Runx-
1) 
The mouse equivalent of AML-1, Runx-1 is a 
transcription factor of the core binding factor family. 
Runx-1 is required for definitive haemopoiesis and 
appears to play an earlier role negatively regulating 
mesodermal commitment towards to haemangioblast 
(Lacaud et al., 
2002; Lacaud 
et al., 2004) 
Erythropoietin 
(Epo) 
Epo is a cytokine essential for erythropoiesis but may 
also be involved to endothelial development. Epo 
treatment enhanced migration, endothelial marker 
expression and tube formation and decreased apopotosis 
in embryoid bodies, embryoid body derived endothelial 
cells and human endothelial progenitor cells. 
(Muller-
Ehmsen et al., 
2006) 
Thrombopoietin 
(TPO) and its 
receptor c-mpl 
A primary physiological regulator of platelet production 
which also plays a role in haemopoietic stem cell (HSC) 
function. TPO treatment or conditional activation of its 
receptor c-mpl has been shown to augment BL-CFC 
formation  in vitro 
(Perlingeiro et 
al., 2003) 
GATA binding 
protein-1 and -2 
GATA-1 and 2 are zinc finger transcription factors. 
GATA-1 null embryos are unable to proceed beyond the 
proethythroblast stage of erythropoiesis though early 
haemopoiesis proceeds normally possibly reflecting 
redundancy with GATA-2. GATA-2 is embryonic lethal 
due to failure of primitive haemopoiesis. In vitro studies 
show upregulation of GATA-2 on day 2 in blast 
colonies, consistent with the timing of haemopoietic 
commitment 
(D'Souza et 
al., 2005; 
Fujiwara et 
al., 1996; Tsai 
et al., 1994) 
Tyrosine kinase 
with Ig and 
EGF factor 
homology 
domains (Tie)-1 
and 2  
Belong to a distinct family of receptor tyrosine kinases 
expressed mainly in endothelial cells. Tie-1 is necessary 
for the establishment of vessel structural integrity 
whereas Tie-2 is important for vascular network 
formation. In addition Tie-2 has been shown to be 
involved in adult but not fetal definitive haemopoiesis.  
(Puri and 
Bernstein, 
2003; Sato et 
al., 1995; 
Takakura et 
al., 1998) 
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Lim Domain 
Only -2 (Lmo2) 
Lmo2 null mice die at E10.5 due to failure of yolk sac 
haemopoiesis. Later work has shown an additional role 
in adult definitive haemopoiesis. The knockout 
phenotype is similar to that of SCL (see 1.3.1.3) 
Biochemical analysis and work in zebrafish suggest that 
it may function in a complex with SCL and GATA-1. 
(Patterson et 
al., 2007; 
Wadman et 
al., 1997; 
Warren et al., 
1994; Yamada 
et al., 1998) 
c-kit c-kit is a receptor tyrosine kinase required for embryonic 
and adult haemopoiesis. c-kit null ES cells die upon LIF 
withdrawal  though c-kit null ICM and epiblast cells 
display a normal phenotype.  
(Bashamboo 
et al., 2006; 
Ronnstrand, 
2004; Russell, 
1979) 
  
1.3.2 Extrinsic factors 
Additional to signalling intrinsic to the embryo are those signals of extrinsic origin. 
Whilst more difficult to model in vitro, extrinsic signalling has been proven to play 
an important role in haemangioblast development. The two chief sources of extrinsic 
signalling are the visceral endoderm and signalling as a result of hypoxia. 
1.3.2.1 Hypoxia 
Hypoxia plays a crucial role in the initial generation of mesoderm, and formation of 
vascular and haemopoietic derivatives in early development. Its effects are mediated 
through Hypoxia inducible transcription factors (Hif), Hif1α (which in normoxic 
conditions is degraded but is stabilised in hypoxic conditions by inhibition of Hif1α 
hydroxylase I) and Hif1β which is constitutively expressed. The effects of hypoxia 
include accelerated expression of Bmp4, Flk-1 and Brachyury, all of which promote 
the early development of haemopoietic and vascular endothelial lineages (Ramirez-
Bergeron et al., 2004). Hif1β knockout mice have defects in vascular remodelling 
and haemopoiesis in the extraembryonic yolk sac (Maltepe et al., 1997) and Hif1β-/- 
ES cells show reduced expression of Flk-1 and a decreased number of blast colonies 
in in vitro models (Ramirez-Bergeron et al., 2004). Vascular Endothelial Growth 
Factor (VEGF) plays an important role in the embryonic response to hypoxia. 
Binding of Hif1α to the hypoxia response element (HRE) of VEGF in ES cells 
increases VEGF concentrations thus inhibiting apoptosis both in vitro (Brusselmans 
et al., 2005) and in vivo in quail eggs (Nanka et al., 2006). 
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1.3.2.2 Visceral endoderm 
Explant culture experiments have demonstrated the importance of factors secreted 
from the visceral endoderm in specifying haemopoietic and vascular endothelial cell 
fate. Embryos from which the visceral endoderm is removed fail to express β-H1 -
globin, Gata1 or Flk-1 but can be rescued by donor visceral endoderm from other 
embryos (Belaoussoff et al., 1998). Candidates for these important soluble factors 
include Indian hedgehog (ihh) and Bmp4 (Dyer et al., 2001; Farrington et al., 1997). 
The relative importance of Bmp4 to haemopoietic and endothelial specification is 
difficult to quantify as it plays such an important role in earlier mesoderm patterning 
events. However, recent work by Park et al., demonstrated that inactivation of 
Bmpr1a (Alk3), a receptor for Bmp4, resulted in embryonic lethality due to vascular 
but not haemopoietic defects (Park et al., 2006). Ihh is able to substitute for visceral 
endoderm and promote haemopoietic and endothelial development in epiblasts 
stripped of visceral endoderm. Whether this is physiological has not yet been 
established (Dyer et al., 2001). However, the ihh knockout mouse does display 
vascular defects and dies in utero suggesting ihh does have a physiological role to 
play in vasulogenesis if not the initial specification of haemopoietic and endothelial 
lineages which are both able to form in the absence of ihh (Byrd et al., 2002; Vokes 
et al., 2004). 
1.4 The role of Flk-1 in early development  
Flk-1, a receptor tyrosine kinase, is also known as vascular endothelial growth 
factor-receptor-2 (VEGFR-2), and Kinase Domain Receptor (KDR) in humans. It 
plays a key role in the formation of the circulatory system in the embryo where it is 
expressed on the putative haemangioblast and endothelial lineages (Schuh et al., 
1999; Shalaby et al., 1995). Expression of the receptor is maintained on adult 
endothelial cells in which it mediates angiogenesis, making it an important target in 
the pathology of many human diseases including cancer, Rheumatoid Arthritis, 
ocular neovascularising disease and cardiovascular disease (Zachary, 2001). 
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1.4.1 The role of Flk-1 in embryogenesis and in vitro models 
of embryogenesis 
1.4.1.1 The role of Flk-1 in differentiation to haemopoietic and 
endothelial lineages  
Deletion of both Flk-1 alleles in the mouse is embryonic lethal between E8.5 and 
E9.5 due to a lack of developing vasculature. Knocking out one allele has no effect 
suggesting that the requirement for Flk-1 is not concentration dependent (Shalaby et 
al., 1995; Shalaby et al., 1997). The yolk sac blood islands are absent at E7.5 as 
mesenchymal aggregates fail to form and there are no organised blood vessels in Flk-
1 null embryos. There are also very few haemopoietic progenitors, although it is not 
clear whether this is a direct effect of the Flk-1 knock-out or occurs due to the lack of 
blood vessels adversely influencing the haemopoietic microenvironment. Cells in the 
Flk-1null animals expressing lacZ under the Flk-1 promotor were found in the 
amnion and mesothelium, indicating that Flk-1 may normally be involved in their 
migration (Shalaby et al., 1997) . 
 
The embryonic lethality of the Flk-1 knockout mouse makes it difficult to investigate 
its role fully in vivo. However, expression studies have shown that Flk-1 is expressed 
on early haemopoietic as well as endothelial progenitors in the yolk sac (E8.5-9.5) 
(Kabrun et al., 1997) and Flk-1 involvement has been demonstrated in the 
development of both lineages in embryoid body models (Hidaka et al., 1999; Kabrun 
et al., 1997; Nishikawa et al., 1998a). Fehling et al., identified Flk-1 along with 
Brachyury as markers of the population of embryoid body cells from which the BL-
CFC arose (Fehling et al., 2003) and more recent experiments by Huber et al., 
identified cells in the primitive streak which again expressed both Flk-1 and 
Brachyury and which were able to clonally differentiate in vitro into both 
haemopoietic and endothelial lineages (Huber et al., 2004) (see section 1.2.4.3).  
 
The precise role of Flk-1, particularly in haemopoietic development, has been 
difficult to elucidate. Reported expression of Flk-1 on early haemopoietic progenitors 
is lost in most definitively differentiated haemopoietic cells (Kabrun et al., 1997; 
Nishikawa et al., 1998a)  though it is reportedly expressed on (some) haemopoietic 
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stem cells in the adult (Gerber et al., 2002; Ziegler et al., 1999). Initially it was 
thought that down-regulation of Flk-1 in haemopoietic cells and its retention in 
endothelial cells may be an important signal in the differentiation of haemangioblast 
cells (Yamaguchi et al., 1993). Subsequent research demonstrated that haemopoietic 
differentiation was possible in the absence of Flk-1 though to a lesser extent and with 
greater dependency on the correct microenvironment suggesting a role in cell 
migration and proliferation (Hidaka et al., 1999; Schuh et al., 1999). A migratory 
role is supported by the presence of Flk-1 positive haemopoietic progenitors at E7.5 
in the embryo despite an absence of such progenitors at E8.5 (Schuh et al., 1999; 
Shalaby et al., 1995; Shalaby et al., 1997) and by the apparent importance of VEGF-
A, a ligand for Flk-1, in the migration of VEGFR positive cells from the posterior to 
the anterior of the embryo (Hiratsuka et al., 2005a). 
 
One important question is whether Flk-1 is required for haemopoietic differentiation? 
The answer may be sometimes. In vitro work has reported haemopoietic progenitors 
to both express Flk-1 and be derived from a Flk-1 positive population (Kabrun et al., 
1997; Nishikawa et al., 1998a) although Flk-1 knockout ES cells are still able to 
form cells of the haemopoietic lineage in vitro  (Hidaka et al., 1999). Work published 
by Ema et  al., demonstrated that Flk-1 expression is not always indicative of 
function as its early expression is both promiscuous and extensive within the 
mesodermal lineages which may explain this apparent paradox (Ema et al., 2006). 
Additionally, new research using a Flk-1 concentration-responsive cre-lox P-driven 
fluorescent reporter system suggests that the origins of haemopoiesis in vivo are 
heterogenous with haemopoietic cells arising from both Flk-1 positive (possibly the 
haemangioblast population) and Flk-1 negative (possibly representing a more lineage 
restricted population – see 1.2.3.6) population (Ueno and Weissman, 2006). It is 
possible that Flk-1 is required for a subset of haemopoiesis, perhaps that arising from 
the bipotential haemangioblast but not for all early haemopoiesis.   
 
The role of Flk-1 in the formation of the vascular endothelial lineage appears more 
straightforward. The Flk-1 knockout animal forms no blood vessels (Shalaby et al., 
1995), Flk-1 is required for adult angiogenesis and its expression remains on adult 
endothelial cells. The Flk-1 concentration-responsive cre-lox P-driven fluorescent 
reporter system used by Ueno and Weissman demonstrated that all endothelial cells 
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in the yolk sac were derived from Flk-1 positive precursors (Ueno and Weissman, 
2006). In vitro, however, there are reports of endothelial formation from Flk-1 
knockout ES cells (Schuh et al., 1999). Though the identification of the endothelial 
cells was made through using expression of endothelial markers (some of which have 
since been demonstrated to be expressed on the haemopoietic lineage; (Fleming, 
2005) the panel of markers used still seems to define the endothelial cell. Perhaps 
this is once again evidence for a migratory role for Flk-1 which can be overcome by 
a differing microenvironment in vitro or alternatively evidence of adaptation of the 
Flk-1 knockout ES cells. More recent research, in Zebrafish, has postulated a role for 
Flk-1 signalling in the specification of arterial and venous fates. Disruption of the 
gridlock gene in Zebrafish led to formation of insufficient numbers of arterial cells 
and reduction or loss of the aorta. This phenotype could be suppressed by injection of 
VEGF cDNA or addition of a small molecule GS4012, postulated to activate VEGF 
signalling, suggesting a role for Flk-1 in arterial specification (Hong et al., 2006).  
 
1.4.1.2 The role of Flk-1 in cardiac and neural development 
In addition to its role in haemopoietic and endothelial development Flk-1 has also 
been implicated in both cardiac and neural development. The first indication that Flk-
1 was involved in developmental processes other than haemopoietic and endothelial 
development came with the identification of its expression in retinal progenitor cells 
(Yang and Cepko, 1996). Flk-1 activation of the mitogen activated protein kinase 
(MAPK) pathway has subsequently been demonstrated as a mitogenic signal in 
cultured peripheral ganglia and central nervous system neurons (Khaibullina et al., 
2004; Rosenstein et al., 2003; Sondell et al., 1999) and Flk-1 has also been 
implicated in neural protection and development (reviewed(Rosenstein and Krum, 
2004).  
 
The involvement of Flk-1 in cardiac development has been discovered more recently. 
The heart is formed by two populations of mesodermal cells which migrate through 
the primitive streak,  the anterior splanchnic mesoderm which contributes to the 
initial stages of cardiogenesis and the pharyngeal mesoderm which migrates to the 
site of cardiogenesis later at around E9.5 (Kelly, 2005). The role of Flk-1 in the 
initial stages of cardiogenesis is illustrated in Figure 1-13.  
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Figure 1-13. Proposed role of Flk-1 in specifying mesodermal differentiation towards 
either a cardiac or haemangioblastic fate. Cells with haemangioblastic or cardiac potential 
can be separated at day 3.25 of embryoid body development based upon their expression of 
Flk-1. Cells with haemangiogenic potential express Flk-1 at day 3.25 whereas cells with 
cardiac potential don’t upregulate expression until day 4.25 (Kattman et al., 2006). 
 
Lineage tracing experiments identified a Flk-1 positive intermediate population 
which appears to develop as cells exit the primitive streak and begin to migrate 
towards  the cardiac cresent (Ema et al., 2006). Further study, using embryoid bodies 
as a model of cardiogenesis (Boheler et al., 2002; Sachinidis et al., 2002), 
demonstrated an increase in expression of cardiac markers in response to VEGF and 
a marked decrease upon treatment with an anti-Flk-1 antibody (Chen et al., 2006). 
Work by the Keller group first identified that the cardiogenic mesoderm population 
was derived from a population which was Brachyury positive but Flk-1 negative at 
E3.25, the point of BL-CFC/haemangioblast formation (Kouskoff et al., 2005) and 
then demonstrated that at E4.25 a new Flk-1 positive population was generated 
which was identified to contain the majority of cardiac potential within the 
differentiation model and which had the potential to form cardiac, endothelial and 
visceral smooth muscle lineages (Kattman et al., 2006). 
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1.4.2 Flk-1 signalling  
The signalling mechanisms mediated by the receptor tyrosine kinase Flk-1 have been 
little characterised in the embryo, but due to its importance therapeutically, research 
has been conducted in primary human endothelial cells and cell lines on the human 
equivalent of murine Flk-1, KDR.  Flk-1/KDR has seven immunoglobulin-like 
domains extracellularly and a split tyrosine kinase domain intracellularly (see Figure 
1-14). It binds its dimeric ligand, vascular endothelial growth factor (VEGF), in the 
second and third Ig-like domains which leads to receptor dimerisation and 
transphosphorylation of tyrosine residues in its intracellular tail. KDR activation 
initiates a series of signalling cascades, illustrated in Figure 1-15, which in the adult 
mediate cell migration, survival and proliferation (Neufeld et al., 1999). 
 
 
Figure 1-14 Schematic of the Flk-1 receptor based upon sequence information for 
NM_010612 from NCBI (http://www.ncbi.nlm.gov) accessed on November 11th 2006. 
Positions of tyrosine phosphorylation on the cytoplasmic portion of the receptor upon 
receptor stimulation are illustrated. Numbers illustrate the base pair position in the cDNA 
sequence from the start codon at 1 and (in bold) amino acid positions. 
 
VEGF causes dimerisation of the KDR receptor and transphosphorylation of key 
tyrosine residues in the cytoplasmic tail including tyrosines at positions 951, 1054, 
1059, 1175 and 1214 (Lamalice et al., 2004; Matsumoto et al., 2005; Takahashi et 
al., 2001). Phosphorylation of Y1054 and Y1059 (1052 and 1057 in murine Flk-1) 
increases intrinsic tyrosine kinase activity of Flk-1 (Dougher and Terman, 1999; 
Kendall et al., 1999). Proteins containing a Src homology-2 (SH2) domain (a module 
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of ~100 amino acids which binds the phospho-tyrosine via a conserved domain and 
binds 3-6 residues C-terminal to the tyrosine via a variable pocket which confers 
specificity) are then able to bind to phosphorylated tyrosine residues to potentiate 
Flk-1 signalling (Guo et al., 1995). The following major signalling pathways 
activated through the receptor are illustrated in Figure 1-15; phospholipase C- γ 
(PLC- γ) related signalling (McLaughlin and De Vries, 2001), the PI3K pathway and 
the Mitogen Activated Protein Kinase (MAPK) pathway (discussed further in 
sections 1.4.2.1,1.4.2.3 and 1.4.2.2 respectively). SHP-1 (SH2 domain containing 
protein tyrosine phosphatase) (Guo et al., 2000; Kroll and Waltenberger, 1997) and 
SHP-2 (Gallicchio et al., 2005; Kroll and Waltenberger, 1997) are also thought to 
associate with the Flk-1 receptor and are possibly involved in attenuating KDR 
signalling.  
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Figure 1-15 Summary of KDR signalling in human endothelial cells. Modified from (Olsson 
et al., 2006). Binding of the VEGF dimer causes receptor dimerisation of phosphorylation of the 
key tyrosine residues illustrated.  Signalling is then potentiated by the binding and 
phosphorylation of SH2 domain containing intermediate signalling molecules. Activation of the 
signalling cascades illustrated leads to a variety of effects on endothelial cell proliferation, 
survival, migaration, vascular permeability and gene transcription. Signalling is thought to be 
negatively regulated by dephosphorylation of tyrosine residues by SHP-1 and SHP-2 tyrosine 
phosphatases though the specific residues involved in this have not yet been elucidated. VEGF – 
vascular endothelial growth factor; KDR – kinase domain receptor, human homologue of Flk-1; 
FAK-focal adhesion kinase; PI3K-phosphoinositide 3-kinase; PKB-protein kinase B; eNOS-
endothelial nitric oxide synthase; Shb-src homology 2 domain-containing transforming protein B; 
SHP -Src homology domain containing protein tyrosine phosphatase; Nck-non-catalytic region of 
tyrosine kinase adaptor protein; PLC-phospholipase C; DAG-diacyl glycerol; PKC-protein kinase 
C; VRAP-VEGF-receptor associated protein; MEK-MAP-ERK kinase; ERK1/2-extracellular-
related kinase-1 an 2 
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1.4.2.1 Phospholipase C 
Phospholipase C-γ is an SH2-containing protein activated upon phosphorylation by a 
receptor tyrosine kinase. Activated PLC-γ cleaves the membrane lipid 
phosphoinostiolbisphosphate (PI(3,4)P2) to form inositol triphosphate (IP3) and 
diacylglycerol (DAG) which is required for actvation of the novel protein kinase C 
(PKC) isoforms. IP3 induces calcium release from the endoplasmic reticulum, 
allowing activation of the classical PKC isoforms which are dependent upon both 
DAG and calcium for activation (Carpenter and Ji, 1999). Activation of PKCs leads 
to activation of downstream signalling pathways including MAPK signalling 
(Doanes et al., 1999; Gliki et al., 2001) and activation of eNOS (endothelial Nitric 
Oxide Synthase) (Lin and Sessa, 2006) which mediate proliferation and cellular 
permeability respectively. 
 
Activation of PLC-γ by KDR is thought to occur either via a direct SH2 interaction 
with between the lipase and the receptor, via an adaptor molecule or using both 
mechanisms. The main candidate tyrosine for a direct PLC-γ interaction is Y1175 
initially identified using adenovirally introduced point-mutated KDR into the NIH-
3T3 fibroblast cell line (Takahashi et al., 2001). Y951 has also been identified as a 
potential candidate for PLC-γ activation mediated via Y951 binding by the adaptor 
protein VRAP (VEGF Receptor Associated Protein, also known as TSad and 
Sh2d2a) (Matsumoto et al., 2005; Wu et al., 2000b). The identity of the PKC isoform 
activated downstream of PLC-γ has not been confirmed. Candidates include PKC-δ 
(Gliki et al., 2001; Kuriyama et al., 2004) PKC-α, and PKC-µ (PKD) downstream of 
PKC-α (Wong and Jin, 2005). 
1.4.2.2 Mitogen Activated Protein Kinase Signalling 
Mitogen Activated Protein Kinase signalling is transduced through 4 main pathways 
which respond to a combination of growth factors, mitogens and stress and transduce 
their signals through a phosphorylation cascade. The pathways of particular 
relevance in endothelial cells appear to be the VEGF activated Extracellular Related 
Kinase (ERK1/2) pathway (Boulton et al., 1991) and the VEGF and stress activated 
p38 MAPK pathway (Rouse et al., 1994) both of which are illustrated in Figure 1-16.  
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Figure 1-16 Illustration of the MAPK pathways activated by Flk-1 signalling in 
endothelial cells. MAP kinase signalling is organised in a three-tier hierarchy. Stimulation 
of a growth factor receptor (or in the case of p38 activation, stress) causes phosphorylation 
and activation of MAP kinase kinase kinase which in turn phosphorylates MAP kinase 
kinase activating it and enabling phosphorylation of the MAP kinase which mediates the 
biological response.  
1.4.2.2.1 ERK1/2 signalling 
Receptor tyrosine kinases typically activate the MAPK pathway through Grb2-Sos-
Ras-Raf. In the activated KDR receptor, however, the MAPK signalling pathway is 
reportedly activated through Protein kinase C (PKC), which is itself activated by 
PLC-γ (Doanes et al., 1999; Gliki et al., 2001) . KDR activation does activate Ras, 
possibly through the Shc-Grb-2 complex, but expression of a dominant negative Ras 
mutant does not inhibit MAPK activation despite inhibiting Ras mediated MAPK 
activation by other receptor systems in human umbilical vein endothelial cells 
(HUVECs) (Doanes et al., 1999).  Two structurally unrelated inhibitors of PKC 
(Calphostin and Bisindoylmalemide)  can block MAPK activity (Doanes et al., 1999; 
Gliki et al., 2001) though Bisindoylmaleimide is not selective at the concentration 
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used (5µM) and may have inhibited GSK-3α or β or Protein Kinase-A (PKA). 
Despite the apparent reliance of MAPK activation on PKC, a truncated Raf, lacking 
its kinase domain, also abrogated MAPK signalling in response to activation of 
KDR, indicating the Ras-Raf interaction still has a role to play in MAPK signalling 
through KDR (Doanes et al., 1999). In addition a study by Yashima et. al. 
demonstrated variation in the mechanism of MAPK activation between human cell 
sources. VEGF appeared to activate the MAPK pathway through a PKC-mediated 
mechanism in HUVECs and human aortic endothelial cells (HAECs), but in human 
subcutaneous microvascular endothelial cells (HMVECs) MAPK activation seemed 
dependent only on the classical Ras-Raf pathway (Yashima et al., 2001). A PKCδ 
inhibitor (rottlerin) inhibits MAPK signalling whereas Go6976, which inhibits 
PKCα, does not, indicating MAPK is at least partially activated by the delta form of 
PKC (Gliki et al., 2001). Although this is the first example of a receptor tyrosine 
kinase activating the MAPK kinase pathway through PKC, accompanied by a Ras-
Raf interaction, it does occur through other receptors including seven transmembrane 
Gαq G protein-coupled receptors (vanBiesen et al., 1996). 
1.4.2.2.2 p38 signalling  
KDR can activate the p38 MAPK pathway in endothelial cells leading to increased 
stress fibre formation and promoting migration (Yashima et al., 2001). Recently 
Lamilice et al., demonstrated that association of the adaptor proteins Nck and Fyn 
with phosphorylated Y1214 in KDR mediated activation of this pathway (Lamalice 
et al., 2006). 
1.4.2.3 Phosphoinositide-3-kinase signalling 
Phosphoinositides are a family of integral membrane lipids which can act as second 
messengers in cell signalling when phosphorylated at specific residues on their 
inositol rings. The phosphoinositide-3-kinases (PI3K) are a family of kinases which 
phosphorylate the 3’ position of the inositol ring. Phosphorylation of inositol lipids at 
this position allows binding and membrane localisation of proteins which contain a 
plekstrin homology (PH) domain such as Protein Kinase B (PKB) (Cantley, 2002; 
Vanhaesebroeck et al., 2001; Vanhaesebroeck and Waterfield, 1999). PI3K 
signalling is negatively regulated by the PTEN (Phosphatase and Tensin homolog) 
phosphatase. Mutation causing loss of PTEN activity causes constitutive activation 
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of the PI3K pathway leading to increased cell proliferation and decreased apoptosis. 
As PTEN is the most commonly lost tumour suppressor in human cancers, the PI3K 
pathway is of great interest as a drug target (Hennessey et al., 2005; Simpson and 
Parsons, 2001).  
 
 
Figure 1-17 Schematic of PI3K (class IA) signalling mediated by KDR in human adult 
endothelial cells. Ligand binding leads to activation of PI3K by an as yet unconfirmed 
mechanism possibly involving Shb. The most common PI3K product is PI(3,4,5)P3 which binds 
to the PH (pleckstrin homology) domain of PDK-1 localising it to the membrane where it 
phosphorylates and activates PKB/Akt. This intiates a phosphorylation cascade leading to the 
phosphorylation of downstream substrates including BAD,GSK-3,eNOS and mTOR. The 
mechanism of KDR-mediated PI3K involvement in migration is unresolved. PTEN-Phosphatase 
and tensin homologue; Shb-Src homology 2 domain-containing transforming protein B; PI3K-
phosphoinositide 3-kinase; p85-class IA PI3K regulatory subunit; p110-classIA PI3K catalytic 
subunit; PDK-1-Phosphoinositide-dependent kinase-1; PKB-Protein kinase B; BAD-BCL-
associated death promoter; GSK-1-Glycogen synthase kinase 3; mTOR-Mammalian target of 
rapamycin; eNOS-Endothelial nitric oxide synthase; p70S6K-p70S6 kinase; S6-S6 ribosomal 
protein. 
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PI3K signalling mediated through KDR activation (illustrated in Figure 1-17), has 
been demonstrated to play a role in cell migration via focal adhesions (Holmqvist et 
al., 2004), cell survival via Akt/PKB (Fujio and Walsh, 1999) and vascular 
permeability via eNOS activation (Bates and Harper, 2002; Fulton et al., 1999; Lin 
and Sessa, 2006).  
 
There are 3 classes of PI3Ks, characterised according to their substrate specificity 
and structural characteristics; 
 
Class I PI3K are heterodimeric, composed of a regulatory and a catalytic subunit. 
They preferentially phosphorylate phosphotidylinositide-4,5 bis-phosphate (PtdIns 
(4,5)P2) (Vanhaesebroeck and Waterfield, 1999). The class is further divided into 
Class IA and Class IB. Class IA signal downstream of tyrosine kinase receptors and 
are recruited to the receptor via the p55 or p85 SH2 domain-containing regulatory 
subunits. Catalytic activity is mediated by p110 α,β or δ catalytic subunits (Cantley, 
2002; Cantrell, 2001; Vanhaesebroeck et al., 2001; Vanhaesebroeck and Waterfield, 
1999). Class IB PI3Ks signal downstream of G protein coupled receptors. They are 
recruited to the receptor via the p101 regulatory subunit and kinase activity is 
mediated the p110γ catalytic subunit.  
Class II PI3K isoforms (α,β and γ) are activated downstream of polypeptide growth 
factor receptors, chemokine receptors and integrins. They are characterised by their 
C-terminal C2-domain which facilitates calcium-independent phospholipid binding 
and a phox homology (PX) domain which binds to PtdIns(3)P and PtdIns(3,4)P2 
tethering the classII PI3K to the membrane (Cantrell, 2001). 
Class III PI3K exist in a complex with a serine/threonine kinase. It phosphorylates 
only PtdIns (Cantrell, 2001).  
 
Research into the role of PI3Ks downstream of KDR/Flk-1 has focussed on the class 
IA PI3Ks. Phosphorylation of Y801and Y1175, in the cytoplasmic portion of Flk-1, 
has been demonstrated to be necessary for the activation of PI3K in a chimeric 
receptor construct. The construct contained the extracellular domain of human c-fms, 
fused with the transmembrane and intracellular domains of Flk-1, and was expressed 
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in porcine aortic endothelial cells (PAEs). Inhibition of the PI3K pathway in these 
cells with either wortmannin or rapamycin, or site directed mutagenesis of Y801 and 
Y1175, abrogates the chimeric receptors ability to stimulate cell growth implying 
that PI3K signalling downstream of Flk-1 is important for endothelial cell 
proliferation (Dayanir et al., 2001). More recently, work using the same PAE cell 
line but with a point mutation at Y1175 in the cytoplasmic tail of the chimeric 
receptor, demonstrated a decrease in Shb phosphorylation. Subsequent work in PAE 
cells expressing KDR demonstrated that decreasing Shb expression led to loss of 
stimulation of PI3K activity, in particular, PI3K-mediated migration. This suggests 
that a direct or indirect interaction between Y1175 in the cytoplasmic tail of the KDR 
receptor and Shb may potentiate PI3K signalling (Holmqvist et al., 2004). Like PLC-
γ, the p85 subunit of PI3K is able to bind the adaptor protein VRAP which binds to 
Y951 in the cytoplasmic tail of Flk-1. An associated with the adaptor protein Gab-1 
has also been reported (see section 1.4.2.4) suggesting that association with the 
adaptor proteins Shb and Gab-1 may be another route by which KDR mediates 
activation of PI3K (Matsumoto et al., 2005; Wu et al., 2000b). 
1.4.2.4 Other Flk-1 mediated signalling 
The activation of different signalling pathways by one receptor is often achieved 
through adaptor molecules. Gab-1 has recently been identified as one such important 
adaptor for KDR signalling. Following VEGF stimulation of Bovine Aortic 
Endothelial Cells (BAECs), Gab-1 phosphorylation increased and the protein co-
immunoprecipitated with Grb-2, Shc, PI3K, SHP-2 and PLC-γ. Additionally, siRNA 
knockdown of Gab-1 in human microvascular endothelial cells (HMVECs) 
demonstrated a decrease in VEGF stimulated phosphorylation of PLC-γ, ERK1/2, 
Src and PKB/Akt indicating functional involvement of Gab-1 in mediating signalling 
downstream of KDR (Laramee et al., 2007). 
 
Shear stress is an important mediator of vasculogenesis and angiogenesis. Yamamoto 
et al., demonstrated an upregulation and activation of Flk-1 on embryonic stem cells 
subjected to shear stress (Yamamoto et al., 2005).  Wang et al., demonstrated that 
both VEGF and shear stress could activate NFκB-mediated gene transcription via 
Akt/PKB-mediated activation of Iκβ kinase (IKK) which in turn phosphorylates Iκβ 
causing its degradation and the release and translocation to the nucleus of NFκB. In 
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this case Akt/PKB activation is thought to be mediated by a novel adaptor protein 
CBL (Casitas B-lineage lymphoma) (Wang et al., 2004). 
1.4.2.5 Flk-1 signalling during development  and in developmental 
models  
The importance of Y1173 (which has been demonstrated to bind PLC-γ, Shb and 
PI3K in KDR) was demonstrated in a knock-in mouse in which tyrosine 1173 
(Y1175 KDR) in the cytoplasmic tail of Flk-1 was substituted for a phenylalanine 
residue. The mutation resulted in early embryonic lethality at E8.5-9.5 resembling 
the Flk-1 knockout mouse suggesting that Y1173 is key in transducing Flk-1 
signalling at this time (Sakurai et al., 2005). Shb itself may also play an important 
role in development. An ES cell line expressing an SH2 mutant of Shb displayed a 
greatly decreased ability for blood vessel formation in an embryoid body model 
suggesting it plays a crucial role, at least in vitro, in the differentiation of vascular 
structures (Rolny et al., 2005). 
 
Little investigation of signalling downstream of Flk-1 during development has been 
performed. 30 minute VEGF stimulations of embryoid body-derived cells expressing 
Flk-1 demonstrated activation of the MAPK pathway, but not the PI3K pathway 
(Park et al., 2004). However, both pathways are known to be activated transiently by 
VEGF in adult endothelial cells and the VEGF-induced increase in phosphorylation 
of down-stream mediators in both pathways is often decreased or abolished by the 30 
minute time point making it difficult to draw definitive conclusions from this study 
(Bernatchez et al., 2001; Dayanir et al., 2001; Gerber et al., 1998; Takahashi and 
Shibuya, 1997). In zebrafish, inhibition of Flk-1 and Flt-1 with small molecule 
inhibitor 676475, greatly reduced ERK phosphorylation analysed using 
immunoblotting or whole-mount embryo immunostaining, suggesting a role for 
VEGF signalling in the activation of the MAPK pathway (Hong et al., 2006). 
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1.5 Aims 
There has been much research into KDR (human Flk-1) signalling in adults as KDR 
mediates VEGF-induced angiogenesis and is therefore important in a number of 
pathological conditions including cancer. The Flk-1 knockout in mice is embryonic 
lethal by E9.5 due to a lack of formation of vasculature or blood (Shalaby et al., 
1995; Shalaby et al., 1997) demonstrating that Flk-1 signalling also plays a key role 
in embryonic development, specifically development of the vasculature and blood. 
However, despite extensive knowledge of adult KDR signalling little is known about 
the signalling pathways activated by Flk-1, a receptor tyrosine kinase, during 
development, and the importance of these individual signalling pathways in 
haemopoietic and endothelial differentiation. The overall aim of this project was 
therefore to study the Flk-1 generated signals involved in ES cell differentiation to 
haemopoietic, endothelial and cardiomyocyte cell lineages.  Specific objectives of 
the project included: 
• Elucidation of the intracellular signals activated by VEGF, in murine ES 
cells, during differentiation. The signalling pathways of particular interest 
were those activated by VEGF in adult endothelial cells which include the 
MAPK pathway, the PI3K pathway and other signalling and adaptor 
molecules which associate with Flk-1 (Dayanir et al., 2001; Doanes et al., 
1999; Dougher and Terman, 1999; Gille et al., 2001; Gliki et al., 2001; Guo 
et al., 1995; Kroll and Waltenberger, 1997; Meyer et al., 2003; Takahashi et 
al., 2001; Wu et al., 2000a). 
• To use Flk-1 null ES cells and specific inhibitors to investigate the 
importance of various Flk-1-mediated signals in haemopoietic, endothelial 
and cardiac specification. 
• To generate an ES cell line upon the background of the Flk-1 null ES cell line 
(obtained from Professor William Stanford, University of Toronto) which 
conditionally express Flk-1. The aim was to use this cell line to investigate 
the temporal importance of Flk-1 in haemopoietic, endothelial and cardiac 
differentiation. 
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2.1 Cell lines and tissue culture 
2.1.1 Cell lines 
2.1.1.1 E14tg2A murine embryonic stem cell line 
The E14tg2A murine embryonic stem cell line (clone R63) was a kind gift of Dr. 
Owen Witte, UCLA, California (Era and Witte, 2000). The E14tg2A cell line is 
stably transfected with a tetracycline-regulated transactivator construct pCAG20-1. 
 
2.1.1.2 R1 embryonic stem cell line 
The R1 murine embryonic stem cell line was a kind gift of Professor William 
Stanford, University of Toronto, Ontario (Nagy et al., 1993) 
 
2.1.1.3 Flk-1-/- embryonic stem cell line 
The Flk-1-/- murine embryonic stem cell line was a kind gift of Professor William 
Stanford, University of Toronto, Ontario. Flk-1 /  ES cells were originally derived 
from Flk-1+/  cells which were produced from the R1 parentals by gene-targeting of 
the lacZ gene into the first exon of Flk-1 placing it under the transcriptional control 
of Flk-1 regulatory elements (Shalaby et al., 1995). Selection in high concentrations 
of G418  allowed generation of the homozygous knockout (Shalaby et al., 1997).  
  
2.1.1.4 D4T 
D4T is an embryonic stem cell derived endothelial cell line, a kind gift of Dr. 
Georges Lacaud, Paterson Institute, University of Manchester, UK. 
 
2.1.1.5 Human Umbilical Vascular Endothelial Cells (HUVECs) 
HUVECs were isolated by Dr. James Hewison, with appropriate ethical and parental 
consent, from human umbilical veins of new born babies (Jaffe et al., 1973). 
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2.1.1.6 OP9 
OP9 is a murine macrophage colony-stimulating factor-deficient bone marrow-
derived stromal cell line which is commonly used to support haemopoietic 
differentiation (Nakano, 1995). 
2.1.1.7 BaF/3  
An immortalised murine bone marrow derived pro-B cell line dependent on 
interleukin-3 (IL-3) for proliferation (Palacios and Steinmetz, 1985). 
 
2.1.2 Tissue culture 
All cells were maintained at 37°C in a humidified incubator with 5% (v/v) CO2. Cell 
counts were performed using a haemocytometer. 
2.1.2.1 Embryonic stem cell culture 
Embryonic stem cell lines (R1, E14tg2A and Flk-1-/-) were routinely cultured on 92 x 
17mm NUNC dishes coated with 0.1% (w/v) porcine gelatine in knockout 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 15%(v/v) 
knockout serum replacement, 2mM Glutamine, 50μM 2-mercaptoethanol, 1% non-
essential amino acids and 1000U/ml Leukaemia inhibitory factor (LIF), or 4ul/ml 
recombinant LIF conditioned media (batch tested in house in self-renewal and 
stimulation experiments) from the HEK293LIFV5 cell line (Park et al., 2003) 
generated by stable expression of a V5 epitope-tagged LIF gene in HEK293 cells (a 
kind gift of Dr. Konstantinos Anastassiadis, University of Technology, Dresden). 
0.1% (v/v) Hyclone serum (Perbio, Hyclone, UK) was used to supplement media of 
R1 and Flk-1-/- ES cells. The cultures were passaged by application of ~0.5ml 
Trypsin/Ethylenediaminetetraaceticacid (EDTA) for 5 minutes at 37°C and 
mechanical agitation to dissociate the cells. Cell passage was performed every two to 
three days to keep cell density sub-confluent (< 1.5x106 cells per dish) thus 
preventing differentiation. Cultures were passaged for no longer than 3 weeks 
(Paling et al., 2004). 
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2.1.2.2 D4T  
D4T cells were routinely cultured on T75 tissue culture flasks coated with 0.1% 
(w/v) porcine gelatine. They were maintained in Iscoves’ Modified Eagle Medium 
(IMDM) supplemented with 10% ES cell differentiation tested Foetal Calf Serum 
(FCS), 50ng/ml endothelial cell growth supplement (ECGS) and 150µM 
monothioglycerol (MTG). Cells were grown to confluence and passaged 1 in 3 by 
application of trypsin/EDTA and mechanical agitation. 
 
2.1.2.3 Human Umbilical Vein Endothelial Cells 
Human umbilical vein endothelial cells (HUVECs) were isolated by Dr. James 
Hewison from human umbilical veins of newborn babies by digestion with 
collagenase at 1mg/ml in Hanks Balanced Salt Solution (HBSS) for 45 minutes and  
cultured in endothelial cell growth medium for up to 4 passages . 
 
2.1.2.4 OP9 cells 
OP9 cells were cultured on NUNC tissue culture dishes in α-Modified Eagle Medium 
(α-MEM) supplemented with 20% (v/v) FCS, 2mM glutamine and 50µM 2-
mercaptoethanol. Cells were grown to confluence and passaged 1 in 4 by application 
of trypsin/EDTA and mechanical agitation. 
 
2.1.2.5 BaF/3 cells 
BaF/3 cells were cultured in non-tissue-culture treated plastic in RPMI 1640 medium 
supplemented with 10% (v/v) FCS, 20µM 2-mercaptoethanol, 100U 
penicillin/streptomycin, 2mM glutamine and 5-10% JWW3/WEH1 3B conditioned 
media cells as a source of IL-3. Cells were regularly passaged by serial dilution 
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2.1.3 Freezing/thawing cells 
For storage, cells were gently resuspended in cold freezing media as follows; 
 
Basic freezing media 
Glasgow modified eagle medium (GMEM) supplemented with 2mM glutamine, 
50μM 2-mercaptoethanol, 1% (v/v) non-essential amino acids, 1mM sodium 
pyruvate. 
 
ES cells: 1x106cells/ml in basic freezing media supplemented with 10% (v/v) 
dimethylsulphoxide (DMSO) and 10% ES screened foetal bovine serum (FBS)  
 
D4T cells: One confluent T75 flask into 3ml basic freezing media supplemented 
with 40% FCS and 10% DMSO 
 
OP-9 cells: 1x106/ml in basic freezing media supplemented with 40% FCS and 10% 
DMSO. 
 
BaF/3 cells: ≥ 2x106/ml in 90% FCS and 10% DMSO 
 
The cells were then aliquoted into 1ml nunc cryovials and placed at -80°C overnight 
before being transferred for long term storage in liquid nitrogen. For recovery, cells 
were thawed rapidly at 37ºC, gently resuspended in 10ml of appropriate growth 
media and pelleted at 1000r.p.m. (~140g) for 5 minutes in a Jouan CR412 centrifuge 
before resuspension in complete media.   
 
2.1.4 Screening cells for mycoplasma 
Mycoplasma are a relatively common bacterial contaminant of cultured cell lines. 
The bacteria have no cell wall and are therefore resistant to most antibiotics. They 
are difficult to visualise under the microscope due to their small size but their 
presence is deleterious and can skew experimental results (Macpherson, 1966). To 
detect any potential mycoplasma contamination cells were screened for mycoplasma 
using the Stratagene Mycosensor PCR assay kit. Briefly cell culture supernatant was 
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boiled with Stratagene resin to remove cell culture components such as metabolites 
and FCS. This boiled supernatant was then used as the PCR template in a PCR 
reaction (2.4.3.4) designed to amplify a 315bp band using a mycoplasma primer mix. 
Positive and negative controls and an internal control template were also included. 
The resultant products were run on a 2% agarose gel (2.4.2.3) to check for 
mycoplasma contamination. No mycoplasma contamination was found in any of the 
cell lines used in this study. 
 
Table 2-1Tissue culture consumables 
Product Supplier Cat. number 
Growth medium   
α-Modified Eagle Medium (α-MEM) Invitrogen, Paisley, UK. 22571-020 
Endothelial cell growth medium Promocell, Heidelberg, 
Germany. 
C-22010 
Glasgow’s Modified Eagle Medium 
(GMEM) 
Invitrogen 21710-025 
Iscove’s Modified Eagle Medium 
(IMDM) 
Invitrogen 21980-032 
knockout Dulbecco's Modified Eagle 
Medium (DMEM) 
Invitrogen,  10829-018 
RPMI 1640 Invitrogen 21875-059 
Medium supplements   
endothelial cell growth supplement  
(ECGS) 
R&D systems, Abingdon, 
UK 
231-BC-025 
ESGRO/LIF Chemicon, Hampshire, UK. ESG1106 
Fetal Calf Serum – BaF/3 Sigma, Dorset, UK.  
Fetal Calf Serum – D4T and OP-9 Invitrogen 16000-044 
lot#1168507 
200mM L-Glutamine Invitrogen 25030-024 
Hyclone Fetal Calf serum  - ES cells  Perbio, Hyclone, UK. SH30070.03E 
Knockout serum replacement Invitrogen 10828-028 
2-mercaptoethanol (2-ME) Bio-Rad, Hemel 
Hempstead  
Hertfordshire 
161-0710 
Monothioglycerol (MTG) Sigma M6145 
100X Non-essential amino acids (NEAA) Invitrogen 11140-050 
Penicillin/streptomycin Invitrogen 15140-122 
Porcine gelatin Sigma G1890 
Other reagents   
Collagenase type II Sigma C-6885 
DMSO Sigma D2650 
10 X Hanks Balanced Salt Solution 
(HBSS) 
Invitrogen 14060-040 
Mycosensor PCR kit Stratagene, Amsterdam, 
The Netherlands. 
302109 
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Phosphate Buffered Saline (PBS) Invitrogen 14200-067 
Trypsin/ Ethylenediaminetetraaceticacid 
(EDTA) 
Invitrogen 25200-072 
Tissue culture plastic ware   
15ml centrifuge tubes Greiner Bio-one (GBO), 
Gloucestershire, UK. 
188271 
50ml centrifuge tubes GBO 227261 
NUNC cryovials Fisher Scientific, 
Leicestershire, UK. 
CRY-960-
070B 
NUNC tissue culture dish 60 x 15mm Fisher  TKT-110-
010S 
NUNC tissue culture dish 92 x 17mm Fisher TKT-110-
070A 
NUNC T25 tissue culture flask Fisher TKT-130-
050P 
NUNC T75 tissue culture flasks Fisher TKT-130-
130R 
3ml Pasteur Pipettes GBO 612398 
Petri dishes 60 x 15mm GBO 628160 
Petri dishes 100 x 20mm GBO 664102 
10ml Pipettes, Sterile, Single Wrapped GBO 607180 
25ml Pipettes, Sterile, Single Wrapped GBO 760180 
150mm unplugged glass pipette Fisher FB50251 
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2.2  ES differentiation protocols 
The development of embryoid bodies (three dimensional aggregates of embryonic 
stem cells) mimics early embryogenesis and can be used to dissect the formation of 
particular cell lineages (see section 1.2.2 for additional detail). The main uses of 
embryoid bodies in this study are illustrated in Figure 2-1 below.  
 
 
Figure 2-1 Illustration of some of the models of development used during the study 
 
3.75 days 
10 days 
Embryonic stem cells Primary embryoid bodies Secondary blasts 
Hanging drops 
2 days 2 days 
‘none’ ‘few’ ‘many’ 
3-4 days 
Suspension culture 96 well cardiac assay 
2-6 days 
2 days 
Sprouting endothelial assay 
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2.2.1 Primary embryoid body culture 
The primary embryoid body formation protocol was adapted from Kennedy et. al., 
1997 and Keller et. al.,1993. The cytokines added have been shown to promote 
differentiation towards the mesodermal lineage. 
  
For formation of embryoid bodies ES cells were resuspended at 1 x 104/ml in IMDM 
and either 40% ES-Cult or 50% of the in house equivalent (2% methylcellulose plus 
1.2% sodium bicarbonate in IMDM). This was supplemented with 15% FCS 
screened for its ability to support ES cell differentiation to form secondary blast 
colonies (ES FCS), 200μg/ml holotransferrin (Kennedy et al., 1997), 450μM MTG, 
50μg/ml L-ascorbic acid (Kennedy et al., 1997; Robertson et al., 2000), 10μg/ml 
recombinant human insulin (Johansson and Wiles, 1995; Keller et al., 1993), 
10ng/ml basic fibroblast growth factor (bFGF) (Faloon et al., 2000) and 2ng/ml 
recombinant human Activin A (Faloon et al., 2000; Johansson and Wiles, 1995). The 
culture mixture was vortexed and aliquotted into 30mm petri dishes, two of which 
were incubated with one 30mm dish of water in a 100mm petri dish at 37ºC in a 
humidified atmosphere of 5% (v/v) CO2. 
 
2.2.2 Secondary blast formation 
Secondary blast formation is an expansion and further differentiation of the Blast 
Colony Forming Cell (BL-CFC) the in vitro equivalent of the haemangioblast, and as 
such can be used as a measure of its formation as well as a tool to further study 
mesodermal differentiation. A cell density of at least 5x104/ml is important for 
efficient blast formation though the presence of D4T conditioned media (Kennedy et 
al., 1997) does alleviate this to some extent. The stage at which embryoid bodies are 
dissociated and replated into the secondary blast assay is also important and differs 
between ES cells lines. It is important to dissociate primary embryoid bodies for 
replating of their constituent cells into the secondary blast assay during the narrow 
temporal window of BL-CFC formation which is marked by upregulation of Flk-1 
(Fehling et al., 2003; Huber et al., 2004). In E14tg2A cells this occurs between days 
3.5 and 4. 
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To expand mesodermal cells from the first round of embryoid body formation, day 
3.75 primary embryoid bodies were washed off the culture dishes with Phosphate 
buffered saline (PBS) then washed a further two times in 50ml of PBS at 1500r.p.m. 
(~350g) for 5 minutes to remove remaining methylcellulose. Embryoid bodies were 
then dissociated in 2ml of Trypsin/EDTA for 3 minutes at 37ºC and the 
Trypin/EDTA was neutralised with 2ml ES FCS. The cells were washed in PBS (5 
minutes at ~140g) before being re-suspended at 5x104/ml in IMDM with 40% ES-
Cult, 10% ES FCS, 25% D4T conditioned media, 450μM MTG, 5ng/ml recombinant 
murine vascular endothelial growth factor (mVEGF) (Kennedy et al., 1997), 
200μg/ml holotransferrin, , 25μg/ml L-ascorbic acid, and 5ng/ml recombinant murine 
interleukin-6 (IL-6) (Mikkola et al., 2003). The culture mixture was vortexed and 
aliquoted as before into 30mm petri dishes, two of which were incubated with one 
30mm dish of water in a 100mm petri dish at 37ºC in a humidified atmosphere of 5% 
(v/v) CO2. 
 
2.2.3 Sprouting endothelial assay 
The sprouting endothelial assay was performed using Stem Cell Technologies ES-
Cult Endothelial Collagen and Medium protocol. Firstly, ES cells were differentiated 
into embryoid bodies by seeding at 1.34 x 103/ml in IMDM supplemented with 40% 
ES-Cult, 15% ES FCS, 10µg/ml rh-insulin, 450μM MTG, 50ng/ml mVEGF, 
100ng/ml bFGF, 10ng/ml IL-6 and 2U/ml recombinant human erythropoietin (EPO). 
The mixture was aliquotted into 30mm bacterial Petri dishes in 1.5ml aliquots using 
a 2ml syringe and 18G blunt needle. Two Petri dishes were incubated with one 
30mm Petri dish of water in a 100mm bacterial Petri dish at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2. After 10-11 days the embryoid bodies were counted 
and gently washed off the dishes with IMDM. They were washed twice in IMDM 
(1000 r.p.m for 5 minutes) and resuspended at 2500EBs/ml in IMDM. 0.1ml of EBs 
was then added to 1.7ml of ES-Cult endothelial basal medium and 0.3ml of IMDM 
supplemented with 50ng/ml mVEGF, 100ng/ml bFGF, 10ng/ml IL-6 and 2U/ml EPO 
and gently swirled to mix. 1.2ml of collagen solution was added and pipetted to mix 
before 1.5ml was aliquotted into each of two 30mm bacterial Petri dishes using a 
p1000 Gilson pipette. As before two 30mm culture dishes were placed with one 
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30mm dish of water in a 100mm bacterial petri dish and incubated at 37ºC in a 
humidified atmosphere of 5% (v/v) CO2. 
 
2.2.4 Haemopoietic plaque assay 
The haemopoietic plaque assay was adapted from (Hidaka et al., 1999; Nakano et al., 
1994; Stanford et al., 1998). A 6 well dish of semi-confluent OP-9 cells was seeded 
with 1 x 104 undifferentiated ES cells per well in OP-9 medium (α-MEM 
supplemented with 20% (v/v) FCS, 2mM glutamine and 50µM 2-mercaptoethanol) 
and cultured at 37ºC in a humidified atmosphere of 5% (v/v) CO2 for 5 days to 
induce formation of mesodermal plaques. After 5 days trypsin/EDTA was added to 
dissociate the plaques (and OP9s). Following neutralisation of the trypsin/EDTA 
with ES FCS the cells were resuspended in OP9 medium and centrifuged for 5 
minutes at ~140g. The washed cells were plated onto 10cm NUNC dishes (3 x 10cm 
dishes/6well plate) and incubated for 30 minutes at 37ºC to allow adhesion of the 
OP-9s. Non-adherent cells were counted and replated at 1.2 x 105/well onto a fresh 6 
well dish of confluent OP9s for a further 7 days to induce differentiation of 
haemopoietic plaques. 
 
2.2.5 Cardiomyocyte assay  
The cardiomyoyte assay was adapted from (Sachinidis et al., 2003a) and a method 
provided by the FUNGENES EU consortium. ES cells were resuspended at 2.5 x 
104/ml in IMDM supplemented with 20% ES FCS and 450µM MTG. 20µl drops of 
the cell suspension were pipetted onto the lids of 100mm bacterial petri dishes which 
were then inverted and replaced on the petri dishes over 7ml of PBS. The dishes 
were incubated in a humidified incubator with 5% CO2 at 37ºC for two days. After 
two days the drops were aspirated off the lids of the petri dishes using a p1000 
pipette and re-plated in 10ml of fresh media in a 100mm bacterial Petri dish. 
Following a further two day incubation period, individual embryoid bodies were 
placed in fresh media into wells of a 96 well plate which were coated in 0.2% (w/v) 
gelatine. Individual wells were scored for the appearance of beating areas of cells 
indicative of cardiomyocyte formation daily from 2 to 6 days later. Media was 
changed as necessary. 
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Table 2-2 Differentiation protocol consumables 
Product Supplier Cat. number 
Growth media 
α-MEM Invitrogen 22571-020 
ES Cult endothelial collagen 
and medium 
Stemcell Technologies 
Inc, Canada. 
05810 
ES-Cult M3120 base 
methylcellulose 
Stemcell Technologies  03120 
1X IMDM Invitrogen 21980-032 
IMDM (powder) Invitrogen 42200-014 
Methylcellulose Sigma M0512 
Medium supplement   
rhActivin A R & D systems 338-AC-005 
L-ascorbic acid Sigma A4544 
bFGF Peprotech, London, UK. 100-18B 
rhEPO R & D systems 287-TC-500 
FCS Invitrogen 16000-044 (lot #1168507) 
200mM L-Glutamine Invitrogen 25030-024 
rmIL-6 Peprotech 216-16B 
rhInsulin Sigma 19278 
2-mercaptoethanol Bio-Rad 161-0710 
MTG Sigma M6145 
Sodium Bicarbonate Invitrogen 25080-060 
holo-transferrin Sigma T-0665 
mVEGF Peprotech 450-32B 
Other reagents 
Trypsin/EDTA Invitrogen 25200-072 
PBS Invitrogen 14200-067 
Tissue culture plastic ware 
18G blunt needle Fisher SZR-175-587L 
15ml centrifuge tubes GBO 188271 
50ml centrifuge tubes GBO 227261 
NUNC 6 well tissue culture dish Fisher TKT-190-110E 
NUNC tissue culture dish 92 x 
17mm 
Fisher TKT-110-070A 
3ml Pasteur Pipettes GBO 612398 
Petri dishes 30 x 10mm  Fisher PDS-140-170S 
Petri dishes 60 x 15mm GBO 628160 
Petri dishes 100 x 20mm GBO 664102 
Petri dishes ( non tissue culture) Fisher PDS-140-050F 
10ml Pipettes, Sterile, Single 
Wrapped 
GBO 607180 
25ml Pipettes, Sterile, Single 
Wrapped 
GBO 760180 
2ml syringe Central Stores  
150mm unplugged glass pipette Fisher FB50251 
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2.3 Inhibitors used in the study 
Details of inhibitors used to study signalling pathways activated by Flk-1 and their 
functional importance in in vitro differentiation protocols are given in table 2-3 
below. 
Table 2-3 Inhibitors used in study 
Inhibitor name and 
selected reference 
Target of 
inhibitor 
Inhibitor structure  Calbiochem 
catalogue 
number 
LY294002 
2-(4-morpholinyl)-8-
phenyl-4H-1benzopyran-4-
one 
 
(Vlahos et al., 1994) 
PI3K  440202 
U0126 
1,4-Diamino-2,3-dicyano-
1,4-bis(2-
aminophenylthio)butadiene 
 
(Favata et al., 1998) 
MEK1/2  662005 
PD98059 
2’Amino-3’-
methoxyflavone 
 
(Alessi et al., 1995) 
MEK1  513000 
Calphostin 
UCN-1028c 
 
(Kobayashi et al., 1989) 
PKC  208725 
O
O
CH3OH
CH3MeO
MeO
OH O
O
CH3
O
O
CH3 O
O
OH
O
O
O
N
O
O
NH2
OMe
NH2
S
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CN
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Gö6976 
12-(2-Cyanoethyl)-
6,7,12,13-tetrahydro-13-
methyl-5-oxo-5H-
indolo(2,3-a)pyrrolo(3,4-
c)-carbazole 
 
(Martiny-Baron et al., 
1993) 
PKCα, 
β1,β2, and 
PKD 
 36525 
VEGFR2 kinase 
inhibitor-1 
(z)-3-[(2,4-Dimethyl-
3(ethoxycarbonyl)pyrrol-
5yl)methylidenyl]indolin-
2-one 
 
(Sun et al., 1998) 
Flk-1  676480 
VEGFR2 kinase 
inhibitor-2 
z-5-Bromo-
3(4,5,6,7tatrahydro-1H-
indol-2-ylmethylene)-1,2-
dihydroindol-2-one 
 
(Sun et al., 2000) 
Flk-1   676485 
 
 
2.4 Biochemical and functional techniques 
2.4.1 Cell stimulation and preparation of cell extracts 
Dissociated embryoid bodies were stimulated with VEGF to allow investigation of 
Flk-1 (VEGF receptor 2) coupled signalling pathways using immunoblotting.  
Embryoid bodies were dissociated (see section 2.2.2), washed three times in PBS (5 
minutes at 1000r.p.m.) and re-suspended at 1-2x106/ml in Glasgow modified eagle 
media (GMEM/BHK-21) supplemented with 2mM Glutamine, 50μM 2-
mercaptoethanol, 1% (v/v) non-essential amino acids and 20mM HEPES. The cells 
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were serum starved for 3 hours at 37ºC then stimulated with 20ng/ml recombinant 
murine vascular endothelial growth factor (VEGF) (Peprotech) for appropriate time 
course at 37ºC. Following stimulation cells were pelleted at full speed (~20800 x g) 
in an eppendorf 5417R refridgerated microcentrifuge. The supernatent was aspirated 
and the pellet lysed in ~30-50μl per 106 cells of cold solubilisation buffer (50mM 
Tris-HCl pH7.5, 150mM Sodium Chloride, 1% (v/v) Nonidet P40, 10% (v/v) 
glycerol, 5mM EDTA, 1mM Sodium Vanadate, 1mM Sodium Molybdate, 10mM 
Sodium Fluoride, 40μg/ml Phenylmethylsulphonylfluoride (PMSF), 0.7μg/ml 
Pepstatin A, 10μg/ml Aprotinin, 10μg/ml Leupeptin, 10μg/ml soyabean trypsin 
inhibitor. The lysates were spun down for 2 minutes at full speed to pellet nuclear 
debris and the supernatants were stored at -20ºC. Where the effect of a small 
molecule inhibitor was under investigation this was added at the required 
concentration 30 minutes prior to stimulation. 
 
2.4.2 Bradford assay 
Protein concentrations in whole cell lysates were determined using the Bradford 
assay (Bradford, 1976) which utilises an absorption shift in Coomassie brilliant blue 
dye at 595nm when bound to arginine and hydrophobic residues in a protein. The 
relationship between this absorption shift and the amount of protein present is linear 
in the range 2-120µg/ml. Generation of a standard curve using between 2-12μg of 
BSA mixed well in 1ml of 1 in 5 Bradford Reagent was used to extrapolate protein 
concentrations in diluted whole cell lyates. 100μl of each sample was placed in 
duplicate wells of a clear, flat bottomed 96 well plate and read at 595nm using a 
Versamax microplate reader (Molecular Devices). Lysates were diluted as required 
to equalise sample concentrations determined by Bradford assay and boiled in SDS-
sample buffer (5X sample buffer; 10% SDS (w/v), 50% glycerol (v/v) 200mM Tris-
HCl pH 6.8, 5% 2-mercaptoethanol and ~ 2% bromophenol blue in milliQ water). 
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2.4.3 Protein resolution and immunoblotting 
2.4.3.1  Sodium-dodecyl-sulphate Polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE is a technique by which proteins are separated according to their mass 
and charge by application of a current. The protein sample  or cell extract is boiled in 
a buffer containing 2-mercaptoethanol which denatures quaternary structures and 
disulphide linkages and SDS, an ionic detergent which denatures the secondary and 
non-disulphide structures of the protein and coats the linearised protein. SDS binds at 
a rate of 1.4g SDS per 1g Protein which gives all SDS-bound proteins roughly the 
same charge to mass ratio, and hence allows separation of proteins by polypeptide 
size alone. The samples are loaded into a gel matrix containing a lower resolving gel 
and upper stacking gel in which the proteins are focussed into a single sharp band. 
The stacking gel is a non-restrictive large pore matrix with a pH of 6.8, that of the 
Tris-glycine reservoir buffer. At pH 6.8 glycine is weakly ionised and has low 
mobility but NaCl also present in the buffer is fully ionised and has greater mobility 
upon application of a current. The protein sample is of intermediate mobility. These 
differences in electrophoretic mobility allow formation of a NaCl/glycine boundary 
which migrates through the stacking gel concentrating the proteins into a focussed 
band. The small pore resolving gel has a pH of 8.8 at which glycine is strongly 
ionised and has greater effective mobility migrating through the proteins and 
allowing their separation (Laemmli, 1970). 
 
The gels were prepared using Bio-Rad’s mini Protean II and III gel electrophoresis 
equipment assembled according to the manufacturer’s guidelines. The percentage of 
acrylamide used in the resolving gel was dependent upon the size of the target 
protein/s (see Table 2-4 below): 
 
Table 2-4 Resolving power of differing acrylamide percentages in PAGE 
% acrylamide Size of target protein (kDa) 
6 60-250 
7.5 40-200 
10 25-200 
12 15-100 
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The resolving gel was prepared at the required percentage of acrylamide and ~ 4.5 ml 
was poured into the gel casting apparatus and carefully overlaid with ddH2O (for 
details of gel composition see Table 2-5). 
 
 
 
 
 
 
 
Table 2-5 Acrylamide resolving gel compositions 
% acrylamide Bis/Acrl (ml) Milli-Q H2O 
(ml) 
1M TRIS-
HCL pH 6.8 
(ml) 
10% (w/v) 
SDS (ml) 
6.0 3.0 6.35 5.6 0.25 
6.5 3.25 6.1 5.6 0.25 
7.0 3.5 5.85 5.6 0.25 
7.5 3.75 5.6 5.6 0.25 
8.0 4.0 5.35 5.6 0.25 
10 5.0 4.35 5.6 0.25 
12 6.0 3.35 5.6 0.25 
15 7.5 1.85 5.6 0.25 
 plus 50μl 10% (w/v) Ammonium persulphate (APS) and 20μl 
Tetramethylethylenediamine (TEMED) for acrylamide cross-linking reaction 
 
Following aspiration of the ddH2O from above the set resolving the stacking gel 
(1.67ml Acrylamide/Bisacrylamide solution, 6.0ml milliQ water, 1.25ml 1M Tris-
HCl pH 6.8, 0.15ml 10% (w/v) SDS plus 50μl 10% (w/v) APS and 20μl TEMED) 
was layered on top and a well forming comb inserted. Between 5 and 15μl of sample 
was loaded into each lane. 10μl of 1% (v/v) SDS-PAGE broad range molecular 
weight marker (biorad) made up in 1x SDS sample buffer and boiled was also loaded 
into one lane on each gel. The gels were run at 80mV to stack and 160mV to resolve 
in 1x running buffer (10x running buffer; 3%(w/v) Tris, 1%(w/v) SDS, 14.4% (w/v) 
glycine in milliQ water).  
2.4.3.2 Immunoblotting 
Immunoblotting or Western Blotting transfers protein from SDS-PAGE gels onto 
nitrocellulose paper to allow detection of proteins using dyes or antibody based 
detection systems (Burnette, 1981). 
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Following gel electrophoresis, the separated proteins were transferred onto 
nitrocellulose membranes by semi-dry transfer using the Pharmacia LKB Novoblot 
electroblotting equipment. The graphite electrodes of the semi-dry transfer apparatus  
were dampened with semi-dry transfer buffer (39mM glycine 48mM Tris base, 
1.3mM SDS, 20% (v/v) methanol in milliQ water) and the transfer sandwich was 
assembled on the lower electrode as follows;. four sheets of 8.5x5.2cm 3MM 
Whatman chromatography paper, nitrocellulose blotting membrane of the same size, 
the SDS-PAGE gel and finally four more pieces of Whatman paper all soaked in 
semi-dry transfer buffer. All air bubbles were expelled and transfer was performed at 
40mA/gel for 1 hour. Following transfer, the nitrocellulose was stained with Ponceau 
S solution to allow visualisation and marking of the SDS-PAGE broad range 
molecular markers on the blot. The Ponceau was rinsed off with Tris-buffered saline 
(TBS) (10x TBS; 1.5M NaCl, 0.2M Tris in 2l, pH7.5 with HCl) and the sites on the 
membrane which transferred proteins had not bound were ‘blocked’ with one of the 
following protein blocks for 1 hour on a rocker at room temperature; 5% block (5% 
(w/v) Bovine serum albumen (BSA), 1% (w/v) ovalbumen, 0.05%(w/v) sodium 
azide in TBS); 5% MARVEL powdered milk in TBS or 2% ECL advance blocking 
solution depending upon the antibody used on a rocker at room temperature. Excess 
block was washed off and blots were incubated with primary antibody at 4ºC for 3 – 
16 hours (see Table 2-6). 
 
 
Table 2-6 Antibody list 
Primary antibody 
Antibody Source Blocking conditions Diluent Dilution 
Incubation 
period 
(hours) 
Primary antibodies 
4G10 mouse 5% block 1% block 0.1µg/ml 3 
α-phospho-
ERK1/2 
rabbit 5% block 1% block 1:1000 16 
α- ERK1/2 Rabbit 5% block 1% block 1:1000 16 
α-phospho-  
Flk-1* 
Rabbit ECL advance  
block 
1% block 1:500 16 
α- Flk-1* Rabbit ECL advance  
block 
1% block 1:500 16 
α-phospho- Rabbit 5% block 1% block 1:1000 16 
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GSK-3α/β 
α- GSK-3β Rabbit 5% block 1% block 1:1000 16 
α-p85 (PI3K) rabbit 5% block 1% block 1:1000 3 
α-phospho-
PKB/Akt 
Rabbit 5% block 0.3% 
block 
1:1000 16 
α- PKB/Akt Rabbit 5% block 1% block 1:1000 16 
α-phospho- 
PKB/Akt 
substrate 
Rabbit 5% block 0.3% 
block 
1:1000 16 
α-phospho-PKC 
(pan) 
Rabbit 5% milk 
0.1% Tween 
3% block 1:1000 16 
α-SHP-2 Rabbit 5% block 1% block 1:2000 16 
α-phospho-S6 Rabbit 5% block 1% block 1:1000 3 
Secondary antibodies 
Mouse-HRP Goat - TBS, 
0.1% 
Tween 
1:10000 1-2 
Rabbit-HRP Goat - TBS, 
0.1% 
Tween 
1:20000 
(*1:5000) 
1-2 
 
The blots were then washed with one TBS wash followed by three TBST (TBS with 
0.05%v/v Tween) washes and a final TBS wash and incubated with an appropriately 
diluted horse radish peroxidase (HRP)-conjugated secondary antibody made up in 
TBSN (TBS with 0.05% (v/v) NP40) for 1-2 hours. The blots were washed as before 
with an additional final TBS wash to remove remaining detergent then developed in 
ECL or ECL advanced chemiluminescent solutions according to the manufacturers’ 
protocol. The resultant ECL signal was visualised by exposure of the membrane to 
Kodak X-AR5 film and developed in a dark room using a RGII Fuji X-Ray film 
developer. 
2.4.3.3 Stripping and re-probing immunoblots 
Blots to be reprobed with a different antibody were rinsed in TBS then stripped for 
45 minutes at 55ºC in stripping buffer (6.25% (v/v) 1M Tris-HCl pH 7.5, 2%(w/v) 
SDS, 0.77% (v/v) 2-mercaptoethanol). Following stripping blots were rinsed 
thoroughly in TBSN (2-mercaptoethanol waste was disposed of in the appropriate 
waste bottle) and blocked for 1 hour in used 5% block. The block was rinsed off and 
the blots were re-probed as before.  
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2.4.4 Fluorescence activated cell sorting (FACS) (flow 
cytometry) 
2.4.4.1 Overview of flow cytometry 
During this study flow cytometry was used for molecular analysis of cell surface 
expression of Flk-1. Flow cytometry utilises a focussed beam of laser light projected 
through a liquid stream of single cells or other particles. Photomultiplier Tubes detect 
fluorescence emission and scattering of the light by the cells and extrapolate their 
relative size, granularity and fluorescence. A standard flow cytometer is illustrated in 
Figure 2-2. 
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Figure 2-2 Diagram of a simple flow cytometer.  A stream of individual cells flows 
through a laser beam at up to 1000 cells (events) per second. Diffracted, refracted, reflected 
and emitted light is detected in photomultiplier tubes and the light signals are converted into 
electronic signals for analysis and interpretation. Adapted from ‘introduction to flow 
cytometry’ from Becton Dickinson online accessed 21st March 2007. 
http://www.bdbiosciences.com/immunocytometry_systems/support/training/online/ITF/
start.html. 
 
The basic physical properties of cell size and cell granularity or complexity are 
measured using the forward scatter (defracted light) and side scatter (refracted and 
reflected light) as illustrated in Figure 2-3. These properties can be used to separate 
different populations of cells in a mixed cell population (e.g blood).  
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Figure 2-3. Principles of forward scatter and Side scatter. Forward scatter is diffracted 
light detected along the axis of incident light which is related to cell surface area and thus 
cell size. Side scatter includes reflected and refracted light which is detected at 90º to the 
incident beam and is related to cell complexity and granularity. Adapted from ‘introduction 
to flow cytometry’ from Becton Dickinson online accessed 21st March 2007. 
http://www.bdbiosciences.com/immunocytometry_systems/support/training/online/ITF/
start.html 
 
The main use of flow cytometry is in the analysis of fluorescence. Types of 
fluorescence measured include autofluorescence, fluorescence of a fluorescently 
tagged protein (e.g. proteins tagged with Green Fluorescent Protein), fluorescence of 
a chemical bound to a component of the cell (e.g. propidium iodide or 7-
aminoactonomycin-binding to DNA to allow analysis of the cell cycle) or 
fluorescence of a fluorochrome-linked antibody bound to its specific antigen. In this 
study fluorochrome labelled antibodies were used for molecular analysis of cell 
surface expression of the receptor tyrosine kinase, Flk-1. Figure 2-4 illustrates the 
mechanism of detection of fluorescent molecules.  
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Figure 2-4 Mechanism of fluorescence analysis in flow cytometry. The fluorochrome 
absorbs the energy of the laser and releases it as heat, vibration and photons of a longer 
wavelength (in the case if fluoroscein 520nm) which is detected by a photomultiplier tube. 
Adapted from ‘introduction to flow cytometry from Beckton Dickenson online accessed 21st 
Marchm2007.thttp://www.bdbiosciences.com/immunocytometry_systems/support/traini
ng/online/ITF/start.html 
 
Emitted fluorescence from each cell is converted from a detector current pulse to a 
voltage pulse which is converted to a log value proportional to its intensity. These 
values can be displayed in a number of ways, most frequently as either a dot plot  or 
contour plot displaying two parameters against each other (e.g. forward scatter vs. 
side scatter) or as a histogram plot in which one parameter is plotted against its 
frequency (e.g. fluorescence). In the case of fluorochrome-labelled antibodies the 
fluorescence intensity is proportional to the degree of antigen expression. To control 
for non-specific binding of antibody to the cells an isotype matched control antibody 
with no specificity for the cell type under study is incubated separately. 
 
In addition to the analysis of cell populations flow cytometry can also be used to sort 
populations based on their physical characteristics or fluorescence. The target 
population is selected using computer software and cells of interest are then given a 
charge. When they pass through positively and negatively charged deflector plates 
they are deflected out of the stream allowing collection and further analysis 
HO O
COOH 
Cell 
Antigen 
Antibody 
Fluorescein 
molecule 
Incident light  Emitted light 
λ = 488nm (Blue laser) λ = 520nm (FL1) 
Heat energy Vibration 
Chapter 2 – Materials and methods 
 81
2.4.4.2 Flow cytometry methods used in study 
2.4.4.2.1 Analysis of Flk-1 expression 
Embryoid bodies or blasts were dissociated using the same protocol as for secondary 
blast formation. Approximately 0.5x106 cells per sample were aliquotted into 1.5ml 
eppendorf tubes and washed twice in cold FACS block (5% (v/v) FCS, 0.02% (w/v) 
sodium azide in PBS) (30s at low speed in a refrigerated micro centrifuge) before 
being re-suspended in 100μl of cold FACS block and incubated with 1μg/ml of 
blocking antibody (α-mouseCD16/CD32 FcγIII/II receptor) for 15 minutes on ice. 
5μg/ml of primary antibody (α-mouseFlk-1) or isotype control antibody (rat IgG2aκ) 
was then added and cells were incubated on ice for 30-60 minutes. The cells were 
then washed twice in 1ml FACS buffer and re-suspended in 100μl FACS buffer with 
1μl of the secondary antibody, (fluoroscein isothiocyanate) FITC labelled rabbit-α-
rat and incubated on ice for a further 30 minutes. The samples were washed three 
times, re-suspended in 500μl of FACS buffer and transferred to FACS tubes. 1μg/ml 
of the vital dye 7-Aminoactinomycin-D (7AAD) was added to each tube. Live cells 
were gated on FL3 and 10000 live events were counted to look for an FL1 shift 
between control and Flk-1 stained cells. FACS was performed on the FACSVantage 
and FACSCanto and analysis was performed using CellQuest. 
2.4.4.2.2 Analysis of apoptosis using DiOC6 staining 
DiOC6 is a vital dye which specifically stains mitochondria in a membrane integrity 
dependent manner. Loss of mitochondrial membrane potential is an early irreversible 
event in apoptosis therefore loss of DiOC6 staining is indicative of apoptosis 
(Rottenberg and Wu, 1998). 
  
Cells were dissociated using trypsin and washed in PBS. The cells were resuspended 
in 1ml PBS and 2μl of a 50μM DiOC6 (made up in DMSO) was added. The cells 
were incubated in the dark at room temperature for 30 minutes, washed once and 
then subjected to analysis using the Becton Dickinson FACs Vantage for 
fluorescence on parameter FL1.  
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Table 2-7 Biochemical and functional techniques consumables 
Product Supplier Cat. Number 
Cell stimulations and preparation of cell extracts 
Aprotinin Roche Biochemicals, 
Burgess Hill, UK. 
236624 
Bromophenol blue BD electran 44305 
Bradford reagent Bio-Rad 500-0006 
EDTA Sigma E5134 
Glasgow’s Modified Eagle 
Medium 
Invitrogen 21710-025 
200mM L-Glutamine Invitrogen 25030-024 
Glycerol Sigma G5150 
1M Hepes Invitrogen 15630-056 
Leupeptin Sigma L8511 
2-mercaptoethanol Bio-Rad 161-0710 
100X NEAA Invitrogen 11140-050 
Nonidet P40 VWR, Leicestershire, UK. 560092-L 
Pepstatin Sigma P5318 
PMSF Sigma H0891 
Protein Sepharose A Amersham/GE 
Healthcare, 
Buckinghamshire, UK. 
17-0780-01 
Protein Sepharose G Amersham/GE Healthcare 17-0618-01 
Sodium Chloride Sigma S7653 
SDS VWR 442444-H 
Sodium Fluoride Sigma S6521 
Sodium Molybdate VWR 102542-Q 
Sodium Vanadate Sigma S6508 
Soybean Trypsin inhibitor Sigma T9003 
Trizma base  Sigma T8404 
mVEGF Peprotech 450-32B 
Protein resolution and immunoblotting 
30% Acrylamide/Bis 
37.5:1 
Bio-Rad 161-0158 
Ammonium persuphate Sigma A7460 
Antibodies 
4G10 anti-pY UBI, USA 05-321 
α-phospho-ERK1/2 Cell Signaling 
Technologies, 
Hertfordshire, UK. 
9101S 
α- ERK1/2 Santa Cruz sc-93 
α-phospho-  Flk-1*      
(Tyr 1175) (19A10) 
Cell Signaling 2478 
α- Flk-1* (55B11) Cell Signaling 2479 
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α-phospho-GSK-3α/β Cell Signaling 9331 
α- GSK-3β Cell Signaling 9315 
α-p85 (PI3K) UBI 06-195 
α-phospho-PKB/Akt Cell Signaling 9271 
α- PKB/Akt Cell Signaling 9272 
α-phospho- PKB/Akt 
substrate 
Cell Signalling 9611 
α-phospho-PKC (pan) Cell Signaling 9379 
α-SHP-2 (C18) Santa Cruz, UK sc-280 
α-phospho-S6 Cell Signaling 2211 
Bovine Serum Albumen 
(BSA) 
Roche Biochemicals 735-108 
ECL Amersham/GE Healthcare RPN-2106 
ECL advance Amersham/GE Healthcare RPN-2135 
Gel  loading tips GBO 770280 
Glycine Sigma G8790 
Methanol Fisher M-4056-17 
2-mercaptoethanol Bio-Rad 161-0710 
Nitrocellulose VWR 43610-6D 
Ovalbumen Sigma A5378 
Ponceau S Sigma P7170 
Sodium azide Fisher S-2380-48 
Sodium Chloride Sigma S7653 
SDS VWR 442444-H 
TEMED Sigma T9281 
96 well tissue culture plate 
– flat bottomed 
GBO 655-180 
Trizma base  Sigma T8404 
3MM Whatman paper VWR 3030917 
Flow cytometry 
7AAD Sigma A9400 
DiOC6 Calbiochem 305110 
FACs tubes BD Biosciences 6297461 
FITC-conjugated rabbit α-
rat 
Dako cytomation systems, 
Cambridgeshire, UK. 
F0234 
Phosphate Buffered Saline 
(PBS) 
Invitrogen 18912-014 
Sodium azide Fisher S-2380-48 
Rat α-mouse CD16/CD32 
(FcγIII/II receptor) 
(Mouse Fc block) 
BD Pharmingen, Oxford, 
UK. 
553142 
Rat α-IgG2ακ (isotype 
control) 
BD Pharmingen 553927 
Rat α-mouse Flk-1 BD Pharmingen 555307 
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2.5 Molecular Techniques 
2.5.1 Expansion and purification of plasmid DNA 
2.5.1.1 Preparation of competent Eschericia Coli strain DH5α 
A glycerol stock of DH5α was streaked out onto a fresh 2YT agar plate (16g 
bactotryptone, 10g yeast extract, 10g NaCl, 15g bacto-agar made up to 1l and 
autoclaved) using good aseptic technique and grown inverted overnight at 37ºC. A 
colony off the plate was inoculated into 5ml of 2YT medium (without bacto-agar) 
and incubated overnight at 37 ºC with moderate agitation (~250 r.p.m). The 
following day the culture was diluted 1:100 in 100ml 2YT broth and grown at 37 ºC 
with moderate agitation until an Optical Density of 0.48 was reached. The culture 
was then chilled on ice for 5 minutes before centrifugation for 5 minutes at 1380g 
(3000r.p.m) in a Beckman RC5B with a JA14 rotor at 4ºC. The bacterial pellet was  
gently resuspended in 40ml of  solution TfbI (30mM KCl, 100mM RbCl, 10mM 
CaCl2, 50mM MnCl2 and 15% (v/v) glycerol adjusted to pH 5.8 with 0.2M acetic 
acid), chilled on ice for 5 minutes and   centrifuged at 1380g for 5 minutes at 4ºC.  
The supernatant was carefully removed and the smeared pellet was resuspended in 
4mls of TfbII solution (10mM MOPS, 75mM CaCl2, 10mM RbCl, 15% (v/v) 
glycerol adjusted to pH 6.5 with KOH) and incubated on ice for 15 minutes. 
Working aliquots were snap frozen in a dry-ice/ethanol bath and stored at -80ºC. 
 
2.5.1.2 Transformation of competent E.Coli 
Competent bacteria were thawed at room temperature and chilled on ice for 10 
minutes. Plasmid DNA was added at a concentration of <100ng/200µl cells, mixed 
gently and left on ice for 30 minutes. The bacteria were then heat shocked at 42ºC for 
90s and returned to ice for 2 minutes. 4 volumes of Luria-Bertani (LB) broth (10g 
bacto-tryptone, 5g yeast extract, 5g NaCl made up to 1l and autoclaved) were added 
and the bacteria incubated at 37ºC for 45 minutes. The required amount of bacteria 
(depending on expected transformation efficiency) were then plated out onto 2YT 
agar plates containing an appropriate antibiotic (ampicillin at 100µg/ml or 
kanamycin at 50 µg/ml). 
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2.5.1.3 Small-scale plasmid preparation (mini-preps) 
A single bacterial colony was picked and grown up in 3ml of 2YT or LB, with 
addition of an appropriate antibiotic, overnight, at 37ºC with vigorous shaking. 1ml 
of culture was removed to an eppendorf and pelleted by centrifugation at full speed 
for 1 minute in a microcentrifuge.  
The DNA was then extracted using either the Sigma Genelute plasmid mini-prep kit, 
following the manufacturer’s protocol, or by an alkaline lysis protocol.   
Alkaline lysis protocol 
The cell pellet was lysed in 100µl of solution I (50mM glucose, 10mM EDTA, 
25mM Tris-HCl pH8.0). The chromosomal DNA and cell debris were then 
precipitated in 200µl of fresh solution II (0.2M NaOH, 1% (w/v) SDS) and 150µl of 
ice cold solution III (3M potassium acetate, 11.5% glacial acetic acid). The cell 
debris were pelleted at full speed in a refridgerated microcentrifuge at 4ºC and the 
plasmid DNA extracted using phenol:chloroform extraction and ethanol 
precipitation. (2.4.1.5 and 2.4.1.6) 
Sigma Genelute protocol 
The cell pellet was resuspended in 200µl of resuspension solution containing RNase 
and lysed by addition of 200µl of lysis solution with gentle inversion. This solution 
was left to clear for 5 minutes then neutralised by addition of 350µl of neutralisation 
solution which caused precipitation of chromosomal DNA and cell debris. The cell 
debris was pelleted by centrifugation at full speed in a microcentrifuge. The cleared 
lysate containing the plasmid DNA was transferred to the pre-equilibrated binding 
column and centrifuged for 30s at ≥12000g. The column was then washed in optional 
wash solution (medium salt buffer) followed by wash solution (70% ethanol) to 
ensure removal of contaminants before being eluted in 50-100µl of autoclaved 
milliQ water and stored at - 20ºC. 
 
2.5.1.4 Large scale plasmid preparation (midi or maxi prep) 
The Qiagen midi-prep and maxi-prep kits were used following the manufacturers 
protocols to purify large amounts of ultra-pure supercoiled plasmid for use in 
applications such as transfection and sequencing. Briefly, a fresh bacterial culture 
was grown overnight at 37ºC with vigorous shaking in LB or 2YT with appropriate 
antibiotic selection. Bacteria were harvested by centrifugation at 6000 x g for 15 
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minutes at 4ºC in a Sorvall RC5B centrifuge with a JA14 rotor. Plasmid purification 
was performed using a modified alkaline lysis protocol followed by binding of 
plasmid DNA under low salt and appropriate pH conditions to a Qiagen anion 
exchange resin column. Impurities such as RNA and protein were removed in a 
medium salt wash. A high salt buffer was used to elute plasmid DNA which was then 
concentrated and desalted in an isopropanol precipitation, resuspended in autoclaved 
milliQ water and stored at -20ºC.  
 
2.5.1.5   Phenol chloroform extraction  
DNA in solution was extracted with an equal volume of buffer saturated 
phenol:chloroform (1:1) and centrifuged for 1 minute at full speed (~20000g) in a 
microcentrifuge. The upper aqueous phase was removed into a fresh tube and 
extracted with an equal volume of chloroform. This was again centrifuged at full 
speed for 1 minute and the upper aqueous phase was again removed into a fresh tube. 
DNA was then extracted by ethanol precipitation. 
 
2.5.1.6 Ethanol precipitation 
0.1 volume of 3M sodium acetate and 2 volumes of 100% ethanol were added to the 
DNA containing solution and mixed thoroughly. The tube was incubated in a dry-ice 
ethanol bath until frozen then thawed briefly and spun at full speed (~20000g) in a 
microcentrifuge for 10 minutes. The ethanol was aspirated and the pellet washed 
with 70% ethanol. This ethanol was aspirated (in a class 2 tissue culture hood if it 
was to be used for transfections) and the pellet was left to dry. Once dry the pellet 
was resuspended in an appropriate volume of autoclaved Tris-EDTA (TE) buffer 
(10mM Tris-HCl pH 8.0, 0.1M EDTA pH 8.0) or autoclaved milli-Q water and 
stored at -20ºC. 
 
2.5.1.7 Quantification of DNA 
DNA was quantified using a GeneQuant II spectrophotometer which measured 
absorbance at 260nm and 280nm and calculated DNA concentration as follows: 
Concentration of DNA (µg/ml) = Dilution factor x 50* x A260 
* The standard consideration that 1.0 A260 dsDNA = 50µg/ml 
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The A260 /A280 ratio can used as a guide to DNA purity. A ratio of >1.8 indicates 
little protein contamination. However, this ratio is pH sensitive and can often be 
unreliable if water is used as the diluent. 
 
2.5.2 Manipulation and analysis of DNA  
2.5.2.1 Restriction enzyme digest 
Restriction enzyme digests were performed to linearise plasmids, remove a target 
sequence from a plasmid, create compatible cohesive ends for ligation or as a 
diagnostic tool for analysis of ligation products. Digests were performed using 
restriction enzymes supplied by New England Biolabs provided with the appropriate 
10x buffer and 100x BSA (10mg/ml) if required. The standard restriction enzyme 
digest was carried out in 25µl and contained 1-5µg of DNA, 2.5µl of 10X buffer and 
2.5µl of 1mg/ml BSA (when necessary) made up to 24µl with autoclaved milli-Q 
water, to which 1µl of restriction enzyme was added. The digest was then incubated 
at 37ºC for 1-16h. Total reaction volume, amounts of DNA and restriction enzyme 
and incubation temperature and duration varied depending upon the utility of the 
digest, the star activity of the enzyme and the activity of the enzyme being utilised. 
Reactions were stopped were possible by heat activation, or by phenol chloroform 
extraction. Certain restriction enzymes were used together in double-digests. In these 
cases a chart provided by NEB advised of the most suitable buffer/BSA combination. 
Some restriction enzymes were active in PCR buffer allowing removal of a 
purification step during cloning.  
2.5.2.2 Ligation 
Ligation is the joining of linear DNA fragments by formation of phosphodiester 
bonds between 5’ and 3’ hydroxyl termini in duplex DNA catalysed by T4 DNA 
ligase. Prior to ligation both vector and insert were digested by restriction enzymes to 
create compatible ‘sticky’ or ‘blunt’ ends (2.4.2.1). When a single restriction enzyme 
had been used to cut the vector it was then treated with 1µl of calf intestinal alkaline 
phosphatase for 10 minutes at 37ºC to remove the 5’ phosphoryl termini and prevent 
self-ligation of the vector. This reaction was stopped by addition of 1µl of 0.5M 
pH8.0 EDTA. Both insert and vector were gel purified (2.4.2.4) and quantified 
relatively by running on an agarose gel (2.4.2.3), or absolutely via spectrophotometry 
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(2.4.1.7). Ligations were carried out in 20µl volumes containing 2µl 10x T4 DNA 
ligase buffer (50mM Tris-HCl, 10mM MgCl2, 10mM DTT, 1mM ATP, 25µg/ml 
BSA, pH7.5), 100ng of vector, insert, autoclaved milliQ to 18µl and 2µl of T4 DNA 
ligase. Ligations were incubated at 16ºC overnight. Sticky end ligations were 
performed using a 2:1 molar ratio of insert to vector for small inserts and a 4:1 molar 
ratio for larger inserts. Blunt ended ligations were performed with a large excess of 
insert over vector. Absolute amounts of DNA required were calculated using the 
following formula: 
Insert (ng) = N x [(vector (ng) x size of insert (kb)) / size of vector (kb)] 
Were N =  molar ratio of insert to vector 
Control ligations in which ligase, vector or insert were lacking were also performed.  
 
2.5.2.3 Agarose gel electrophoresis 
Agarose gels were used in the analysis of DNA and the purification of DNA 
fragments.  An appropriate quantity of agarose (see table 2-7) was dissolved by 
boiling in Tris-acetate EDTA (TAE) buffer (50 x stock; 242g Tris, 57.1ml glacial 
acetic acid, 100ml 0.5M EDTA pH 8.0). Once cooled, the agarose gel was poured 
into pre-assembled agarose gel tank and a well forming comb was inserted. The set 
gel was placed in an electrophoresis chamber and samples made up in DNA loading 
buffer (6 x loading buffer; 30% (v/v) glycerol, 0.05% (w/v) bromophenol blue) were 
loaded. Electrophoresis was performed at 70-90V for the desired time. The gel was 
stained for 5 minutes in ~0.5µg/ml ethidium bromide in TAE and visualised and 
photographed using a Syngene UV transluminator and Genesnap software.  
 
Table 2-8 Resolving power of differing agarose percentages 
% gel Optimum Resolution for Linear DNA (kb) 
0.5 30 to 1.0 
0.7 12 – 0.8 
1.0 10 to 0.5 
1.2 7 – 0.4 
1.5 3 – 0.2 
2.0 1.5 – 0.05 
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Table 2-9 Plasmids used in this study (maps in Appendix) 
Plasmid Derivation Use 
pcDNA3.1Zeo 
(Invitrogen) 
Mammalian expression 
plasmid containing the CMV 
early immediate promoter and 
Ampicillin and Zeocin 
resistance genes. 
Tractable vector used for 
initial cloning of Flk-1. 
pcDNA3.1Zeo-Ms 
Flk-1 
The Murine Flk-1 sequence 
ligated into pcDNA3.1zeo 
using the XbaI restriction site 
Used to check viability of 
cloned Flk-1 sequence in 
BaF/3 cell line and for 
sequencing. 
pCAGGS-irtTA-
VP16-IRES-puro 
(Anastassiadis et 
al., 2002) 
Reverse Tetracycline 
transactivator with puromycin 
resistance gene. 
Enables regulated expression 
by addition of doxycycline of 
genes expressed in the tet 
response plasmid. 
pKS-TetTK-pA 
(Anastassiadis et 
al., 2002) 
Bluescript vector modified to 
encode tet operators, a 
thymidine kinase (TK) 
promoter and polyA tail.  
Used for insertion of Flk-1 
sequence into TetTK-pA. 
pKS-TetTK-flk-1-
pA 
Flk-1ligated into pKS-TetTK-
pA using the SpeI restriction 
site 
Used to insert TetTK-Flk-1-pA 
sequence into Inshygro vector. 
pKS-Δp85-TetTK-
pA 
Myc tagged p85 subunit 
lacking the binding site for 
the catalytically active p110 
component of PI3K ligated 
into pKS-TetTK-pA. 
To determine the presence of 
functional tetracycline 
transactivator in stably 
transfected R1 ES cells using 
transient tranfection.  
pAcΔPHAkt-GFP-
N1 
pACGFP-N1 vector 
(Clontech) expressing GFP 
tagged Akt PH domain non-
lipid binding mutant 
Optimising transient 
transfection of  R1 ES cells 
using flow cytometry to detect 
GFP expression 
pInshygro 
(Anastassiadis et 
al., 2002) 
Expression vector containing 
4 chicken β-globin chromatin 
insulators flanking the 
multiple cloning site and a 
hygromycin resistance gene. 
Insulators thought to block 
inappropriate action of 
regulatory elements reducing 
likelihood of mosaic 
expression. Hygromycin 
resistance enables selection. 
pInshygro-TetTK- 
Flk-1-pA 
TetTKFlk-1-pA blunt end 
ligated into the multiple 
cloning site of the SnaB1 
digested Inshygro plasmid 
Construct linearised and 
transfected into Flk-1-/- R1 ES 
cells stably expressing 
CAGGS-irtTA-VP16-IRES-
puro 
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2.5.2.4 Gel purification 
DNA fragments excised from agarose gels under UV were purified using a Qiaquick 
gel extraction kit. Briefly, the gel was solubilised at 50ºC buffer QG, loaded onto a 
Qiaquick silica column and spun down. The flow through was discarded and the 
column washed once with buffer QG and once with buffer PE, an ethanol containing 
wash buffer. DNA was eluted in 30-50µl of autoclaved milli-Q water.   
 
2.5.2.5 Sequencing 
Mini-prepped plasmid DNA and sequencing primers were sent to the sequencing 
facility in the South Building, University of Bath or the sequencing facility in the 
Biochemical department at Oxford University. Sequence analysis was performed 
using the Chromas and Sequencher programs.   
 
2.5.3 Cloning and expression analysis 
2.5.3.1 RNA extraction 
RNA extraction was performed for either relative expression analysis or cloning of 
genes of interest. 1-10 x 106 cells were lysed in 1ml of Trizol in a 1.5ml eppendorf 
tube and incubated for 5 minutes at room temperature. For embryoid bodies an 18G 
blunt needle on a 2ml syringe was used to aid homogenisation. 200µl of chloroform 
was added and the tube was vigorously shaken for 15s. After 2-3 minutes incubation 
at room temperature to allow separation of the two phases centrifugation was 
performed at full speed (~20000g) for 15 minutes at 4ºC. The upper aqueous phase 
was transferred to a sterile eppendorf and the RNA was precipitated by addition of 
0.5ml of isopropanol and incubation on ice for 10 minutes. This was followed by a 
10 minute full speed centrifugation step at 4ºC to pellet the precipitated RNA. The 
RNA pellet was washed in 70% ethanol and centrifuged for 5 minutes at 4 ºC. The 
ethanol was aspirated and the pellet left to air dry before being resuspended in 20-
100µl of autoclaved milli-Q water and incubated for 10 minutes at 55ºC to denature 
secondary structure and aid solubilisation of RNA. RNA was stored at -80ºC. 
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2.5.3.2 RNA quantification 
RNA was quantified using the GeneQuant II following the same protocol for DNA 
quantification according to the standard consideration; 
1.0 A260 RNA = 40µg/ml 
If RNA integrity was in question it was checked by running an aliquot of RNA on an 
agarose gel using gel electrophoresis equipment rendered RNAse free by washing in 
3% H2O2. Non-degraded RNA runs in two sharp bands 28s and 18s with the 28s 
band being approximately twice as intense in non-degraded RNA. 
 
2.5.3.3 Reverse Transcription- Polymerase Chain Reaction (RT-PCR) 
RT-PCR utilises reverse transcriptase to synthesise cDNA for amplification in the 
polymerase chain reaction (PCR) from mRNA of expressed genes.  
When RT-PCR was used to produce cDNA from which a full length clone would be 
amplified 50ng of random primers and 1mM dNTPs were mixed with 2µg of RNA in 
17µl total volume, incubated at 65ºC for 5 minutes then immediately chilled on ice 
for 2 minutes. 4µl of first strand sample buffer, 1µl of RNasin and 5mM DTT were 
then added and the reaction was mixed well and incubated at room temperature for 2 
minutes. 1µl (200 units) of superscript II or superscript III reverse transcriptase was 
then added. A duplicate reaction mix containing no reverse transcriptase was 
included for each sample to control for expansion of contaminating genomic DNA 
contamination. Reverse transcription took place as follows in a Techne Touchgene 
gradient PCR machine:  
25º C     10 minutes 
42ºC (50ºC for Superscript III) 50 minutes 
70ºC     15 minutes 
4 ºC     hold 
1µl of Ribonulease H was added to each reaction and incubated at 37ºC for 20 
minutes to specifically degrade the RNA strand of any RNA:DNA hybrids. 
 
When RT-PCR was used to produce cDNA for expression analysis it was first DNase 
treated prior to RT-PCR to remove any contaminating genomic DNA. 1µg of RNA 
was incubated in an 11µl reaction volume with 1µl of 10X DNase buffer and 1µl of 
DNase at 37ºC for 30 minutes. The enzyme was denatured by addition of 1µl of 
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DNase stop solution (0.5M pH8.0 EDTA) and incubation at 65º for 10 minutes. 
0.5ng of oligo-dT was added, mixed well and incubated at 65ºC for 5 minutes.  4µl 
of first strand sample buffer, 1µl of RNasin, 5mM DTT and 500µM dNTPs were 
then added and the reaction was mixed well. Finally 1µl of superscript II was added 
and reverse transcription was performed at 42ºC for 50 minutes followed by a 15 
minutes 70ºC inactivation step in a Techne Touchgene gradient PCR machine. 
Duplicate minus reverse transcriptase reactions were also performed and cDNA was 
stored at -20ºC. 
 
2.5.3.4 Polymerase Chain Reaction (PCR) 
PCR is an enzymatic method for replicating DNA allowing a small amount of DNA 
to be amplified exponentially.  
 For amplification of cDNA for expression analysis the Thermus aquaticus- Taq 
DNA polymerase which has a high amplification rate but low proof reading activity 
was used. 1µl of cDNA from a reverse transcription reaction was amplified in 
Magnesium free buffer (10mM Tris-HCl pH 9.0, 50mM KCl, 0.1% Triton X-100) 
containing 250µM dNTPs, 5pmol of both sense and antisense primers, 2mM MgCl2 
and 0.1µl Taq in a 20µl reaction under the following conditions in a Techne 
Touchgene gradient PCR machine; 
 
Initial denaturation    94 ºC for 5 minutes 
20-40 cycles Denaturation   94ºC for 30s 
  Annealing*   XºC for 30s 
  Elongation   72ºC for 1 minute 
Final elongation    72ºC for 5 minutes 
      4ºC hold 
 
For amplification of cDNA for cloning a proof reading polymerase with higher 
fidelity but a lower amplification rate was used. The Pyrococcus furiosus Pfu proof 
reading polymerase was used most commonly though Pfx, accurase and KOD hot 
start proof reading enzymes were also used. 5µl of cDNA from a reverse 
transcription reaction was amplified in Pfu polymerase reaction buffer (20mM Tris-
HCl pH 8.8, 10mM KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% Triton X-100, 
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0.1mg/ml nuclease free BSA) containing 200µM dNTPs, 12.5pmol of both sense and 
antisense primers and 1µl of Pfu in a 50µl reaction volume under the following 
conditions in a Techne Touchgene gradient PCR machine; 
Initial denaturation   94ºC for 5 minutes 
40 cycles Denaturation  94ºC for 30s 
  Annealling*  XºC for 30s 
  Extension  72ºC for 2 minutes/kb to be amplified 
Final extension   72ºC for 15 minutes 
     4ºC hold 
 
* Annealling temperature was determined empirically for each primer set based upon 
the melting temperature of the primers (2.4.3.5). 
 
2.5.3.5 Primer design 
In designing primers, where ever possible the following rules of primer design were 
adhered to; (Innis MA and Gelfand DH, 1990) 
1. Primers should be between 17 and 28 base pairs in length. 
2. Base composition of 50-60% GC is optimal. 
3. Primers should have a 3′ terminal G, C GC or CG ‘clamp’. 
4. Melting temperature of primers should be in the range 55-80ºC. 
5. 3′ complementarity should be avoided. 
6. Internal self complementarity should be avoided. 
7. Runs of 3 or more Gs or Cs near the 3′ end of primers should be avoided. 
 
Melting temperature or Tm of primers was calculated using the Wallace formula 
Tm  = 4 x (G+C) + 2 x (A + T) 
 
Primers were checked for formation of dimers or secondary structures such as 
hairpins using net primer (http://www.premierbiosoft.com/netprimer/). Primers used 
in this study are detailed in Table 2-10 
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Table 2-10 Primers used in this study 
Name Sequence Annealing 
temp (ºC) 
Use Source 
Flk-1 FL  S TTTTCTAGAATGGAGAGCAAG 
GCGCTGCT 
 
62 
Flk-1 FL AS TTTTCTAGATTAAACAGGAGGT
GAGCGCAG 
62 
Cloning of full 
length Flk-1 
cDNA 
incorporating 
a 5’ XbaI 
restriction site  
Designed 
for this 
study 
GAPDH S TGGAGCCAAACGGGTCATC 59 
GAPDH AS GCTCTGGGATGACCTTGCC 59 
C Beck, 
pers. 
comm.. 
β-actin S TAGGCACCAGGGTGTGATGG 62 
β-actin AS CATGGCTGGGGTGTTGAAGG 62 
Used as 
controls in 
expression 
analysis M.Storm, 
pers. 
comm. 
β-H1 S AGTCCCCATGGAGTCAAAGA 56 
β-H1 AS CTCAAGGAGACCTTTGCTCA 56 
β-major S CTGACAGATGCTCTCTTGGG 56 
β-major AS CACAACCCCAGAAACAGACA 56 
Brachyury S CATGTACTCTTCTTGCTGG 58 
Brachyury 
AS 
GGTCTCGGGAAAGCAGTGGC 58 
Faloon et 
al., 2000 
c-kit S TGTCTCTCCAGTTTCCCTGC 60 
c-kit AS TTCAGGGACTCATGGGCTCA 60 
Expression 
analysis 
Flk-1 S CACCTGGCACTCTCCACCTTC 60 
Flk-1 AS GATTTCATCCCACTACCGAAAG 60 
Expression 
analysis and 
sequencing 
Keller et 
al., 1993 
Scl S ATTGCACACACACGGGATTCTG 56 
Scl AS GAATTCAGGGTCTTCCTTAG 56 
Faloon et 
al., 2000 
VEGF S CCAAAGCCAGCACATAGG 54 
VEGF AS GGTGACATGGTTAATCGG 54 
Expression 
analysis 
Designed 
1688 SEQ CCCGTATGCTTGTAAAGAATGG  
2284 SEQ CAACAACCATTGGCGAGA  
3600 SEQ GGTAGTGTAGTCAGGAGCCCG  
OUTSIDE 
REV SEQ 
TTGCTAACTAGAGAACCCACTG
C 
 
Sequencing Designed 
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Table 2-11 Molecular techniques consumables 
Product Supplier Cat. Number 
Expansion and purification of plamid DNA 
Acetic acid Sigma 537020 
Agar BD Difco 281230 
Ampicillin Sigma A9518 
Bacto-tryptone Sigma T2559 
Bromophenol blue BD electran 44305 
Buffer saturated phenol Invitrogen 13513-039 
Calcium chloride Sigma C5080 
Chloroform Fisher C-4960-17 
EDTA Fisher S75203 
Glucose Sigma G5400 
Glycerol Sigma G5150 
Kanamycin Sigma K4000 
Manganese chloride Sigma M3634 
MOPS Sigma M5162 
Potassium acetate Sigma P1190 
Potassium chloride Sigma P9591 
Qiagen midi prep kit Qiagen, Crawley, West 
Sussex, UK. 
12143 
Qiagen maxi prep kit Qiagen 12362 
Rubidium Chloride Sigma R2252 
Sigma Genelute plasmid 
mini prep kit 
Sigma PLN 70 
Sodium acetate Fisher S75203 
Sodium chloride Sigma S7653 
Trizma Base Sigma T8404 
Yeast extract BD Difco 288620 
Manipulation and analysis of DNA 
Glacial Acetic acid Sigma 537020 
Agarose Invitrogen 15510-027 
Bromophenol blue BD electran 44305 
CIP alkaline phosphatase Invitrogen M0210S 
EDTA Fisher S75203 
Ethidium Bromide Bio-Rad 1610433 
Glycerol Sigma G5150 
Qiaquick gel extraction kit Qiagen 28704 
Restriction enzymes New England Biolabs Various 
T4 DNA ligase Invitrogen 5224017 
Trizma Base Sigma T8404 
Cloning and expression analysis 
Chloroform Fisher C-4960-17 
DNase Promega M6101 
dNTPs Invitrogen 10297-018 
Pfu polymerase Promega M7741 
Primers Invitrogen  -  
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RNase free eppendorfs Eppendorf 3810X 
rRNasin Promega N2511 
Ribonuclease H Invitrogen 18021-014 
Superscript II reverse 
transcriptase 
Invitrogen 18064-014 
Superscript III reverse 
transcriptase 
Invitrogen 18080-044 
Taq polymerase Promega M1661 
Trizol Invitrogen 15596-018 
 
2.6 Preparation and characterisation of 
transfectants 
2.6.1 Transfection 
2.6.1.1 Stable transfection of BaF/3 cells 
BaF/3 cells were washed 3 times in filter sterilised electroporation buffer (25mM 
HEPES, pH7.2, 140mM KCl, 10mM NaCl, 2mM MgCl2, 0.5% Ficoll 400) then 
resuspended  at 2.5 x 107/ml in 0.8ml of electroporation buffer in an electroporation 
cuvette containing 10µg of linearised plasmid DNA. 
Electroporation was performed at 960µF, 450V. Cells were transferred into 20ml of 
complete BaF/3 media for 48 hours after which they were plated at 5 x 104 -2 x 105 
cells/well of a 96 well plate and supplemented with 600µg/ml of zeocin (Invitrogen) 
for selection. Fresh media was added after 1 week to maintain antibiotic resistance 
and resistant clones were then expanded for screening and freezing (see section 
5.2.3). 
 
2.6.1.2 Stable transfection of ES cells 
R1 Flk-1-/- ES cells were washed three times in sterile PBS w/o Ca2+ and Mg2+ and 
resuspended at 1.25 x 107/ml in 0.8ml of PBS w/o Ca2+ and Mg2+ in an 
electroporation cuvette containing 20µg of linearised plasmid DNA. The cuvette was 
incubated on ice for 5 minutes prior to electroporation at 500µF, 250V (Prelle et al., 
2000). After a further 5 minute incubation on ice the cells were plated out at 2 x 
106/10cm dish in ES cell medium supplemented with 1% hyclone FCS. After 24 – 48 
hours appropriate selection was added (hygromycin at 50µg/ml or puromycin at 
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1µg/ml). Cells were washed and media replaced every day until clones were clearly 
visible (approximately 8 days in selection for hygromycin selection and 5-6 days for 
puromycin). 
 
When clones were clearly visible plates were gently washed in PBS which was then 
thoroughly aspirated. Up to 7 clones per plate were picked. Using sterile forceps the 
smooth end of a cloning ring was coated in autoclaved petroleum jelly and placed 
over a colony. A small amount of trypsin-EDTA was then applied to dissociate the 
colony and a 200µl pipette was used to transfer the colony to 1ml of selection media 
in one well of a 24 well plate.  Clones were then expanded for screening and freezing 
(see section 5.2.3.3) 
 
2.6.1.3 Transient transfection of ES cells 
Electroporation was found to significantly decrease the viability of R1 ES cells 
therefore transient transfection was optimised using lipofectamine 2000 lipid based 
transfection system (see section 5.2.3.1). 8µg of plasmid DNA was diluted in 1ml of 
optimem media and mixed with 20µl of lipofectamine 2000 also diluted in 1ml of 
optimem. Following a 20 minute incubation at room temperature the 
plasmid:lipofectamine mixture was added to 1 x 106 cells in 10ml of ES cell media. 
Medium was changed 8 hours later and cells were checked for expression after a 
further 16-64 hours. 
 
2.6.1.4 Screening clones 
To screen Flk-1-/- ES cells transfected with a dox-inducible-Flk-1 construct 
doxycycline was added at 1µg/ml for 24-48 hours to induce expression. Clones were 
screened using RNA extraction followed by RT-PCR or by flow cytometry (2.4.3 
and 2.3.5 respectively). To screen clones transfected with the tet-regulator plasmid 
pCAGGS-irtTA-VP16-IRES-puro cells were transiently transfected with a tet-
response plasmid prior to screening. 
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Table 2-12 Transfection consumables 
Product Supplier Cat. Number 
Transfection 
Cloning rings Made in house by cutting the  wide end off a p1000 
pipette tip with a hot scalpel blade and autoclaving 
doxycycline Sigma D-9891 
Electroporation cuvettes Bio-Rad 1652088 
Ficoll 400  Sigma F-4375 
1M Hepes Invitrogen 15630-056 
hygronycin Calbiochem 400049 
Lipofectamine-2000 Invitrogen 11668-019 
Magnesium Chloride 
(MgCl2) 
Sigma M-9272 
Optimem Invitrogen 31985-047 
Potassium chloride (KCl) Sigma P-9541 
puromycin Calbiochem 540222 
Sodium Chloride (NaCl) Sigma S-7653 
zeocin Invitrogen  R250-01 
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3.1 Introduction 
The receptor tyrosine kinase Flk-1 plays an important role in haemopoietic and 
endothelial development in early embryogenesis (Shalaby et al., 1995) marking the 
population from which the haemangioblast (Blast-Colony Forming Cell (BL-CFC) in 
vitro), the common precursor of haemopoietic and vascular development, arises 
(Choi et al., 1998; Fehling et al., 2003; Huber et al., 2004) (see section 1.4 for further 
discussion). Upon differentiation of the haemangioblast Flk-1 expression is lost on 
haemopoietic precursors, but is maintained on the endothelial lineage into adult life 
(Kabrun et al., 1997). In the adult Flk-1 mediates angiogenesis, an important target in 
the pathology of many human diseases including cancer, Rheumatoid Arthritis, 
ocular neovascularising disease and cardiovascular disease(Zachary, 2001). The 
signalling mediated by the human homologue of Flk-1, KDR has been well 
characterised but little is known about the signalling mediated by Flk-1 during early 
embryogenesis in mouse and man (Zachary, 2001). 
 
Once identified, the signalling pathways activated by Flk-1 during early development 
could be used to further dissect its developmental role. To evaluate signalling 
mediated by Flk-1 in early murine development cells dissociated embryoid bodies or 
blast colonies were utilised. Embryoid bodies were used as a model of early 
embryogenesis and blast colonies were used to evaluate signalling during 
haemopoietic and endothelial commitment. The D4T embryoid body derived 
endothelial cell line (Kennedy et al., 1997) and Human Umbilical Vein Endothelial 
Cells (HUVEC) (Jaffe et al., 1973) were used as control cell lines. Flk-1 surface 
expression was evaluated using flow cytometry and populations of cells expressing 
Flk-1 were stimulated with its ligand VEGF. Activation of specific signals were 
evaluated in cell lysates using immunoblots. Signalling pathways of particular 
interest included the MAPK pathway and the PI3K pathway both of which are 
activated by VEGF in adult endothelial cells and have been reported to play an 
important role in cell proliferation and survival (Dayanir et al., 2001; Doanes et al., 
1999; Gliki et al., 2001).  
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3.2 Flk-1 expression 
The up-regulation of Flk-1 expression marks the appearance of the haemangioblast, 
or BL-CFC population, in the embryo and embryoid body (Fehling et al., 2003; 
Huber et al., 2004). Kabrun et. al. demonstrated Flk-1 expression on embryoid 
bodies cultured in methylcellulose from day 3.25 after initial plating with expression 
peaking at around 50% on day 4 declining to ~ 5% by day 12 (Kabrun et al., 1997). It 
has since been established that the kinetics of Flk-1 expression vary slightly between 
embryonic stem cell lines (Chung et al., 2002; Fehling et al., 2003; Kabrun et al., 
1997). Initial characterisation of Flk-1 expression in differentiating R1 and E14tg2A 
ES cells, the ES cells to be used in this study, was therefore required to identify the 
time points where Flk-1 expression was maximal, such that cells at this stage could 
be used for the analysis of signalling pathways. The kinetics of Flk-1 expression are 
also important in defining the narrow temporal window of formation of the BL-CFC. 
Re-plating of dissociated embryoid bodies containing the BL-CFC population into a 
secondary blast assay allows BL-CFC expansion and differentiation into blast 
colonies. Flk-1 reportedly decreases during blast colony expansion (D'Souza et al., 
2005). The kinetics of Flk-1 expression and its expression levels relative to those in 
primary embryoid bodies were characterised to confirm this decrease and to 
investigate the feasibility of secondary blasts as a tool to dissect Flk-1 signalling 
during BL-CFC expansion and commitment.  
 
Flk-1 expression was detected with a anti-Flk-1 primary antibody raised against the 
extracellular domain of murine Flk-1 and a FITC conjugated secondary antibody. 
Cells were then and analysed by Flk-1 expression using flow cytometry. An isotype-
matched control antibody was used to control for non-specific binding of the anti-
Flk-1 antibody and Fc block was used to block antibody binding to Fc receptors. The 
vital dye 7-Aminoactinomycin (7AAD) was used to gate for viable cells in flow 
cytometry experiments. For an overview of flow cytometry see section 2.3.5.1. 
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3.2.1 Methods of data analysis in flow cytometry 
Traditionally measures of fluorescence intensity in flow cytometry are displayed on a 
logarithmic scale. If a single fluorescent parameter has been measured, data is most 
commonly presented in the histogram format illustrated in Figure 3-1. 
 
 
Figure 3-1 Examples of potential histogram overlays. The purple trace represents the 
isotype or unstained control whilst the green trace represents the antigen specific antibody 
labelled population. Marker M1 is placed to include 5% of the isotype control peak. Marker 
M2 is placed at the intercept of isotype control and antigen specific antibody labelled 
populations. Diagram A show a histogram representative of flow cytometry performed on a 
mixed population of cells which are either positive or negative for the antigen of interest. 
Diagram B is representative of a more homogenous population in which the whole 
population expresses a lower level of antigen.  
 
Data analysis from histogram plots is commonly conducted using markers 
incorporating a low percentage of the control peak, usually 1% or 5%. The 
percentage of antigen labelled cells minus the percentage of control cells within the 
marker is quoted as percentage antigen positive cells. This approach works well for 
populations with high antigen expression and obvious positive and negative 
populations such as Figure 3-1A. However, in populations expressing lower antigen 
levels this approach may exclude some of the cells which appear positive (illustrated 
by marker M1 in Figure 3-1 B). Placement of the marker at the intercept of control 
and antigen specific labelled populations (marker M2 in Figure 3-4B) gets round this 
problem but may yield a falsely high figure. Additionally, marker placement may 
skew the data. In either case, quoting percentage expression is probably inaccurate as 
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the shift of the entire population in Figure 3-1B indicates that the whole population is 
positive but expresses low levels of antigen.  Another method of data analysis in such 
a case is to compare the means or medians of the peaks calculated by the Cellquest 
FACS analysis software. Geometric mean should be used for comparison of log data 
to prevent the skewing of the mean by outliers. 
3.2.2 Flk-1 expression on cells derived from primary 
embryoid bodies 
To establish a time-course of Flk-1 expression in cells developing in primary 
embryoid bodies, expression of Flk-1 was measured on populations of embryoid 
body-derived cells generated from both E14tg2A and R1 ES cell lines between days 
3 and 7 of embryoid body formation. This data was compared with that published in 
the literature (Chung et al., 2002; Fehling et al., 2003; Kabrun et al., 1997).  
 
Histogram plots of a representative time-course for each ES cell line are illustrated in 
Figure 3-2. In many of the traces (including days 4 and 5 in panels A and B) the α-
Flk-1 labelled trace overlaps with the isotype control trace as a single diffuse peak, 
indicating low overall receptor expression with levels varying within the population. 
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Figure 3-2. Flk-1 expression in cells derived from developing embryoid bodies.  Cells 
from dissociated embryoid bodies that had differentiated for between 3 and 7 days, were 
stained with an anti-Flk-1 antibody or an equal concentration of isotype matched control and 
a secondary FITC labelled antibody. The numbers above each plot indicate the number of 
days the primary embryoid bodies had been allowed to differentiate for. The Y axis 
represents cell number while the X axis represents fluorescent intensity. The purple peak 
indicates the isotype control labelled population and the green trace represents the anti-Flk-1 
antibody labelled population. A illustrates a time-course of Flk-1 expression in cells from 
dissociated embryoid bodies of the E14tg2A ES cell line. B illustrates a time-course of Flk-1 
expression in cells from dissociated embryoid bodies of the R1 ES cell line. C illustrates fine 
kinetic analysis of Flk-1 expression in cells from dissociated E14tg2A embryoid bodies. The 
data in Figure 3-2 A and B is representative of 3 complete time-course experiments with the 
exception of data from day 11 R1 primary embryoid bodies (n=1). The data represented in 
Figure 3-2C is representative of 2 complete time-course experiments. 
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Figure 3-3 Time-course of Flk-1 expression in primary embryoid body-derived cells. 
Cells from dissociated embryoid bodies that had differentiated for between 3 and 7 days, 
were labelled with an anti-Flk-1 antibody or an equal concentration of isotype-matched 
control and a secondary FITC labelled antibody prior to analysis on a Becton Dickinson 
FACS Vantage flow cytometer. The percentage of cell expressing Flk-1 and the geometric 
mean intensity were calculated as described in section 3.2.1. Percentage Flk-1 expression 
was calculated using a 5% marker gate. The results shown represent pooled data from ≥3 
individual experiments. A Comparison of % Flk-1 expression in cells from dissociated R1 
and E14tg2A primary embryoid bodies respectively differentiated for between 3 and 6 days. 
B and C Comparison of the geometric mean fluorescent intensities between isotype control 
and anti- flk-1 labelled cells from dissociated E14tg2A and R1 embryoid bodies 
differentiated for between 3 and 6 days. Error bars represent s.e.m, *** p<0.01 in the paired 
students t-test. Analysis of variance (ANOVA) showed no significant difference in 
geometric mean fluorescence intensities between anti-Flk-1-labelled embryoid body-derived 
cells on days 3.75, 4, 5 and 6 in B or days 3,4,5 and 6 in C. X indicates that no Flk-1 
expression data was available. 
 
Figures 3-2A and C and 3-3A and B illustrate the rapid induction of Flk-1 expression 
between days 3 and 4 of EB development using E14tg2A ES cells. Expression 
peaked between days 4 and 6 and began to decline thereafter. Flk-1 expression in R1 
ES cells, shown in figures 3-2B, 3-3A and C, was induced earlier, by day 3 of 
embryoid body formation and declined sooner, indicating that differentiation 
proceeds more rapidly in this cell line. Flk-1 expression peaked at day 4 and declined 
there after, correlating temporally with a similar time-course of Flk-1 expression in 
R1 embryoid bodies performed by Chung et al., (Chung et al., 2002).  
 
Both the percentage of Flk-1 expression and geometric mean fluorescence intensities 
were higher in E14tg2A-derived EBs than in their R1 counterparts indicating that 
cells within these populations expressed higher levels of receptor. As the E14tg2A 
time course experiments were not run in tandem with the R1 cell line it is unclear 
whether this difference is significant. In both ES cell lines the pattern of Flk-1 
expression and the expression levels, in terms of percentage of Flk-1 expression, 
correlate well with data from other workers (Chung et al., 2002; Kabrun et al., 1997). 
Taking into consideration the possible higher Flk-1 expression levels in the E14tg2A 
EBs, their expression profile and the cellularity of the embryoid bodies at different 
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stages, it was decided to perform the signalling experiments using cells from 
dissociated day 5 E14tg2A embryoid bodies.  
 
3.2.3 Flk-1 expression in secondary blasts 
The secondary blast assay is a measure of formation of the transient Blast Colony 
Forming Cell (BL-CFC) that arises around the time of Flk-1 upregulation (primary 
embryoid bodies and secondary blasts are illustrated in Figure 2-1). Embryoid bodies 
containing the BL-CFC population are dissociated and replated into fresh 
methylcellulose with growth factors including VEGF and D4T conditioned medium 
to allow expansion and differentiation of the BL-CFC population (Choi et al., 1998; 
Faloon et al., 2000; Kennedy et al., 1997). The onset of Flk-1 expression marks 
formation of the BL-CFC. Using the time-course of Flk-1 expression in primary 
embryoid bodies (Figures 3-2 and 3-3) the window of BL-CFC formation was 
identified as day 3.5-4 for E14tg2A EBs.  
 
Flk-1 expression is down-regulated upon haemopoietic commitment but maintained 
on endothelial cells  (Kabrun et al., 1997; Nishikawa et al., 1998a; Zachary, 2001) 
suggesting the receptor should be retained by some of the differentiating BL-CFC 
population.  Northern Blotting by D’Souza et. al. demonstrated down-regulation of 
Flk-1 expression upon blast colony expansion (D'Souza et al., 2005). In order to 
further investigate the kinetics and levels of Flk-1 expression in secondary blasts 
flow cytometry was again utilised.  
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Figure 3-4 Flk-1 expression in dissociated secondary blast cells.  Secondary blasts were 
derived from re-plated dissociated day 3.75 E14tg2A primary embryoid bodies and 
expanded for between 2 and 5 days.  The blast colonies were then dissociated and their 
constituent cells stained with either an anti-Flk-1 antibody or an equal concentration of 
isotype-matched control and a secondary FITC labelled antibody. The numbers above the 
plots indicate the numbers of days of blast colony expansion the cells underwent. The Y axis 
represents cell number and the X axis represents fluorescent intensity. The purple trace 
indicates the isotype control population whilst the green trace indicates the anti-Flk-1 
antibody stained population. The data shown are representative of 3 complete time-course 
experiments with the exception of day 5 which is representative of 2 individual experiments. 
 
The data shown in Figure 3-4 demonstrates that in contrast to Flk-1 expression in 
primary embryoid body-derived cells, Flk-1 expression in secondary blasts appears 
to separate into two clear populations, Flk-1 positive and Flk-1 negative. The 
fluorescence intensity of the Flk-1 positive population is also higher than that 
observed in the primary embryoid bodies (see Figure 3-2), suggesting higher levels 
of receptor expression on the positive cells. 
          2                        3                         4                           5 
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Figure 3-5. Flk-1 expression in dissociated secondary blast cells. Secondary blasts were 
derived from re-plated dissociated day 3.75 E14tg2A primary embryoid bodies and expanded for 
between 2 and 4 days.  The blast colonies were then dissociated and constituent cells stained with 
either an anti-Flk-1 antibody or an equal concentration of isotype matched control, and a 
secondary FITC-labelled antibody prior to flow cytometric analysis on a Becton Dickinson 
FACS Vantage flow cytometer. The percentage of cells expressing Flk-1 and geometric mean 
intensity were calculated as described in section 3.2.1. The percentage of Flk-1 expression was 
calculated using a 5% marker gate. Results shown represent pooled data from 4 individual 
experiments. A. The percentage Flk-1 expression on day 3.75 EBs and day 2-4 secondary blast-
derived cells are shown. B. Comparison of the geometric mean fluorescent intensities between 
the isotype control and anti-flk-1 labelled cells in day 3.75 EBs and day 2-4 secondary blast-
derived cells are shown. Error bars represent s.e.m, ** = p≤ 0.05 in the paired students t-test. 
Analysis of variance (ANOVA) followed by Tukey’s post-hoc test on geometric mean 
fluorescent intensity data showed a significant decrease in expression by day 3 (≤0.01). No 
significant decrease was demonstrated between days 3 and 4.  
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The time course of Flk-1 expression by secondary blast-derived cells illustrated in 
Figure 3-5, demonstrated a significant decrease in Flk-1 expression between days 2 
and 3 of blast colony formation coinciding with the appearance of haemopoietic 
clusters on the periphery of the blast colony. This indicates that the down-regulation 
of Flk-1 may be due to haemopoietic commitment. These results correlate well with 
data from D’Souza et. al., who observed a rapid decrease in Flk-1 cDNA in blast 
colonies between days 1 and 2 using Northern Blotting (D'Souza et al., 2005). The 
difference in timing of this decrease may be due in part to the use of different ES cell 
lines but is probably due in the main to the greater stability and longevity of the 
protein.  
3.2.4 Effect of VEGF on Flk-1 expression in primary 
embryoid bodies 
Recent work in human endothelial cells has demonstrated that unlike other receptor 
tyrosine kinases VEGF treatment does not increase the rate of Flk-1/KDR receptor 
internalisation. In fact, in short term stimulation assays VEGF stimulation actually 
increased KDR (kinase domain receptor, human Flk-1) recycling to the membrane 
from intracellular vesicles thus increasing extracellular expression (Gampel et al., 
2006). To investigate whether longer term VEGF signalling in early development 
may affect surface expression of Flk-1, either through increasing trafficking of the 
receptor to the membrane or by directing differentiation towards a Flk-1 expressing 
population, E14tg2A ES cells were allowed to differentiate into primary embryoid 
bodies in methylcellulose in the presence or absence of 50ng/ml VEGF over 5 days. 
Flk-1 surface expression on the cells of dissociated embryoid bodies was then 
analysed using flow cytometry.  
 
The data in Figure 3-6 shows a significant increase in Flk-1 surface expression cells 
from dissociated day 5 primary embryoid bodies cultured for 5 days in the presence 
of 50ng/ml exogenous VEGF. This correlates well with findings by Gampel et al., 
(Gampel et al., 2006) in shorter term experiments. However, it is unclear whether the 
increase in Flk-1 expression represents increased receptor expression by individual 
cells or an increase in differentiation of cells within the embryoid body towards the 
BL-CFC/endothelial lineage. 
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Figure 3-6 Effect of VEGF on surface expression of Flk-1.  E14tg2A ES cells were 
allowed to differentiate into primary embryoid bodies over 5 days in the presence and 
absence of 50ng/ml VEGF. After 5 days dissociated embryoid body cells were stained with 
an anti-Flk-1 antibody or an equal concentration of isotype-matched control, and a secondary 
FITC-labelled antibody prior to flow cytometric analysis on a Beckton Dickenson FACS 
Vantage flow cytometer. The percentage of Flk-1 expression was calculated using a 5% 
marker as described in section 3.2.1. Results show pooled data from 3 individual 
experiments. Error bars represent s.e.m, *** p≤ 0.01 in the unpaired students t-test.  
 
3.3 VEGF-induced Flk-1 signalling 
Flk-1 plays an important role in the development and differentiation of the common 
precursor of both haemopoietic and endothelial development and knowledge of Flk-
1-mediated signalling could provide further insight into mechanisms by which these 
cell types are specified. Although signallingmediated by the human homologue of 
Flk-1, KDR in human endothelial cells is relatively well characterised there is no 
evidence to suggest activation of the same pathways in Flk-1-expressing dissociated 
primary embryoid body cells.  
 
VEGF stimulation of dissociated embryoid body and secondary blast cells expressing 
Flk-1 was used to model and investigate signalling at specific stages of development. 
Cells were stimulated with VEGF and proteins in the resulting whole cell lysates 
were separated using SDS-PAGE before being blotted onto nitrocellulose paper. The 
membranes were probed with antibodies that specifically detect phosphorylated 
signalling molecules. The duration of serum starvation of cells prior to stimulation 
and the concentration of VEGF used for stimulations were optimised to allow the 
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maximal window for signal visualisation. Cells were serum starved for 3 hours to 
reduce basal signalling and subsequently stimulated with 20ng/ml mVEGF. 
3.3.1 VEGF induced protein phosphorylation 
Flk-1 is a receptor tyrosine kinase. Upon activation with VEGF, Flk-1 
transphosphorylates tyrosine residues within its cytoplasmic tail, initiating activation 
of phosphorylation-dependent signalling cascades. For initial characterisation of 
VEGF-induced Flk-1-mediated phosphorylation events day 5 embryoid body cells 
expressing Flk-1 were stimulated with VEGF over a 30 minute time-course. VEGF 
stimulated whole cell lysates were blotted and probed for proteins containing 
phosphorylated tyrosine residues using the 4G10 anti-phospho-tyrosine antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 VEGF-stimulated Flk-1-mediated tyrosine phosphorylation.  Immunoblot of 
whole cell lysates from day 5-dissociated primary EB cells stimulated with 20ng/ml VEGF 
over a 30 minute time-course and probed with the anti-phosphotyrosine antibody 4G10. 
Representative of two individual experiments. The blot was re-probed with the anti-SHP-2 
antibody to control for equal protein loading. Molecular markers are illustrated at 97,116 and 
200kDa 
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Figure 3-7 demonstrates few proteins for which tyrosine phosphorylation increases 
upon VEGF stimulation. The only protein for which tyrosine phosphorylation 
appears to increase is the protein at ~ 230kDa. This is the approximate size of the 
Flk-1 receptor itself so this increase in phosphorylation probably represents 
transphosphorylation of tyrosines on the cytoplasmic tail of the receptor.  
 
3.3.2 Effect of VEGF on MAPK signalling 
In adult endothelial cells VEGF stimulation has been shown to activate the Mitogen 
Activated Protein Kinase (MAPK) pathway, which is important for growth, 
differentiation and development in endothelial cells (Doanes et al., 1999; Gliki et al., 
2001; Takahashi and Shibuya, 1997) (see section 1.4.2.2). Activation of this pathway 
can be monitored by the phosphorylation state of the downstream Extracellular signal 
Regulated Kinases 1/2 protein (ERK1 and 2), which require phosphorylation on 
threonine 202 and tyrosine 204 for full activation. ERK1/2 are usually activated only 
transiently and turn on the ‘immediate early genes’ within minutes (Lodish et al., 
1999). Previous work in rat sinusoidal endothelial cells has demonstrated that VEGF-
induced ERK activation peaked between 3 and 5 minutes and declined to near basal 
levels after 10 minutes (Takahashi and Shibuya, 1997). Little work has taken place to 
characterise the existence (or kinetics) of Flk-1-induced MAPK activation in early 
developmental models. A single study performed a 30 minute VEGF stimulation of 
day 3 embryoid body cells expressing Flk-1 and demonstrated VEGF-induced 
phosphorylation of ERK1/2 (Park et al., 2004). However, as noted above, maximal 
ERK phosphorylation upon cytokine stimulation generally occurs over a shorter time 
course. To confirm Flk-1-mediated MAPK activation and to establish its kinetics a 
time-course of VEGF stimulation was therefore performed in embryoid body and 
secondary blast-derived cells.  
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Figure 3-8 VEGF- induced MAPK signalling. Primary embryoid bodies and secondary 
blasts were dissociated with trypsin-EDTA, D4T cells were stimulated on the Petri dishes in 
which they were cultured. Cells were serum-starved for 3 hours at 37ºC prior to stimulation 
with 20ng/ml VEGF for between 1 and 30 minutes as indicated. Immunoblotting was 
performed and blots were probed with an anti-p-ERK1/2 antibody then stripped and 
reprobed with either anti-SHP-2 or anti-ERK1/2 antibodies to check for equal loading. A. 
Immunoblot of day 5 dissociated E14tg2A primary embryoid bodies stimulated with VEGF. 
The blot shown is representative of 5 individual experiments. B. Immunoblot of day 5 
dissociated R1Flk-1-/- primary embryoid bodies stimulated with VEGF.  The blot shown is 
representative of 2 individual experiments. C. Immunoblot of day 2 dissociated secondary 
blast cells stimulated with VEGF. The blot shown is representative of 3 individual 
experiments. D. Immunoblot of D4T embryoid body derived endothelial cells stimulated 
with VEGF. The blot shown is representative of 3 individual experiments.  
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Initial experiments demonstrated that ERK1/2 was phosphorylated by VEGF 
stimulation in primary embryoid bodies, secondary blasts and D4T embryoid body-
derived endothelial cells (included as control) (Figure 3-8A, C and D). The observed 
increases in ERK phosphorylation were transient, occurring within 1 minute, peaking 
between 2 and 5 minutes and decreasing back to basal levels by between 5 and 10 
minutes of VEGF stimulation. Day 4 R1 embryoid bodies yielded similar results 
(data not shown). The VEGF-induced ERK phosphorylation profile is typical of 
ERK1/2 activation and correlates well with previous work in rat sinusoidal 
endothelial cells (Takahashi and Shibuya, 1997). However, an increase in ERK1/2 
phosphorylation over basal was not visualised upon 30 minutes VEGF stimulation, in 
contrast to findings by Park et. al. (Park et al., 2004). 
 
To verify that VEGF was acting to induce ERK1/2 phosphorylation through the Flk-
1 receptor the experiment was repeated using day 4 R1Flk-1-/- embryoid bodies 
(Figure 3-8B). VEGF stimulation provoked no increase in ERK phosphorylation 
confirming that VEGF was acting through the Flk-1 receptor.   
 
3.3.3 Is VEGF-mediated ERK signalling activated via 
PLCγ? 
Work in HUVECs suggests that in adult human endothelial cells VEGF-induced 
MAPK activation occurs through a phospholipase C-γ  (PLCγ)-dependent Protein 
Kinase C (PKC)-mediated mechanism rather than the classical Ras-Raf pathway 
(Doanes et al., 1999; Gliki et al., 2001; Yashima et al., 2001). However, further work 
by Yashima et al., demonstrated that the mechanism of VEGF activation of the 
MAPK pathway may be heterogenous between endothelial cells of different origins. 
Whilst VEGF appeared to activate the MAPK pathway through a PKC-mediated 
mechanism in HUVECs and human aortic endothelial cells (HAECs), in human 
subcutaneous microvascular endothelial cells (HMVECs) MAPK activation seemed 
dependent only on the classical Ras-Raf pathway (Yashima et al., 2001). 
 
In order to elucidate any potential role for PLCγ in Flk-1-mediated MAPK 
activation, VEGF activation of PKC (a downstream effector of PLCγ) in primary 
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embryoid body-derived cells was first investigated.  There are three classes of PKC 
isoforms; classical, novel and atypical all of which require phosphorylation for their 
activation (Newton, 2003). In addition to phosphorylation, activation of the classical 
isoforms (α, βI, βII and γ) is dependent upon both calcium and Diacylglycerol 
(DAG). The novel isoforms (δ,η,θ and ε) do not require calcium for their activation 
but are still dependent upon DAG and the atypical isoforms (λ and ζ) require only 
phosphorylation for their activation (Violin and Newton, 2003). VEGF-stimulated 
primary embryoid body-derived cell lysates were immunoblotted and blots were 
probed with antibodies specific for phosphorylated classical and novel PKC isoforms 
and phosphorylated PKC–δ (implicated in VEGF-induced MAPK activation in 
HUVECs (Gliki et al., 2001)).  
 
A 
 
 
 
 
 
B 
 
 
 
 
 
Figure 3-9 Effect of VEGF stimulation on phosphorylation of classical and novel PKC 
isoforms and more specifically phosphorylation of the novel isoform PKCδ.  Dissociated 
day 5 embryoid body cells were serum-starved for 3 hours then stimulated with 20ng/ml 
VEGF for between 1 and 30 minutes as indicated. Immunoblotting was performed and blots 
were probed with either an anti-phospho-PKC which detects phosphorylation of the classical 
and novel PKC isoforms or an anti-phospho-PKCδ antibody then stripped and reprobed with 
an anti-SHP-2 antibody to check for equal loading of protein. 2 individual experiments are 
illustrated in both A and B. 
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Figure 3-9A illustrates an increase in total phosphorylation of classical and novel 
PKC isoforms after 2 minutes of VEGF stimulation which decreases back to basal 
levels by 5 minutes. No obvious increase in PKCδ phosphorylation over basal levels 
was visualised upon VEGF stimulation (Figure 3-9B).  
 
To investigate whether the VEGF-induced PKC activation observed in Figure 3-9A 
mediates downstream MAPK activation, Calphostin C, a pan-PKC inhibitor derived 
from Cladosporium Cladosporioides and gö6976, an inhibitor of the classical 
calcium dependent class of PKCs consisting PKCα, β1 and β2 which also inhibits 
PKCμ (PKD) were used. Primary embryoid bodies were dissociated and serum 
starved for 3 hours. They were then incubated with Calphostin C or gö6976 for a 
further 45 minutes prior to stimulation with 20ng/ml VEGF. MAPK activation was 
examined using immunoblots of the cell lysates. ERK1/2 phosphorylation in Figure 
3-10 does not appear to decrease in the presence of Calphostin C applied at 250nM 
or 1μM (the concentration used by Gliki et al., to demonstrate PKC reliance of KDR 
induced MAPK activation in HUVECs). However, a slight decrease in ERK1/2 
phosphorylation is seen in lysates from cells preincubated with 3μM gö6979 prior to 
VEGF stimulation. At this concentration in vitro studies using isolated proteins 
showed only inhibition of PKCα βI, βII γ or PKD (Martiny-Baron et al., 1993) but 
selectivity over other kinases in unclear. If activation of the MAPK pathway by Flk-1 
were mediated through any PKC isoform a decrease in ERK phosphorylation would 
be expected upon inhibition of the classical and atypical PKC isoforms with 
Calphostin C. As no such decrease was observed it appears likely that in embryoid 
body-derived cells activation of the MAPK pathway by Flk-1 is meditated through 
the classical Ras-Raf pathway.  
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Figure 3-10 Effect of PKC inhibition on ERK1/2 phosphorylation. Dissociated day 5 
embryoid bodies were serum-starved for 3 hours prior to a 45 minute incubation with a 
DMSO control, Calphostin C (A) or gö6979 (B). Cells were then stimulated with 20ng/ml 
VEGF for 0, 2 or 10 minutes. Immunoblotting was performed and blots were probed with an 
anti-phospho ERK1/2 antibody then reprobed with an anti-ERK1/2 antibody to check for 
equal loading. A is representative of 2 individual experiments. B is an individual experiment. 
  
3.3.4 Effect of VEGF stimulation on PI3K signalling 
In adult endothelial cells VEGF stimulation has been shown to activate the class IA 
Phosphoinositide-3-kinase (PI3K) pathway, thought to be involved in cell 
proliferation (Dayanir et al., 2001; Hamada et al., 2005), survival (Fujio and Walsh, 
1999; Gerber et al., 1998), migration (Holmqvist et al., 2004) and eNOS activation 
(Bates and Harper, 2002; Fulton et al., 1999; Lin and Sessa, 2006). Class IA PI3K 
isoforms (see section 1.4.2.3) are expressed from the single cell stage of development 
and play an important role in early developmental processes (Lu et al., 2004; Riley et 
al., 2005) including haemopoiesis (Bone and Welham, 2007; Clayton et al., 2002; 
Haneline et al., 2003; Okkenhaug et al., 2002). An endothelial cell specific 
Tie2CrePTEN construct has been used to investigate the role of PI3K signalling in 
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endothelial cells during development. Animals deficient in PTEN, a phosphatase 
which negatively regulates PI3K signalling, died at E11.5 due to bleeding and 
cardiac failure caused by impaired recruitment of pericytes to the blood vessels and 
cardiomyocytes to the heart. Studies in vitro, and using the heterozygous mutant, 
showed enhanced proliferation of endothelial cells in the PTEN mutant suggesting a 
proliferative role for PI3K in the endothelium (Hamada et al., 2005). 
 
Activation of PI3K signalling can be monitored by the phosphorylation status of the 
downstream mediators of the PI3K pathway including protein kinase B (PKB), 
Glycogen Synthase Kinase-3-α/β (GSK-3-α/β), and S6 ribosomal protein (see Figure 
1-17). The PI3K pathway is usually activated transiently and can directly regulate 
apoptosis, migration, the cell cycle and translation (Lodish et al., 1999). Previous 
work in bovine aortic endothelial cells (BAECs), porcine aortic endothelial cells 
(PAEs) and HUVECs has demonstrated maximal VEGF-induced PKB/Akt 
phosphorylation between 7.5 and 30 minutes  of treatment declining  thereafter 
(Bernatchez et al., 2001; Dayanir et al., 2001; Gerber et al., 1998). Little work has 
taken place to characterise the existence (or kinetics) of Flk-1-mediated PI3K 
activation in early developmental models. A single study performed a 30 minute 
VEGF stimulation of day 3 embryoid body cells expressing Flk-1 but did not observe 
any VEGF-induced increase in PKB/Akt phosphorylation (Park et al., 2004). 
However, as noted above, maximal PI3K phosphorylation upon cytokine stimulation 
may occur over a shorter time-course. To investigate if VEGF/ Flk-1 mediate PI3K 
activation in an in vitro model of early development a time-course of VEGF 
stimulation was performed using both embryoid body and secondary blast-derived 
cells. The D4T embryoid body-derived endothelial cell line and HUVECs were also 
stimulated as controls. Activation of the PI3K pathway was probed using the 
following antibodies which recognise phosphorylated downstream effectors of PI3K: 
α-phospho-PKB – detects endogenous levels of Akt1, only when phosphorylated at 
Ser473. 
α-phospho-GSK-3α/β – detects endogenous levels of GSK-3, only when 
phosphorylated at Ser21 of GSK-3α or Ser9 of GSK-3β. 
α-phospho-GSK-3β – detects endogenous levels of Ser9 of GSK-3β. 
α-phospho-PKB substrate – Detects peptides and proteins containing phosphor-
Ser/Thr preceded by Lys/Arg at positions -5 and -3. 
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α-phospho-S6 – detects endogenous levels of S6 ribosomal proteins,  only when 
phosphorylated at Ser235 and Ser236. 
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Figure 3-11 Effect of VEGF stimulation on phosphorylation status of downstream 
mediators of PI3K. Primary embryoid bodies and secondary blasts were dissociated with 
trypsin-EDTA, D4T cells and HUVECs were stimulated in the Petri dishes in which they 
were cultured. Cells were serum-starved for 3 hours at 37ºC prior to stimulation with 
20ng/ml VEGF for between 1 and 30 minutes as indicated. Immunoblotting was performed 
and blots were probed with anti-p-PKB, anti-p-GSK-3α and β, anti-p-PKB substrate and 
anti-p-S6 antibodies then stripped and re-probed with anti-PKB, anti-GSK-3α/β or SHP-2 
antibodies to check for equal loading. A. Immunoblot of day 5 dissociated E14tg2A primary 
embryoid bodies stimulated with VEGF. The blots shown are representative of individual 
experiments as follows α-p-PKB n=3, α-p-GSK-3 n=5, α-p-PKB substrate n=2. B. 
Immunoblot of dissociated day 4 R1Flk-1-/- embryoid bodies stimulated with VEGF. C. 
Immunoblot of day 2 dissociated secondary blast cells stimulated with VEGF. The blots 
shown are representative of 2 individual experiments. D. Immunoblot of D4T embryoid 
body derived endothelial cells stimulated with VEGF. The blots shown are representative of 
3 individual experiments. E. Immunoblot of HUVECs stimulated with VEGF. The blots 
shown are representative of 2 individual experiments. 
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The levels of phosphorylation of neither PKB, GSK-3α/β nor S6 ribosomal protein 
showed any consistent change upon VEGF stimulation over a 30 minute time-course 
in primary embryoid bodies (Figure 3-11A), secondary blasts (Figure 3-11C) or D4T 
embryoid body derived endothelial cells (Figure 3-11D). These results correlate with 
the lack of PKB phosphorylation seen upon 30 minute VEGF stimulation in day 3 
primary embryoid bodies (Park et al., 2004). However, Figure 3-11E shows that 
VEGF stimulation of HUVECs did elicit increased phosphorylation of all three 
downstream mediators as previously described (Gerber et al., 1998) demonstrating 
that this was not due to the methodology used. Basal phosphorylation levels of GSK-
3α/β and S6 were high demonstrating that the PI3K is active in these cells. This high 
basal level was also observed αp-S6 blots in VEGF-stimulated day 4 Flk-1-/-R1 EB-
derived cells suggesting it is not due to endogenous activation of PI3K through the 
Flk-1 receptor (Figure 3-11B). 
 
3.3.5 Effect of PI3K and MEK inhibition on VEGF/Flk-1-
mediated MAPK and PI3K signalling 
Many papers have been published discussing the existence of cross-talk between the 
PI3K and MAPK pathways in different cell systems.  Work in ES cell self-renewal 
has shown that PI3K inhibition increases ERK phosphorylation implying that PI3K 
negatively regulates the MAPK pathway in ES cells (Paling et al., 2004). In the 
vascular endothelium PI3K has been shown to play an inhibitory role in VEGF-
induced MAPK-dependent tissue factor expression (Blum et al., 2001). More 
recently, a study in zebrafish has implicated opposing roles of VEGF-induced PI3K 
and MAPK activation as important for endothelial specification towards either an 
arterial (MAPK) or venous (PI3K) fate (Hong et al., 2006). It is thought that this 
cross-talk may be mediated by PKB phosphorylation and inactivation of Raf, an 
upstream effector of MAPK signalling in many cell types (Zimmermann and 
Moelling, 1999). However, in other cell types there is no such evidence of cross-talk 
(Chiu et al., 2005) and in some cases PI3K appears to activate rather than inhibit 
MAPK signalling (Bhatt et al., 2002). To investigate any potential cross-talk between 
these two pathways upon VEGF stimulation EB-derived cells were incubated with 
specific inhibitors of each pathway prior to VEGF stimulation and the effects on 
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phosphorylation of downstream effectors were monitored. U0126, a non-competitive 
specific inhibitor of MEK1 and MEK2 activity (Favata et al., 1998), was used to 
inhibit the MAPK pathway and LY294002 (Vlahos et al., 1994), a reversible 
competitive inhibitor of PI3K with a 19-fold selectivity for class IA over class II 
PI3K, was used to inhibit the class IA PI3K pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12 Effect of PI3K and MAPK inhibition on VEGF-stimulated ERK1/2 
activation. Dissociated day 5 embryoid bodies were serum-starved for 3 hours prior to a 45 
minute incubation with a DMSO control, 10μM U0126 (MAPK inhibitor) or 10μM 
LY294002 (PI3K inhibitor). Cells were then stimulated with 20ng/ml VEGF for 0, 2 or 10 
minutes. Immunoblotting was performed and blots were probed with either anti-phospho 
ERK1/2 or anti-phospho-S6 ribosomal protein antibodies then stripped and reprobed with 
anti-ERK1/2 and anti-SHP-2 antibodies to check for equal loading. The blots shown are 
representative of 3 individual experiments 
 
Figure 3-12 illustrates that as expected, incubation of the EB-derived cells with the 
MEK1/2 inhibitor U0126 prior to VEGF stimulation abrogated VEGF-induced 
ERK1/2 phosphorylation. However, pre-treatment with U0126 appeared to have no 
effect on S6 phosphorylation. Incubation of the cells with the PI3K inhibitor 
LY294002 prior to VEGF stimulation abrogated S6 phosphorylation but also 
appeared to increase ERK phosphorylation suggesting that the PI3K pathway is 
acting to negatively regulate the MAPK pathway in these cells (as we reported in 
Paling et al., in 2004 in ES cells). These findings correlates well with data from both 
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adult endothelial cells and angioblasts undergoing commitment to either arterial or 
venous fates in which VEGF-induced MAPK activation increases upon inhibition of 
the PI3K pathway with either LY294002 or an irreversible highly selective PI3K 
inhibitor, wortmannin (Blum et al., 2001; Hong et al., 2006). 
3.4  Discussion 
Primary embryoid bodies and secondary blasts were used as models of early 
development. Their constituent cells were used to study Flk-1 expression and VEGF-
induced signalling. Results are summarised below and in Figure 3-13: 
3.4.1 Summary 
• Flk-1 is expressed in dissociated primary E14tg2A embryoid body cells from 
day 3.5 of formation with expression peaking between days 4 and 6. In R1 
dissociated embryoid body cells Flk-1 is expressed from day 3 peaking 
between days 4 and 5. 
 
• Flk-1 expression in secondary blast-derived cells declines upon blast 
expansion. In contrast to expression in primary embryoid body-derived cells 
expression in secondary blast-derived cells occurs within a restricted 
population. 
 
• VEGF stimulation of primary embryoid body-derived cells and secondary 
blast-derived cells results in auto-phosphorylation of Flk-1 and activation of 
the MAPK pathway (demonstrated by ERK1/2 phosphorylation). 
 
• VEGF stimulation of Primary embryoid body-derived cells also activates the  
PLCγ1 pathway (demonstrated by PKC phosphorylation).  
 
• Preliminary evidence suggests that activation of the MAPK pathway in 
primary embryoid body-derived cells is not mediated by PLC γ1. 
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• VEGF stimulation of Flk-1 expressing primary embryoid body-derived cells 
or secondary blast-derived cells does not appear to activate signalling through 
PI3K. 
 
• Inhibition of the PI3K pathway with the pharmacological inhibitor LY294002 
reduces phosphorylation of the downstream mediator S6 ribosomal protein 
and increases VEGF-induced ERK1/2 phosphorylation. 
 
• Inhibition of the MAPK pathway with the pharmacological inhibitor of 
MEK1/2, U0126, abolishes phosphorylation of their downstream target 
ERK1/2 but has no effect on PI3K signalling, measured by the 
phosphorylation status of S6 ribosomal protein. 
 
3.4.2 Flk-1 expression 
3.4.2.1 Flk-1 expression in dissociated Primary embryoid body cells 
Flk-1 surface expression on primary embryoid body-derived cells, measured by flow 
cytometry, was very heterogenous with a range of expression levels within the 
population. Flk-1 expression profiles differed between the two ES cell lines used. 
Differences in Flk-1 expression profiles between groups using different ES cell lines 
have been previously reported and it appears that these may in part be due to 
differences in the lines themselves in addition to differences in the differentiation 
protocols used (Chung et al., 2002; Fehling et al., 2003; Kabrun et al., 1997). In 
E14tg2A primary embryoid bodies Flk-1 expression first arose between day 3 and 
3.5, peaked between days 4 and 6 and declined thereafter. In R1 primary embryoid 
bodies Flk-1 expression was seen earlier at day 3 after plating, expression peaked at 
day 4 and declined thereafter, closely correlating with previous Flk-1 expression 
profiles performed using these cells (Chung et al., 2002). Though there was a slight 
temporal difference in Flk-1 expression, which points to slower differentiation in the 
E14tg2A ES cell line vs the R1 ES cell line, the overall pattern of Flk-1 expression in 
both cell lines followed previously published in vitro data (Chung et al., 2002; 
Kabrun et al., 1997). Leahy et al., ascribe day 3.5-4.5 of embryoid body development 
as equivalent to day 6.5-7.5 of embryonic development. Flk-1 is first expressed at 
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around day 7 in the embryo, (Leahy et al., 1999) therefore the up-regulation of Flk-1 
in both E14tg2A and R1 EB-derived cells also correlates well with its reported 
expression in the embryo proper.  
 
Early Flk-1 expression marks the haemangioblast, the common precursor of both 
haemopoietic and endothelial cells, and its in vitro equivalent the Blast Colony 
Forming Cell (BL-CFC) (Fehling et al., 2003; Huber et al., 2004). This suggests that 
early expression (day 3-4.5 in R1 EBs and day 3.5-5 in E14tg2A EBs) marks this 
transient population. Thereafter it is likely that the declining Flk-1 population largely 
represents cells of the endothelial lineage as by day 6 of embryoid body development 
Flk-1 is reportedly lost from the haemopoietic lineages (Kabrun et al., 1997). 
 
3.4.2.2 Flk-1 expression in dissociated secondary blast cells 
Flk-1 expression in secondary blast-derived cells was more homogenous than that of 
primary embryoid body-derived cells with clear positive and negative populations. 
Initially, expression also appeared to occur at higher levels on a greater proportion of 
cells, probably due to the culture conditions allowing preferential expansion of the 
BL-CFC over other cell populations which had developed within the embryoid 
bodies. Flk-1 expression in these cells remained elevated until day 2 of blast colony 
formation and declined thereafter. Blast colony development has been described as a 
sequential process involving both proliferation and differentiation events. During the 
first 2 days of blast colony formation the BL-CFC proliferates forming a tight ball of 
cells (D'Souza et al., 2005). During this time surface expression of Flk-1, itself a 
marker of the BL-CFC, remains elevated. Haemopoietic cells then begin to develop 
around this core. The mature blast colony consists of a vascular smooth muscle and 
endothelial core with haemopoietic cells clustered around the periphery (D'Souza et 
al., 2005). The decline in Flk-1 expression from day 3 of blast colony formation 
correlates with the timing of blast expansion and confirms the decrease in Flk-1 
determined using gene expression analysis by D’Souza et al., who observed a rapid 
decrease in Flk-1 cDNA in blast colonies between days 1 and 2  (D'Souza et al., 
2005). The difference in timing of this decrease may be due in part to the use of 
different ES cell lines but is probably due in the main to the greater stability and 
longevity of the protein, compared to RNA The down-regulation of Flk-1 expression 
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upon blast expansion is probably due to its reported down-regulation upon 
haemopoietic commitment (Kabrun et al., 1997). The surface expression that remains 
presumably lies in the non-committed secondary blast population and in committed 
endothelial cells.  
3.4.2.3 Effect of culture in VEGF on Flk-1 expression in dissociated 
day 5 primary embryoid body-derived cells 
Primary embryoid bodies were cultured for 5 days in the presence or absence of 
50ng/ml exogenous VEGF to investigate any possible effects of VEGF on Flk-1 
expression. Day 5 primary embryoid body-derived cells showed a modest but 
significant increase in the percentage of cells expressing Flk-1 on their surface in the 
presence of exogenous VEGF. Possible explanations for this are; that the addition of 
VEGF to the developing embryoid bodies directed differentiation towards the BL-
CFC and endothelial lineages meaning that a greater proportion of cells in the 
embryoid body expressed Flk-1, or that addition of VEGF increased the amount of 
Flk-1 receptor expressed by cells within the Flk-1 positive population. However, 
because Flk-1 expression is so heterogenous within primary embryoid body-derived 
cells and the increase in Flk-1 surface expression is numerically small it is difficult to 
ascertain which of these hypotheses may be correct.  
 
Interestingly, the observed increase in Flk-1 expression upon culture in VEGF 
correlates well with the increase of surface Flk-1 expression in human adult 
endothelial cells upon shorter term VEGF stimulation reported recently (Gampel et 
al., 2006). Gampel et al., reported that unlike in other receptor tyrosine kinase 
systems, where ligand stimulation causes receptor internalisation, VEGF stimulation 
of Flk-1 in HUVECs and HMVECs increased the rate of constitutive receptor 
cycling and thus increased surface Flk-1 expression. Although the results in this 
study correlate well with the results from Gampel et al., the increase in Flk-1 
expression observed in their system was the result of shorter term assays (up to 24 
hours) and it is unclear whether an increase in receptor cycling could be maintained 
over a longer time-course. Shorter-term VEGF stimulation studies utilising confocal 
microscopy would clarify whether VEGF does induce an increase in Flk-1 receptor 
cycling in primary embryoid body-derived cells. If this is the case it is possible that 
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increased receptor cycling could be mediated through activation of the MAPK 
pathway. Studies in neural stem cells have demonstrated that bFGF can cause up-
regulation of Flk-1 surface expression through activation of the MAPK pathway 
(Xiao et al., 2007). In short-term stimulation experiments VEGF does stimulate Flk-1 
mediated ERK1/2 activation (see Figure 3-8), it is therefore possible that this 
increase in Flk-1 surface expression is part of a VEGF-induced autocrine loop. The 
effect of ERK activation on Flk-1 expression could be evaluated using an mES cell 
line expressing tet-regulatable constitutively active MEK-1 (generated by Professor 
Melanie Welham, unpublished data) and/or by using pharmacological inhibitors of 
the MAPK pathway such as U0126 or PD98059 (see section 4.3.1). As the MAPK 
pathway is important for differentiation (Burdon et al., 1999), its constitutive 
activation or inhibition may well affect the timing or balance of differentiation within 
the embryoid body making this approach difficult.  This approach may therefore be 
better suited to short term assays for example in the study of the effects of VEGF-
stimulation on Flk-1 receptor cycling in embryoid body derived cells using confocal 
imaging. 
 
An increase in Flk-1 protein expression upon addition of VEGF has been seen in rat 
kidney explants in longer term assays.  Kidney explants from E14 rats, incubated in 
the presence of 5ng/ml VEGF  for 6 days, demonstrated increased Flk-1 protein 
expression measured by immunoblotting when compared with explants cultured in 
the absence of VEGF (Tufro et al., 1999). Unfortunately we were unable to optimise 
Flk-1 immunoblotting in our system during this experiment so it is unknown whether 
the observed increase in Flk-1 surface expression was accompanied by an increase in 
total Flk-1 expression, as demonstrated by Tufro et al., indicating an increase in Flk-
1 transcription, or no such increase indicating that the increase in Flk-1 surface 
expression was due to increased receptor trafficking as observed by Gampel et al. 
Increased Flk-1 transcription could be investigated using semi-quantitative RT-PCR 
or quantitative PCR to monitior levels of Flk-1 gene expression in cells of embryoid 
bodies cultured in the presence or absence of exogenous VEGF. The effect of VEGF 
on Flk-1 receptor trafficking could be investigated using a similar strategy to that 
used by Gampel et al. Flk-1 positive embryoid body-derived cells could be sorted 
using FACS or a magnetic based cell sorting system such as the MACS system.  
Following short-term VEGF-stimulation cells could be fixed and permeabilised and 
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an anti-Flk-1 antibody could be used to study localisation of the Flk-1 receptor in 
VEGF stimulated and unstimulated Flk-1-expressing cells using confocal 
microscopy. 
 
Initially, a more thorough characterisation of the perceived effect of VEGF on Flk-1 
expression in embryoid body-derived cells might include a more complete time 
course of Flk-1 surface expression in the presence and absence of VEGF to assess 
when the increase in surface expression first occurs and whether the kinetics of Flk-1 
expression are altered in the presence of exogenous VEGF.  The effect of VEGF on 
Flk-1 surface expression may be greater if the effects of endogenous VEGF could be 
diminished by use of a neutralising antibody or more simply by the use of VEGF null 
ES cells (Ng et al., 2004)  
 
To further dissect the mechanism by which culture of embryoid bodies with 
exogenous VEGF increases Flk-1 expression immunohistochemistry or confocal 
microscopy could be used better quantify the percentage of cells expressing Flk-1 in 
the presence and absence of VEGF to determine whether the overall percentage of 
cells expressing Flk-1 changes. If changes in the percentage of cells expressing Flk-1 
were seen gene expression profiling of lineage specific genes including Brachyury, 
Scl, Pecam-1, Pax-6, Nodal and Gata-6 could be used to further assess any effects on 
lineage commitment.  
3.4.3 VEGF induced Flk-1 signalling 
3.4.3.1 VEGF- induced protein tyrosine phosphorylation 
VEGF stimulation of dissociated primary embryoid body cells did not appear to 
greatly affect the tyrosine phosphorylation status of proteins within the cells, at least 
as measured by immunoblotting with an anti-phosphotyrosine antibody. Increased 
tyrosine phosphorylation of a protein of ~230kDa was thought to be likely to 
represent autophosphorylation of the fully glycosylated Flk-1 receptor, as observed 
by other researchers in different cell types (Dougher and Terman, 1999; Kendall et 
al., 1999; Neufeld et al., 1999). This lack of obvious tyrosine phosphorylation 
cascades does not mean that Flk-1 is not mediating many signalling processes in 
these cells however, only that they are more subtle. 
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3.4.3.2 VEGF- induced activation of the MAPK pathway 
In adult endothelial cells VEGF stimulation has been shown to activate the Mitogen 
Activated Protein Kinase (MAPK) pathway, which is important for growth, 
differentiation and development of endothelial cells (Doanes et al., 1999; Gliki et al., 
2001; Takahashi and Shibuya, 1997). ERK1/2, a downstream effector of the MAPK 
pathway is usually activated only transiently (Lodish et al., 1999; Takahashi and 
Shibuya, 1997). However, only a longer term 30 minute VEGF stimulation of 
embryoid body derived cells had previously been reported to activate MAPK 
signalling (Park et al., 2004). Initial experiments demonstrated that ERK1/2 were 
transiently phosphorylated by VEGF stimulation of primary embryoid body-derived 
cells (Figure 3-11A), cells derived from secondary blasts (Figure 3-11C) and D4T 
embryoid body-derived endothelial cells (included as a control; Figure 3-11D) with 
phosphorylation peaking at 2 minutes and declining to basal by 30 minutes. This 
VEGF-induced ERK1/2 phosphorylation profile is typical of ERK1/2 activation and 
correlates well with previous work in rat sinusoidal endothelial cells (Takahashi and 
Shibuya, 1997). An increase in ERK1/2 phosphorylation over basal was not 
visualised following 30 minute VEGF stimulation in contrast to findings reported by 
Park et. al. (Park et al., 2004)  though in this previous study, extensive time-course 
experiments were not performed. This is possibly due to the comparatively higher 
background ERK1/2 phosphorylation observed in our study that may have been 
caused by culture of the embryoid bodies in serum containing medium. Park et al., 
utilised serum-free culture conditions which may have decreased basal ERK1/2 
phosphorylation allowing a greater window for visualisation of increases in ERK1/2 
phosphorylation. Increasing the duration of serum-starvation of embryoid body-
derived cells prior to VEGF-stimuation to 5 hours however, did not decrease basal 
ERK phosphorylation in this study.  
 
3.4.3.3 Is VEGF- mediated ERK1/2 signalling activated via PLCγ? 
VEGF stimulation of day 5 primary embryoid body-derived cells caused a transient 
increase in PKC phosphorylation. Phosphorylation peaked at 2 minutes and was back 
to basal levels by 5 minutes correlating well with previous reports of VEGF-induced 
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PKC activation in bovine aortic endothelial cells (BAECs) in which VEGF 
stimulated formation of 3H-DAG peaked by 5 minutes stimulation (Xia et al., 1996).  
 
Work in HUVECs suggests that in adult human endothelial cells VEGF-induced 
MAPK activation occurs through a phospholipase C-γ  (PLCγ)-dependent Protein 
Kinase C (PKC)-mediated mechanism rather than the classical Ras-Raf pathway 
(Doanes et al., 1999; Gliki et al., 2001; Yashima et al., 2001). However, further work 
by Yashima et. al. demonstrated that the mechanism of VEGF activation of the 
MAPK pathway may be heterogenous between endothelial cells of different origins 
(Yashima et al., 2001). As VEGF-induced PKC phosphorylation occurred within the 
correct time frame that could allow PKC to mediate MAPK activation, the role of 
PKC in EB-derived cells was investigated further. Previous studies that have 
implicated VEGF-induced PLCγ1 signalling through PKC activation, as a 
mechanism of MAPK activation, have relied heavily on the use of pharmacological 
inhibitors. PKC-mediated MAPK activation was demonstrated by Gliki et al., and 
Doanes et  al., when inhibition of PKC with 1μM Calphostin C also inhibited VEGF-
induced activation of the MAPK pathway (Doanes et al., 1999; Gliki et al., 2001). 
Initial investigations were therefore carried out using the same conditions to ascertain 
whether this result would be replicated in embryoid body-derived cells. No inhibition 
of VEGF-stimulated ERK1/2 phosphorylation was observed when cells were 
preincubated with 1μM Calphostin C. This suggests that VEGF-induced activation of 
the MAPK pathway in embryoid body-derived cells is not dependent on PKC.  
 
Flk-1-mediated activation of the classical α  and novel δ PKC isoforms has been 
implicated in experiments performed in human endothelial cells (Gliki et al., 2001; 
Kuriyama et al., 2004). Immunoblotting was therefore also performed with an anti-
phospho-PKCδ antibody to investigate VEGF-induced PKCδ activation in primary 
embryoid body-derived cells. No increase in PKCδ phosphorylation was observed 
suggesting PKCδ may not be activated by VEGF stimulation in this system. Further 
investigations in which embryoid body-derived cells were pre-incubated with the 
classical PKC inhibitor Gö6796 prior to VEGF stimulation also demonstrated no 
inhibition of ERK1/2 phosphorylation at 30 or 300nM Gö6796, although some 
inhibition was seen at 3μM Gö6796. Gliki et al., used the inhibitor at 1μM, but 
reported no such effect. As this experiment was only carried out once during the 
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course of my study, this finding is by no means conclusive. The reported IC50 of 
Gö6796 against isolated PKCα and β is 2.3nM (Martiny-Baron et al., 1993). It is 
therefore possible that any inhibition of VEGF stimulated ERK1/2 phosphorylation 
seen upon incubation with 3μM Gö6796 may have been due to non-specific 
inhibition or toxicity of the inhibitor.  
 
The investigations conducted as part of this study suggest that PKC may not be an 
important mediator of VEGF-induced activation of the MAPK pathway in murine 
embryoid body-derived cells, a result also observed in Human Microvascular 
Endothelial Cells (HMVECs) (Yashima et al., 2001) thus this result is not without 
precedent. However, as the efficacy of PKC inhibition was not determined, 
additional, more detailed studies are required to confrm these observations. Possible 
further studies could include assessment of PKC inhibition using in vitro kinase 
assays. Alternatively, the effect of inhibition of PLCγ, with a pharmacological 
inhibitor such as U73122 (Bleasedale et al., 1989) on MAPK activation could be 
investigated and activation of PKC could be used to confirm PLCγ inhibition. If 
PKC/PLCγ involvement were demonstrated, the role of specific isoforms could be 
investigated in more detail using antibodies to detect phosphorylation of specific 
PKC isoforms upon VEGF-stimulation. Alternatively, incubation of embryoid body-
derived ES cells with isoform specific inhibitors such as rottlerin, followed by VEGF 
stimulation and immunoblotting with the pan-phospho-PKC antibody, or, siRNA 
knockdown of specific PKC isoforms in Flk-1 expressing ES cells (see chapter 5), 
again monitored by immunoblotting with a pan-phospho-PKC antibody, could be 
used to investigate the isoform specificity of VEGF-stimulated PKC activation.    
 
3.4.3.4 VEGF does not appear to activate PI3K in primary embryoid 
body- derived cells 
VEGF stimulation of primary embryoid body-derived cells, secondary blast-derived 
cells and the D4T embryoid body-derived endothelial cell line failed to demonstrate 
any increase in phosphorylation in a number of downstream effectors of PI3K 
signalling. However, VEGF stimulation of HUVEC cells with the same 
concentration of murine VEGF over the same time-course did demonstrate 
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phosphorylation of downstream effectors of the PI3K signalling pathway suggesting 
the time-course and ligand concentration used were not the cause of this apparent 
lack of activation. There are a number of possibilities to explain these results. Firstly, 
 
it is possible that VEGF does induce PI3K activation but to only a small degree such 
that the increase in phosphorylation of downstream effectors is small compared to 
basal levels of PI3K activation and therefore difficult to visualise by 
immunoblotting. The EB-derived cells and D4T cells exhibited significant 
phosphorylation of downstream effectors, even under non-treated conditions (see 
Figure 3-11 A,C and D) indicative of high basal levels of PI3K activity. The high 
basal levels of PI3K activity could mask any potential stimulatory effect of VEGF on 
further activation of this pathway. If this is the case elucidation of any VEGF-
induced contribution to cellular PI3K activity would be difficult. High basal levels of 
PI3K activity were also seen in VEGF-stimulated Flk-1 null embryoid body-derived 
cells suggesting that the high levels of basal PI3K activation were not mediated 
through the Flk-1 receptor. Flk-1 mediated PI3K activation could be investigated 
further by measurement of D3 phosphoinositides within the cells, under basal 
conditions and following VEGF stimulation. The interaction of PI3Ks with Flk-1 
could also be investigated using Flk-1 immunoprecipitation and immunblot analysis 
with anti-p85 and anti-Shb antibodies. 
 
If the PI3K pathway is indeed not activated by VEGF stimulation in embryoid body-
derived cells, as the data generated during this study suggests, this could indicate that 
there are significant differences in the requirements for Flk-1 signalling between 
adult and developmental systems. In human endothelial cells VEGF-induced PI3K 
activation is important for a number of processes including proliferation (Dayanir et 
al., 2001; Hamada et al., 2005), migration (Holmqvist et al., 2004), cell survival 
(Fujio and Walsh, 1999; Gerber et al., 1998) and eNOS production (Bates and 
Harper, 2002; Fulton et al., 1999; Lin and Sessa, 2006). The requirements of Flk-1 
signalling during early development and in the adult are somewhat different. For 
example, the eNOS knockout mouse shows no remarkable phenotype demonstrating 
only a limb defect unrelated to the development of haemopoietic and endothelial 
cells (Gregg et al., 1998) whilst in adult endothelial cells eNOS production is an 
important downstream effect of Flk-1 signalling, mediating vascular smooth muscle 
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relaxation. Important requirements for Flk-1 signalling during haemopoietic and 
endothelial differentiation are likely to include migration, proliferation, 
differentiation and cell survival. Proliferative and differentiative signals can be 
transduced through the MAPK pathway which is demonstrably activated upon VEGF 
stimulation (see Figure 3-8). Furthermore, it is possible that cell survival in EB-
derived cells is mediated by other signalling pathways. 
 
A recent study into the importance of PI3K signalling in early development and 
haemopoiesis found that inhibition of the PI3K pathway, pharmacologically using 
the LY294002 inhibitor, or genetically using a PDK-1-/- ES cell line, caused reduced 
cellularity upon embryoid body formation. This reduced cellularity was due to a 
defect in proliferation, rather than an increase in cellular apoptosis. Furthermore, 
inhibition of the PI3K pathway also inhibited expansion of blast colonies. However, 
the formation of the BL-CFC and its differentiation towards the haemopoietic lineage 
were not affected and differentiation towards the haemopoietic lineage was actually 
enhanced (Bone and Welham, 2007). It may be the case that although the PI3K 
pathway is important during development it does not play a role downstream of Flk-1 
signalling during early embryoid body development. Basal levels of phosphorylation 
of the down-stream mediators of PI3K probed for in the immunoblots of VEGF-
stimulated primary embryoid body-derived cells were high, even in Flk-1-/- EBs, 
suggesting activation of this pathway, even during serum-starvation, is not mediated 
by Flk-1 dependent signalling (e.g through a VEGF autocrine loop). Further studies 
using pharmacological inhibitors such as LY294002 and wortmannin to gauge the 
importance of PI3K signalling in VEGF/Flk-1 mediated processes such as 
endothelial differentiation may help to elucidate its role (see section 4.2.1.). 
  
3.4.3.5 Effects of inhibiting the PI3K and MAPK pathways on VEGF-
induced MAPK activation 
Inhibition of the MAPK pathway with the MEK1/2 inhibitor U0126 caused 
inhibition of all ERK1/2 phosphorylation but had no effect on the phosphorylation 
status of the S6 ribosomal protein, a downstream effector of the PI3K pathway. 
Inhibition of PI3K with LY294002 not only inhibited phosphorylation of S6 
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ribosomal protein, but also increased phosphorylation of ERK1/2, suggesting that the 
PI3K pathway inhibits activation of the MAPK pathway in primary embryoid body-
derived cells. ERK1/2 phosphorylation increased not only in the VEGF-stimulated 
samples but also, perhaps to a lesser extent, in the unstimulated control. Increased 
basal ERK1/2 phosphorylation upon pharmacological and genetic inhibition of the 
PI3K pathway was also observed in undifferentiated ES cells by Paling et al., (Paling 
et al., 2004). The results presented here provide evidence of cross-talk between the 
MAPK and PI3K pathways in primary embryoid body-derived cells and correlate 
well with work performed by Blum et al., demonstrating an inhibitory role for PI3K 
in VEGF induced MAPK-dependent tissue factor expression (Blum et al., 2001). 
PI3K was also found to inhibit EGF-induced MAPK signalling in HEK293 cells and 
studies into the mechanism of PI3K inhibition of MAPK signalling in this system 
revealed that the cross-talk between the PI3K and MAPK signalling pathways may 
be mediated by PKB phosphorylation and inactivation of Raf, an upstream effector 
of MAPK signalling in many cell types (Zimmermann and Moelling, 1999). More 
recently, a study in zebrafish has implicated opposing roles of VEGF-induced 
MAPK activation and PI3K activation (which the authors also considered to be 
VEGF-induced) as important for endothelial specification towards either an arterial 
(MAPK) or venous (PI3K) fate (Hong et al., 2006).  
 
As no VEGF-induced phosphorylation of downstream effectors of the PI3K 
signalling cascade was observed in primary embryoid body-derived cells it is 
possible that this pathway is not activated downstream of Flk-1 until later in 
development or in the adult. If this is the case, then it raises questions as to how Flk-
1-mediated PI3K signalling is either initially depressed or subsequently up-regulated. 
It is possible that the adapter protein/s which later couple Flk-1 to PI3K are not 
expressed in Flk-1 positive cells at this time. To investigate this possibility, Flk-1 
immunoprecipitations could be probed with antibodies raised against candidate 
adapter proteins or expression of adapter protein transcripts in embryoid body-
derived cells sorted for Flk-1 expression could be assessed using RT-PCR. Potential 
candidate adaptor proteins linking Flk-1 to PI3K include Gab1, Shb and 
VRAP/TSAd (see section 1.4.2). Of these Shb is required for mesodermal formation 
so is likely to be expressed in conjunction with Flk-1 (Kriz et al., 2006; Rolny et al., 
2005) and Gab1 is expressed during this stage of embryogenesis, though in neither 
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case is their localisation within the embryo reported 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.277409 
accessed 7th September, 2007). VRAP/TSAd expression, however, has not been 
reported at this early stage of embryoid body formation 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.86361 
accessed 7th September 2007) though it has been noted in some blood vessels of the 
day 8 embryoid body by Matsumoto et al., (Matsumoto et al., 2005).  
3.4.4 Conclusions 
E14tg2A embryonic stem cells can be differentiated to form primary embryoid 
bodies as an in vitro model of embryogenesis. Cells from dissociated embryoid 
bodies express the receptor tyrosine kinase Flk-1 from day 3.5 of differentiation, 
with expression peaking between days 4 and 6 and declining thereafter. VEGF 
stimulation of these embryoid body-derived cells results in transphosphorylation of 
the receptor itself and subsequent activation of the MAPK and PLCγ1 signalling 
pathways. However, VEGF does not appear to activate the PI3K pathway in these 
cells, despite VEGF-mediated PI3K signalling playing an important role in adult 
endothelial cells. However, inhibition of the PI3K cascade increases ERK 
phosphorylation suggesting cross-talk between these two pathways. A summary of 
VEGF mediated Flk-1 signalling elucidated so far is shown in Figure 3-13. 
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Figure 3-13 Model of VEGF-induced Flk-1 signalling in early embryoid body 
development based upon signalling studies in chapter 3. 
 
 
 
 
 
PLC γ
RafRas
VEGF
Flk-1
Y1054 
Y1175 
Y1059 
Y951
DAG 
Ca2+
PKC 
MEK
ERK
PI3K 
PKB/Akt autophosphorylation 
Interaction 
Putative 
interaction 
X 
Chapter 4 –  Results 
 138
4  
Chapter 4 
The role of Flk-1 
signalling during ES cell 
differentiation towards 
endothelial and 
cardiomyocyte lineages 
 
 
 
 
 
 
 
 
Chapter 4 –  Results 
 139
4.1 Introduction 
In chapter 3 I discovered that VEGF stimulation of Flk-1 in an embryoid body model 
of development led to activation of the MAPK and PLCγ1 pathways but, unlike in 
adult endothelial cells, not the PI3K pathway. To further elucidate the importance of 
Flk-1-mediated signalling during in vitro models of development functional assays 
were performed to investigate the importance of Flk-1 signalling during ES cell 
differentiation along endothelial and cardiac lineages.  
 
Early research into the role of Flk-1 during development, demonstrated its role in 
endothelial cell specification. The Flk-1 knockout mouse dies due to a failure in 
vasculogenesis (Shalaby et al., 1995) and it has recently been demonstrated that all 
early embryonic endothelial cells arise from Flk-1 positive progenitors (Ueno and 
Weissman, 2006).  The role of Flk-1 in the development of cardiac lineages has been 
discovered more recently. In vivo lineage tracing experiments followed Flk-1 
positive progenitors exiting the primitive streak to the cardiac crescent (Ema et al., 
2006). In vitro models of cardiogenesis have demonstrated that VEGF treatment up-
regulates cardiac markers whilst treatment with an anti-Flk-1 antibody decreases 
their expression (Chen et al., 2006). Furthermore, the Keller group identified a 
second cell population which up-regulated Flk-1 later than cells fated to the 
haemangioblast from which cardiac precursors arose (Kattman et al., 2006).  
 
The temporal requirement for Flk-1 expression and the downstream signals involved 
in cardiac and endothelial specification, vasculogenesis and angiogenesis in the 
embryo have not yet been elucidated. In this chapter in vitro models of 
vasculogenesis/angiogenesis and the formation of beating cardiomyocytes were used 
alongside Flk-1 knockout ES cells and pharmacological inhibitors of Flk-1, the 
MAPK pathway and the PI3K pathway to investigate the importance of the timing of 
Flk-1 expression and its downstream signals during differentiation towards the 
endothelial and cardiomyocyte lineages. 
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4.2 The role of Flk-1 and its downstream 
signalling in endothelial development 
The first step in the generation of a functional circulatory system is the formation of 
a primitive vascular plexus in which nascent vessels consist of a tube of endothelial 
cells (Jain, 2003). Flk-1 is expressed on the early endothelial precursors which 
differentiate into the endothelial cells of these early vessels (Ueno and Weissman, 
2006) and the Flk-1 null animal dies due to a failure in formation of such blood 
vessels (Shalaby et al., 1995). In the adult animal Flk-1 is required for angiogenesis 
and its expression is maintained on adult endothelial cells (Zachary, 2001). The 
precise role of Flk-1 in early vessel formation has been difficult to study due to the 
early embryonic lethality of Flk-1 null mice. A migratory role has been implicated 
for Flk-1 in guiding endothelial precursors (Shalaby et al., 1997) and in vitro work, 
using Flk-1 null ES cells, reported formation of endothelial precursors in an 
embryoid body system, (Schuh et al., 1999) supporting the hypothesis that 
endothelial precursors can be specified in the absence of Flk-1 but fail to migrate in 
vivo causing the lethal phenotype.  
 
To investigate the importance and possible function of Flk-1 and its downstream 
signalling in embryonic vasculogenesis and angiogenesis, an embryoid body-based 
endothelial sprouting assay from Stem Cell Technologies was used. The assay was 
performed in two stages, embryoid body formation, during which vasculogenesis  
occurred (endothelial specification) followed by transplantation of the embryoid 
bodies into a collagen matrix, in which sprouting angiogenesis occurred (angiogenic 
expansion). This allowed dissection of the role of Flk-1 (using Flk-1-/- ES cells and 
the Flk-1 inhibitors, VEGFR2 kinase inhibitors I and II) and the MAPK and PI3K 
pathways (using their inhibitors U0126 and LY294002 respectively) in both 
processes. 
 
The basis of the Stem Cell Technologies endothelial sprouting assay was a procedure 
developed by Feraud et al., as a method of studying early vasculogenesis and 
angiogenesis processes which are relatively inaccessible  for study in the embryo 
(Feraud et al., 2001). Earlier studies had demonstrated formation of extensive 
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vascular structures in a majority of embryoid bodies differentiated for 10-11 days 
(Hirashima et al., 1999; Risau et al., 1988; Vittet et al., 1996; Wang et al., 1992). 
Feraud et. al. demonstrated that when these embryoid bodies were placed in a matrix 
of type I collagen (a major component of pericapilliary connective tissue), in the 
presence of angiogenic growth factors, endothelial cells migrated out and formed 
visible projections in a process of sprouting angiogenesis. Pecam1 and vWF marker 
expression demonstrated that whilst some cellular projections were not attributable to 
the endothelial lineage ~50% of the sprouts were true endothelial sprouts. Embryoid 
bodies cultured in the sprouting phase in the absence of angiogenic cytokines were 
unable to produce sprouts of an endothelial origin. Removal of VEGF from the 
angiogenic cytokine cocktail reduced the number of endothelial sprouts by 80% 
indicating that VEGF signalling plays an important role in the formation of 
angiogenic sprouts in the assay. However, the addition of the growth factor cocktail 
also increased the number of non-endothelial sprouts indicating pleiotrophic effects 
(Feraud et al., 2001).   
 
Upon conducting the sprouting angiogenesis assay it became apparent that the extent 
of sprouting of embryoid bodies under different conditions must be taken into 
account in order for true comparisons between treatments to be made. To this end 
three definitions describing the extent of sprouting from embryoid bodies were used. 
These were many, few or no sprouts, defined as follows, and illustrated in Figure    
4-1: 
 
Many sprouts defined embryoid bodies from which more than 5 visible sprouts of 
greater than the radius of the embryoid body or more than 10 visible sprouts of less 
than the radius of the embryoid body were projected. Embryoid bodies exhibiting 
‘many’ sprouts were considered likely to represent angiogenic sprouting. 
Few sprouts defined embryoid bodies which formed less sprouts than would fit the 
parameters of ‘many’. This degree of sprouting was observed in embryoid bodies 
cultured in the absence of angiogenic cytokines which are reportedly unable to 
produce endothelial sprouts (Feraud et al., 2001).  They were therefore considered 
most likely ‘non-endothelial’. 
No sprouts defined embryoid bodies which formed no sprouting projections in the 
sprouting angiogenesis assay. 
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Figure 4-1The endothelial sprouting assay. Embryonic stem cells were differentiated in 
methylcellulose in the presence of angiogenic cytokines. After 10-11 days they were replated 
into fresh endothelial medium containing a collagen matrix. Sprouting, indicative of 
sprouting angiogenesis, was visible from 2 days onwards. Embryoid bodies under different 
conditions produced many, few or no sprouts (for definitions see previous text). The extent 
of sprouting under different experimental conditions was quantified in duplicate for each 
independent experiment. 
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4.2.1 Effects of inhibition or deletion of Flk-1 on endothelial 
sprouting 
Initial characterisation of the role or requirement for Flk-1 in the endothelial 
sprouting assay was required before the importance of various downstream signalling 
pathways could be dissected. For this a Flk-1 knockout ES cell line and two 
structurally distinct pharmacological inhibitors of Flk-1, VEGFR2 kinase inhibitors I 
and II were utilised. The use of inhibitors allowed dissection of the role of Flk-1 in 
one or both stages of the assay and allowed validation of results gained using the Flk-
1 knockout ES cell line. 
4.2.1.1 Dose optimisation of Flk-1 inhibitors 
Two Flk-1 inhibitors were used in the study; VEGFR2 kinase inhibitor-1 ((z)-3[(2,4-
dimethyl-3(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]indolin-2-one; termed KI1) 
(Sun et al., 1998)  and VEGFR2 kinase inhibitor-2 ((z)-5-Bromo-3-(4,5,6,7 
tetrahydro-1Hindol-2methylene)-1,3-dihydroindol-2-one; termed KI2) (Sun et al., 
2000). The mechanism of action of both was competitive inhibition at the ATP 
binding site. As the Flk-1 inhibitors had not been previously characterised in an ES 
cell system dose optimisation for Flk-1 inhibition was required. The reported IC50 of 
KI1 for inhibition of tyrosine kinase activity in an NIH3T3 cell line engineered to 
overexpress Flk-1 was 70nM. The compound was quoted as having >1000-fold 
selectivity over PDGFRβ, EGF-R and IGF-1R receptor tyrosine kinases (RTKs) (Sun 
et al., 1998). The reported IC50 of KI2 against Flk-1 in a peptide-based 
transphosphorylation assay was also 70nM though KI2 was less selective with regard 
to PDGF-Rβ for which it’s reported IC50 (this time in a biochemical tyrosine 
autophosphorylation assay) was 920nM. IC50’s for inhibition of ligand-induced cell 
proliferation, measured by incorporation of BrdU, were 110nM for inhibition of 
VEGF-induced HUVEC proliferation and 2.11μM for PDGF-induced proliferation of 
NIH-3T3 cells (Sun et al., 2000). As the assays used to measure IC50 values for Flk-1 
and PDGFβR were not identical it is difficult to compare the IC50 values obtained. 
However, the possibility of non-selective inhibition of PDGFβR needs to be taken 
into account when using KI2. 
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As optimisation of specific antibodies detecting tyrosine phosphorylated residues on 
Flk-1 in our immunoblotting system had not been possible Flk-1-mediated ERK1/2 
phosphorylation was used as a measure of Flk-1 activation status. Day 5 embryoid 
bodies were dissociated and the dissociated cells obtained were serum starved for 3 
hours prior to a 30 minute preincubation with the inhibitor or DMSO as a control. 
Cells were then stimulated with 20ng/ml VEGF for 0, 2 or 10 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4-2 VEGF-stimulated primary embryoid body-derived cells pretreated with A) 
VEGFR2 kinase inhibitor-1 and B) VEGFR2 kinase inhibitor-2. Dissociated day 5 
embryoid body-derived cells were serum starved for 3 hours prior to a 30 minute incubation 
with a DMSO control, VEGFR2 kinase inhibitor 1 (KI-1) or VEGFR2 kinase inhibitor-2 
(KI-2). Cells were then stimulated with 20ng/ml VEGF for 0, 2 or 10 minutes. 
Immunoblotting was performed and blots were probed with an anti-phospho ERK1/2 
antibody and then stripped and reprobed with anti-ERK1/2 and anti-SHP-2 antibodies to 
check for equal loading. The blots shown are representative of 2 individual experiments. 
500nM VEGFR2 kinase inhibitor-1 was also used but this did not diminish ERK 
phosphorylation.  
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Figure 4-2 illustrates that 5µM of both VEGFR2 inhibitors appears to partially 
inhibit Flk-1-induced ERK1/2 phosphorylation, possibly shifting the time course of 
Flk-1-mediated ERK1/2 activation which appears to peak at 10 minutes rather than 2 
minutes. Although 10μM of both inhibitors appears to facilitate greater inhibition of 
ERK1/2 phosphorylation inhibition with 10μM KI-2, also appears to inhibit basal 
ERK phosphorylation suggesting off-target inhibition of other signalling pathways 
that activate MAPK signalling. Thus, 5μM of both inhibitors was used in the 
functional endothelial sprouting assay.  
 
4.2.1.2 Importance of Flk-1 for endothelial sprouting in primary 
embryoid bodies 
 
Flk-1 is required for vasculogenesis and angiogenesis in vivo (Jain, 2003; Shalaby et 
al., 1995). To validate the endothelial sprouting assay as a model for the study of the 
involvement of Flk-1 and Flk-1 signalling during endothelial development, 
molecular and genetic approaches were used to characterise its importance in the 
endothelial sprouting assay.  
 
Firstly, the ability of embryoid bodies derived from Flk-1-/- ES cells or R1 parental 
ES cells to form angiogenic sprouts was assessed. As illustrated by Figure 4-3 in the 
presence of cytokines, some Flk-1-/- embryoid bodies did produce ‘many’ sprouts 
though significantly fewer than the percentage of wild type R1 embryoid bodies. 
This suggests that either the Flk-1-/- EBs contained less angiogenic precursors, that 
the sprouts from these embryoid bodies were not of endothelial origin or that 
expansion of all angiogenic precursors was not possible.  
 
Sprouting was reduced in the absence of angiogenic cytokines, as previously 
reported (Feraud et al., 2001). There was no significant difference between the 
number of sprouting Flk-1-/- embryoid bodies compared with R1 embryoid bodies in 
the absence of cytokines.   
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Figure 4-3 Comparison of sprout formation between R1 and Flk-1-/- primary embryoid 
bodies.  R1 and Flk-1-/- primary embryoid bodies were cultured with angiogenic cytokines 
for 10 days prior to being placed in a collagen matrix, with (+cyto) or without (no cyto) 
angiogenic cytokines, for 2 days to promote sprouting indicative of angiogenesis.  The 
percentage of embryoid bodies sprouting was quantified using the parameters set out in 
section 4.2. Results shown represent pooled data from 6 experiments. The chart illustrates 
the percentage of embryoid bodies from each culture condition which exhibited ‘many’ 
sprouts indicative of sprouting angiogenesis. Error bars represent s.e.m. ANOVA 
demonstrated significant differences between the four culture conditions which were 
analysed further using Tukeys honestly significant difference post-hoc test. Significant 
differences are illustrated *** p<0.01.  
 
To confirm that the reduction in sprouting observed with Flk-1 null EBs was due to 
the lack of Flk-1 expression, rather than other differences between the cell lines, R1 
wild type EBs in the assay were incubated with the Flk-1 inhibitors VEGFR2 kinase 
inhibitor-1 (KI-1) and VEGFR2 kinase inhibitor-2 (KI-2). Additionally, treatment 
with KI-1 or KI-2 in the first stage of embryoid body formation, the second stage of 
angiogenic sprouting or both stages of the assay allowed investigation of the relative 
importance of Flk-1 during each of the two phases of the assay, which represent 
endothelial specification and angiogenic expansion respectively. The results are 
***
***
***
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summarised in Figure 4-4 (KI-1 treatment) and 4-5 (KI-2 treatment). Both inhibitors 
generally decreased the extent of sprouting. Treatment with 5µM KI-1 (illustrated in 
Figure 4-4) in either the first or both phases of the assay significantly decreased the 
number of embryoid bodies exhibiting ‘many’ sprouts though not to the extent 
observed in Flk-1-/- embryoid bodies in the same experiments. Treatment with 5μM 
KI-1 in the second phase of the assay also appeared to decrease the number of 
embryoid bodies with ‘many’ sprouts though this decrease was not statistically 
significant. This decrease in sprouting supports the data from Flk-1-/- embryoid 
bodies though the decrease in sprouting was less dramatic. This may be due to 
incomplete inhibition of Flk-1 or instability of the inhibitor in a long-term assay. 
 
Treatment of embryoid bodies during both the first phase of development and in the 
second sprouting phase with 5µM VEGFR2 kinase inhibitor-2 significantly inhibited 
their ability to sprout (Figure 4-5). Inhibition of Flk-1 with KI-2 in both phases 
appeared to further decrease sprouting when compared with inhibition in either the 
first or second phase suggesting an additive mechanism. Treatment with 500nM KI-2 
showed a similar pattern of inhibition of sprouting though to a lesser extent in the 
first phase. As this experiment was only performed once it is unclear whether this 
inhibition was significant. The KI-2 data supports data previously obtained using 
Flk-1-/- embryoid bodies (Figure 4-3) and validates the assay as a mechanism for 
studying the involvement of Flk-1 signalling in vasculogenesis and angiogenesis. 
Comparing results obtained using either KI-1 or KI-2 it is clear that KI-2 had a 
greater inhibitory effect on endothelial sprouting. This could be due to incomplete 
inhibition by KI-1, the possibility of off-target effects of KI-2 or a combination of 
both factors. 
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Figure 4-4 Comparison of sprout formation between R1 and Flk-1-/- primary embryoid 
bodies and those treated with the Flk-1 inhibitor VEGFR2 kinase inhibitor-1 (KI-1) Primary 
embryoid bodies were cultured with angiogenic cytokines and in the presence or absence of KI-1 
for 10 days (1st stage) prior to being placed in a collagen matrix, with or without KI-1, for a 
further 2 days (2nd stage) to enable sprouting indicative of angiogenesis to proceed. The 
percentage of embryoid bodies sprouting was quantified using the parameters set out in section 
4.2. Figure 4-4 represents pooled data from 3 independent experiments in which embryoid bodies 
were treated in the first, second or both stages of the assay (as indicated) with 5µM KI-1. The 
graph illustrates the % of embryoid bodies from each culture condition that exhibited ‘many’ 
sprouts indicative of angiogenic sprouting. Error bars represent s.e.m. ANOVA showed 
significant differences in sprouting between different culture conditions which were further 
analysed using Tukeys honestly significantly different post-hoc test. Significant differences, 
where shown, are illustrated as follows **p<0.05, ***p<0.01. 
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Figure 4-5 Comparison of sprout formation between R1 and Flk-1-/- primary embryoid 
bodies and those treated with the Flk-1 inhibitor VEGFR2 kinase inhibitor-2 (KI-2) 
Primary embryoid bodies were cultured with angiogenic cytokines and in the presence or 
absence of KI-2 for 10 days (1st stage) prior to being placed in a collagen matrix, with or 
without KI-2, for a further 2 days to enable sprouting indicative of angiogenesis to proceed..  
The percentage of embryoid bodies sprouting was quantified using the parameters set out in 
section 4.2. The graph represents pooled data from 3 independent experiments using 5μM 
KI-2, and one independent experiment in which EBs were incubated with 500nM KI-2, in 
which embryoid bodies were treated in the first, second or both stages of the assay (as 
indicated) with KI-2. The percentage of embryoid bodies with ‘many’ sprouts, indicative of 
angiogenic sprouting from each culture condition is illustrated. Error bars represent s.e.m. 
ANOVA found significant differences between treatments. These differences were further 
analysed using Tukey’s honestly significantly different post-hoc test. Significant differences, 
where shown, are illustrated as follows ***p<0.01, **p<0.05 
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4.2.1.3 The importance of VEGF in endothelial sprouting from 
primary embryoid bodies 
 
The absence of VEGF from the second phase of the endothelial sprouting assay 
reportedly decreases sprouting by up to 80% (Feraud et al., 2001). To confirm this 
and assess its importance as an extrinsic cytokine in both stages of the assay the 
assay was performed using R1-derived embryoid bodies in the presence and absence 
of extrinsic VEGF for both stages.  
 
Figure 4-6 demonstrates that the absence of extrinsic VEGF significantly decreased 
sprouting by R1 embryoid bodies in both the first and second phases confirming 
preliminary work published by Feraud et. al. upon development of the assay (Feraud 
et al., 2001). The level of reduction in the percentage of embryoid bodies with 
‘many’ sprouts was similar to the 80% previously when extrinsic VEGF was omitted 
in the second phase, a greater reduction than observed in its absence from the first 
phase, although this was not significant. This correlates well with data from Ng et 
al., using VEGF null ES cells. No requirement for VEGF was found during 
endothelial specification but VEGF was required for vessel formation (Ng et al., 
2004). As VEGF is reportedly required for vessel formation the extent of sprouting 
in embryoid bodies cultured in the absence of exogenous VEGF suggests that VEGF 
is being secreted by cells within the embryoid bodies. Semi-quantitative RT-PCR 
using RNA extracted from day 11 embryoid bodies demonstrated the presence of 
VEGF mRNA, confirming its production by the embryoid bodies themselves.  
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Figure 4-6 Comparison of sprout formation in the presence and absence of extrinsic VEGF.  
R1 primary embryoid bodies were cultured for 10 days prior to being placed in a collagen matrix 
for 2 days to promote sprouting indicative of angiogenesis. In both stages embryoid bodies were 
cultured in the presence or absence of a cytokine cocktail within which the cytokine VEGF was 
itself present or absent as indicated. The percentage of embryoid bodies sprouting was quantified 
using the parameters set out in section 4.2. Results shown represent pooled data from 3 
independent experiments illustrating the % of embryoid bodies from each culture condition 
which exhibited ‘many’ sprouts. Error bars represent s.e.m. ANOVA demonstrated significant 
differences between the five culture conditions that were analysed further using Fisher’s least 
significant difference post-hoc test. Significant differences, were illustrated ***p≤0.01  
 
4.2.2 Effect of PI3K inhibition on endothelial sprouting 
 
Work discussed in chapter 3 (see section 3.3.4) demonstrated no apparent activation 
of PI3K upon VEGF stimulation of Flk-1 in cells derived from primary embryoid 
bodies. This contrasts with previous work in adult endothelial cells (Dayanir et al., 
2001; Gerber et al., 1998). In the adult organism PI3K activation promotes 
angiogenesis, at least in part by up-regulating expression of VEGF (Jiang et al., 
2000) making it a popular target in anti-cancer therapeutics (Hennessy et al., 2005). 
PI3K signalling downstream of VEGF/Flk-1 signalling also contributes to 
angiogenesis, promoting endothelial cell migration via an eNOS-dependent 
*** 
*** 
*** 
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mechanism (Morales-Ruiz et al., 2000). Moreover, recent work using embryoid 
bodies as a model of early development has cited involvement of the PI3K and 
MAPK pathways in the divergence of arterial and venous cell fates respectively 
(Hong et al., 2006). As Flk-1 does not appear to mediate PI3K activation in primary 
embryoid bodies, LY294002, a broad range PI3K inhibitor was used to investigate 
whether PI3K is involved in angiogenic sprouting in the endothelial sprouting assay. 
Previous work had demonstrated that complete inhibition of the PI3K pathway using 
either 10µM LY294002 or a PDK-1-/- ES cell line impairs embryoid body formation 
(Bone and Welham, 2007) meaning that only a partial inhibition with 5µM 
LY294002 could be used to investigate the role of this family of kinases in 
endothelial sprouting.  
 
Figure 4-7 illustrates that neither the inclusion of 5µM LY294002 in the assay nor 
the inclusion of 10µM LY294002 in the second, angiogenic expansion phase of the 
assay affected the percentage of embryoid bodies which exhibited ‘many’ sprouts. 
Partial inhibition of this pathway therefore does not appear to affect endothelial 
specification or angiogenic expansion in an embryoid body model of developmental 
vasculogenesis and angiogenesis.  This supports earlier results (see section 3.3.4) in 
which activation of Flk-1, itself an important mediator of endothelial specification 
and angiogenic expansion, did not appear to mediate downstream PI3K signalling.  
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Figure 4-7 Comparison of sprout formation in the presence and absence of the PI3K 
inhibitor LY294002.  R1 primary embryoid bodies were cultured for 10 days prior to being 
placed in a collagen matrix for 2 days to promote sprouting indicative of angiogenesis. In 
both stages embryoid bodies were cultured in the presence or absence of a cytokine cocktail 
The percentage of embryoid bodies sprouting was quantified using the parameters set out in 
section 4.2. Results shown represent pooled data from 3 independent experiments (with the 
exception of 10uM LY294002 (denoted X) which is representative of 2 independent 
experiments. The % of embryoid bodies from each culture condition which exhibited ‘many’ 
sprouts, indicative of angiogenic sprouting, is illustrated. degree of sprouting. Error bars 
represent s.e.m. ANOVA demonstrated no significant differences in the percentage of 
embryoid bodies with ‘many’ sprouts between the cytokine treated embryoid bodies in the 
DMSO control and those cultured in the presence of 5μM LY294002.  
 
 
 
 
 
 
 
 
 
X 
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4.2.3 Effect of MAPK inhibition on endothelial sprouting 
The MAPK pathway is a well characterised downstream effector cascade of Flk-1 
signalling in adult endothelial cells (Doanes et al., 1999; Gliki et al., 2001) and in 
chapter 3 I demonstrated that ERK activation also occurred upon VEGF stimulation 
of embryoid body-derived cells (section 3.3.2). Additionally, MEK-1 over-
expression increases VEGF mRNA levels in fibroblasts (Milanini et al., 1998). In 
vitro experiments using endothelial cell lines and in vivo models of tumourigenesis 
have demonstrated a strong link between inhibition of the MAPK pathway and 
decreased tumour vascularisation and the MEK-1-/- mouse dies at E10.5 due to 
defects in placental vascularisation (reviewed in (Depeille et al., 2007), indicating 
involvement of MEK-1 in developmental vasculogenesis. In order to investigate the 
involvement of MEK signalling in vasculogenesis and angiogenesis in a 
developmental model, embryoid bodies within the endothelial sprouting assay were 
incubated in the presence of the pharmacological MEK1/2 inhibitor U0126 in one or 
both phases of the assay. Previous work in chapter 3 demonstrated that VEGF-
stimulated activation of ERK1/2 was completely inhibited by pre-incubation with 
10µM U0126. However, embryoid bodies failed to form upon incubation with 10µM 
U0126 (this finding is discussed in more depth in section 4.3) therefore 5µM U0126 
was used in further studies. 
 
Figure 4-8 illustrates that treatment of developing or sprouting embryoid bodies with 
the MEK1/2 inhibitor U0126 had no significant effect on the ability of embryoid 
bodies in the endothelial assay to form sprouts Inhibition of this pathway therefore 
does not appear to have any effect on vasculogenesis or angiogenesis in embryoid 
bodies. This tallies with evidence from the MEK-1 knockout mouse in which 
embryonic vascularisation was unaffected, despite defects in placental 
vascularisation (Giroux et al., 1999), and the MEK-2 knockout mouse which was 
viable (Belanger et al., 2003), though the lack of a double MEK-1/MEK-2 knock-out 
makes it difficult to postulate whether redundancy between the two kinases masks 
any potential embryonic defect in vasculogenesis.  
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Figure 4-8 Comparison of sprout formation in the presence and absence of the MEK1/2 
inhibitor U0126.  R1 primary embryoid bodies were cultured for 10 days prior to being 
placed in a collagen matrix for 2 days to promote sprouting, indicative of angiogenesis. In 
both stages embryoid bodies were cultured in the presence or absence of a cytokine cocktail 
and within cytokines present, in the presence and absence of the MEK1/2 inhibitor U0126. 
The percentage of embryoid bodies sprouting was quantified using the parameters set out in 
section 4.2. Results shown represent pooled data from 3 independent experiments. The % of 
embryoid bodies from each culture condition which exhibited ‘many’ sprouts, indicative of 
sprouting angiogenesis, are illustrated. Error bars represent s.e.m. ANOVA demonstrated no 
significant differences between the cytokine treated embryoid bodies in the DMSO control 
and those cultured in the presence of U0126.  
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4.3 Effect of MAPK inhibition on embryoid 
body development and Flk-1 expression 
As part of the investigation into the importance of signalling down-stream of Flk-1 in 
embryonic vasculogenesis (and angiogenesis) the MEK-1/2 inhibitor U0126 was 
utilised in the endothelial sprouting assay (see section 4.2.3). However, attempts to 
differentiate R1 embryonic stem cells into embryoid bodies in the presence of 10µM 
U0126 failed. No or very few embryoid bodies formed and those which did form 
were much smaller than their wild type equivalents.  
 
In order to investigate whether MEK-1/2 inhibition had any effect on the proportion 
of cells within the embryoid bodies expressing Flk-1 or the level of Flk-1 expression, 
flow cytometry was used to investigate Flk-1 expression in embryoid bodies treated 
with the pharmacological inhibitors U0126 and PD98059. U0126 is a non-
competitive inhibitor of MEK-1 and 2 kinase activity whereas PD098059 inhibits 
activation of MEK-1. The IC50 for both inhibitors appears to differ depending on the 
agonist used. However, PD098059 cannot readily be used at concentrations greater 
than 50µM due to low aqueous solubility (Alessi et al., 1995). Both inhibitors are 
reportedly selective at the concentrations utilised.  
4.3.1 Effect of MAPK inhibition on embryoid body 
development 
Previous work by Burdon et. al., using PD98059, an inhibitor of MEK-1 activation, 
demonstrated increased self-renewal of ES cells and an inhibition of embryoid body 
growth, particularly at higher concentrations (100µM). This was thought to be due to 
a defect in differentiation rather than proliferation as the number of cells expressing 
Oct-4 (a marker of ES cell self-renewal) within the treated embryoid bodies was not 
only proportionally higher but the absolute number of self-renewing cells increased 
as the embryoid bodies developed (Burdon et al., 1999). The study used the hanging 
drop aggregation method of embryoid body formation (see Figure 2-1). ES cells were 
differentiated in hanging drops in the absence of LIF for 2 days prior to incubation in 
suspension in the presence or absence of PD98059 thus any early effects of MEK-1 
inhibition may have been missed. Additionally, though only noted at higher 
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concentrations of inhibitor, visual inspection of photographs of embryoid bodies 
appears to show a decreased size even in the presence of only 25µM PD098059.  
 
R1 ES cells were differentiated into embryoid bodies in the presence or absence of 
5µM U0126 or 50 µM PD098059 for 4 days before the numbers of embryoid bodies 
formed were counted. The diameter of 50-80 embryoid bodies cultured under each 
condition were measured under a light microscope, using an eye piece graticule, at 
200X magnification. A counting grid was used to randomise the embryoid bodies 
measured.   
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Figure 4-9 Comparison of number embryoid bodies formed in the presence of DMSO 
control or the MAPK inhibitors U0126 and PD98059.  R1 ES cells were differentiated at 
low density (to form between 100 and 1000 embryoid bodies in the DMSO control) to form 
embryoid bodies using a methylcellulose-based differentiation system (see section 2.2.1) in 
the presence of  DMSO, 5 or 10µM U0126 or 50µM PD098059. After 4 days the number of 
embryoid bodies formed under each culture condition in duplicate 2cm Petri dishes were 
counted. The chart represents these figures as a percentage of the DMSO control using 
pooled data from individual experiments as follows; DMSO control and 5µM U0126 n=6, 10 
µM U0126 n=3, 50µM PD098059 n= 2. Error bars represent s.e.m with the exception of that 
annotated X which represents the range. **p≤0.05, *** p≤0.01 in the paired students t-test 
performed on raw data. 
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Figure 4-9 illustrates that ES cells differentiated in the presence of the MEK-1/2 
inhibitor U0126 formed significantly less embryoid bodies than those cultured in the 
presence of a DMSO control (see Figure 4-10). Very few embryoid bodies formed in 
the presence of 10µM U0126 and those which did form were much smaller than the 
DMSO control EBs. ES cells differentiated in the presence of 50µM PD098059 
showed a decrease in embryoid body formation similar to that seen in the presence of 
5 µM U0126.  
 
Figure 4-10 Comparison of embryoid body size between EBs formed in the presence of 
DMSO control and those formed in the presence of MAPK inhibitors U0126 or 
PD98059.  R1 ES cells were differentiated at low density (to form between 100 and 1000 
embryoid bodies in the DMSO control) to form embryoid bodies using a methylcellulose-
based differentiation system (see section 2.2.1) in the presence of  DMSO, 5µM U0126 or 
50µM PD098059. After 4 days 50-80 embryoid bodies formed under each culture condition 
were measured under a x200 objective using an eye piece graticule. The chart represents the 
mean sizes of embryoid bodies under 3 separate conditions.  DMSO control and 5µM U0126 
data is representative of pooled data from 3 individual experiments. 50µM PD098059 data 
(annotated X) is representative of only one individual experiment. Error bars represent s.e.m 
**p≤0.05 in the paired students t-test. 
 
Figure 4-10 illustrates that differentiation of embryoid bodies in the presence of 5µM 
U0126 caused a significant decrease in embryoid body size. Embryoid bodies 
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differentiated in 10 µM U0126 also appeared significantly smaller than the DMSO 
control. However, due to their scarcity there was not a large enough population for a 
fair comparison to be made. The one set of embryoid bodies differentiated in 50µM 
PD098059 which were measured showed a decrease in size which correlated well 
with that seen in embryoid bodies differentiated in 5µM U0126. 
4.3.2 Effect of MAPK inhibition on Flk-1 expression. 
Inhibition of the MAPK pathway with the pharmacological inhibitors U0126 and 
PD098059 decreased both the ability of ES cells to differentiate to form embryoid 
bodies and the size of subsequent embryoid bodies. In order to investigate whether 
this decrease in size effects the proportion of Flk-1 expressing cells within the 
embryoid bodies, ES cells were differentiated as EBs for between 4 and 6 days in the 
presence or absence of the inhibitors  prior to flow cytometric analysis of Flk-1 
surface expression.  
 
Inhibition of MAPK signalling with either U0126 or PD098059 caused a slight 
apparent decrease in Flk-1 expression on days 4 and 5 post-embryoid body formation 
compared to the DMSO control illustrated in Figure 4-11A. Analysis of variance 
performed on geometric mean fluorescence intensity data showed these differences 
as non-significant (Figure 4-11B). This suggests that inhibition of the MAPK 
pathway does not affect the ability of embryoid bodies to differentiate to form BL-
CFC or later endothelial cells. Further analysis of additional mesodermal, 
haemopoietic and endothelial markers would be required to confirm this hypothesis 
(see section 4.5.3 for further discussion). 
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Figure 4-11 Time-course of Flk-1 expression in cells from dissociated embryoid bodies 
treated with DMSO (control), 5µM U0126 or 50µM PD098059. Cells from dissociated 
embryoid bodies differentiated for between 4 and 6 days, were stained with an anti-Flk-1 
antibody or an equal concentration of isotype-matched control and a secondary FITC-
labelled antibody prior to analysis on a Becton Dickinson FACS Canto flow cytometer. The 
percentage of cell expressing Flk-1 and the geometric Mean Fluorescence Intensity were 
calculated as described in section 3.2.1. Percentage Flk-1 expression was calculated using a 
5% marker gate. The results shown represent pooled data from ≥3 individual experiments. 
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A) Comparison of % Flk-1 expression in cells from dissociated primary embryoid bodies 
differentiated for between 4 and 6 days in the presence of either DMSO (control), 5µM 
U0126 or 50µM PD098059.  B) Comparison of the geometric mean fluorescent intensities 
between isotype control and anti-flk-1 labelled cells from dissociated R1 embryoid bodies 
differentiated for between 4 and 6 days in the presence of either DMSO (control), 5µM 
U0126 or 50µM PD098059. Error bars represent s.e.m. Analysis of variance (ANOVA) 
showed no significant differences geometric mean fluorescence intensities between anti-Flk-
1-labelled cells from treated and un-treated dissociated embryoid bodies.  
 
4.4 Importance of Flk-1 in the differentiation of 
ES cells to form beating cardiomyocytes 
In addition to its importance in endothelial and haemopoietic development, recent 
work has implicated a role for Flk-1 in cardiogenesis (Iida et al., 2005). Lineage 
tracing experiments identified a Flk-1 positive intermediate population which 
appears to develop as cells exit the primitive streak and begin to migrate towards  the 
cardiac cresent (Ema et al., 2006). Other studies, using embryoid bodies as a model 
of cardiogenesis (Boheler et al., 2002; Sachinidis et al., 2002), have demonstrated an 
increase in expression of cardiac markers in response to VEGF. Work by the Keller 
group first identified that the cardiogenic mesoderm population was derived from a 
population which was Brachyury positive but Flk-1 negative at E3.25 the point of  
BL-CFC/haemangioblast formation (Kouskoff et al., 2005). Their work has 
subsequently demonstrated that at E4.25 a new Flk-1 positive population is generated 
which was identified to contain the majority of precursors with cardiac potential 
within the differentiation model and which had the potential to form cardiac, 
endothelial and visceral smooth muscle lineages (Kattman et al., 2006).  
 
Despite a strong association between Flk-1 expression and cardiac differentiation, a 
functional requirement for Flk-1 in cardiogenesis had not been proven. To 
investigate a possible functional requirement for Flk-1 in in vitro cardiac 
development a hanging drop-based differentiation protocol, which promotes 
formation of beating cardiomyocytes, was used to compare the timing and efficiency 
of cardiomyocyte differentiation between R1 parental and Flk-1-/- ES cells.  
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Figure 4-12. Comparison of beating cardiomyocyte formation between R1 (wild-type) 
and Flk-1-/- ES cells in an embryoid body-based model of cardiac differentiation. R1 and 
Flk-1-/-ES cells were differentiated in hanging drops for 2 days and in suspension for a 
further 2 days prior to plating of individual embryoid bodies into gelatine coated wells of a 
96-well plate. 96 wells were scored for the appearance of beating foci daily from 6 to 10 
days after the initiation of the assay. The above chart represents pooled data from 5 
individual experiments. Error bars represent s.e.m. **p≤0.05, *** p≤0.01 in the paired 
students t-test.  
 
Figure 4-12 above demonstrates an apparent delay in differentiation of 
cardiomyocytes in Flk-1-/- ES cells compared with the R1 parentals. Though the 
timing of differentiation within the assay differed by up to a day between 
experiments (hence the relatively high error bars), the relationship was constant. The 
initiation of beating areas within Flk-1-/- embryoid bodies begun later than that of the 
wild type and the percentage of embryoid bodies which differentiated to form 
beating foci were significantly lower on days 6 and 7 of the assay. From day 8 of the 
assay there was no difference in the appearance of beating foci between the 2 cell 
lines and by day 10 when the foci of differentiated R1 cells had begun to stop beating 
the percentage of Flk-1-/- embryoid bodies which had differentiated to form beating 
foci was significantly higher than that found in R1 wells at the same time point. 
***
**
**
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However, there was no significant difference in the highest percentage of wells 
exhibiting beating foci between differentiated R1 and Flk-1-/- ES cells. By day 10 
growth of both cell lines had outstripped the confines of the 96 well plate making it 
impossible to continue the experiment. This data suggests a potential role but not a 
requirement for Flk-1 in cardiomyocyte differentiation. 
 
4.5  Discussion 
Functional assays were used to explore the role of Flk-1 and Flk-1-mediated 
signalling in in vitro assays probing endothelial and cardiac development. 
Additionally, pharmacologcal inhibitors of the MAPK pathway were used to 
investigate its role in embryoid body development. 
4.5.1 Summary 
• In the endothelial sprouting assay, used to investigate endothelial 
specification and subsequent angiogenic expansion, significant decreases in 
the percentage of embryoid bodies undergoing sprouting were observed in 
both ES cell lacking Flk-1 or when wild-type R1 ES cells treated with the 
pharmacological inhibitor VEGFR2 kinase inhibitor 2. 
 
• Withdrawal of extrinsic VEGF from the sprouting endothelial assay caused a 
significant decrease in the number of embryoid bodies which under went 
endothelial sprouting. 
 
• Inhibition of the PI3K pathway with the inhibitor LY294002 had no effect on 
endothelial sprouting. 
 
• Inhibition of the MAPK pathway with the MEK-1/2 inhibitor U0126 or the 
MEK-1 inhibitor PD098059 had no significant effect of endothelial 
sprouting. 
 
• Inhibition of the MAPK pathway with MEK1/2 inhibitor U0126 or the MEK-
1 inhibitor PD098059 decreased the efficiency of embryoid body formation 
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by approximately 50%. The embryoid bodies which did form were decreased 
in diameter by approximately 25%. 
 
• Flk-1 expression in embryoid bodies cultured in the presence of the MAPK 
inhibitors for between 4 and 6 days was not significantly altered when 
compared with DMSO (control)-treated embryoid bodies. 
 
• Flk-1-/- ES cells underwent a delay in differentiation to form foci of beating 
cardiomyocytes when compared with R1 parental ES cells. When the first 
beating foci were observed in differentiated R1 cells no beating areas were 
visible in differentiated Flk-1-/- cells. A day later there were still significantly 
fewer beating foci in differentiated Flk-1-/- embryoid bodies compared to R1 
parental embryoid bodies.  
 
• The potential of Flk-1-/- ES cells to differentiate to form beating 
cardiomyocytes, though temporally delayed, was equivalent to that of R1 
parental ES cells. 
 
4.5.2 The role of Flk-1 and its downstream signalling in 
endothelial development 
The requirement of Flk-1 for both embryonic vasculogenesis and adult angiogenesis 
is well characterised (Shalaby et al., 1995; Zachary, 2001). In chapter 3 some of the 
signalling pathways activated downstream of Flk-1 in an embryoid body model of 
development were elucidated. In order to characterise the importance of these 
signalling molecules in endothelial development an embryoid body-based ‘sprouting 
angiogenesis’ assay was used to assess the effects of inhibiting these pathways on 
vasculogenesis and subsequent angiogenesis within embryoid bodies. Prior to 
dissection of the roles of these pathways the importance of Flk-1 signalling as a 
whole was characterised through the use of both genetic and pharmacological 
approaches.  
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4.5.2.1 Importance of VEGF and Flk-1 in sprouting from primary 
embryoid bodies 
The percentage of Flk-1-/- embryoid bodies with ‘many’ sprouts, indicative of 
aprouting angiogenesis was significantly lower than the percentage of sprouting R1 
parental embryoid bodies. Feraud et al., reported that ~50% of sprouting projections 
from wild type embryoid bodies cultured in the presence of angiogenic cytokines 
were endothelial but that none of those found on embryoid bodies cultured in the 
absence of angiogenic cytokines were endothelial in nature (Feraud et al., 2001). As 
there was no significant difference between the percentage of sprouting R1 embryoid 
bodies in the absence of angiogenic cytokines and the percentage of Flk-1-/- embryoid 
bodies which sprouted this may suggest that sprouting of the       Flk-1-/- embryoid 
bodies was non-endothelial in nature. Whole mount EB staining for endothelial 
markers such as Pecam1, Flk-1 and VE-Cadherin, as performed by Vittet et al., 
would enable clarification of the endothelial nature of the sprouts. 
Immunocytochemical analysis of the sprouts using antibodies against endothelial 
markers such as Pecam1 could clarify this (Vittet et al., 1996). 
 
Culture of R1 embryoid bodies in the presence of 5µM of the Flk-1 inhibitor 
VEGFR2 kinase inhibitor-2 (KI-2) during either the endothelial specification or 
angiogenic expansion stages of the assay caused a decrease in endothelial sprouting, 
similar to that seen in Flk-1-/- embryoid bodies. This suggests, as would be expected, 
that Flk-1 is required both for the formation of angiogenic precursors and for 
vasculogenesis and sprouting angiogenesis. Culture of R1 embryoid bodies in the 
presence of 5µM of the Flk-1 inhibitor VEGFR2 kinase inhibitor-1 (KI-1) in the first 
phase of the assay also caused a significant decrease in the percentage of embryoid 
bodies with ‘many’ sprouts though not to the extent of that seen using either KI-2 or 
the Flk-1-/- ES cell line. There are a number of potential explanations for these 
observations. The decreased effect of KI-1 could be due either to incomplete 
inhibition of Flk-1 or instability of the inhibitor in long-term culture. However, as 
optmisation of an α-phospho-Flk-1 antibody for immunoblotting had been 
unsuccessful at this point both dose-optimisation and stability studies for the Flk-1 
inhibitors were difficult to perform. As endothelial cells first emerge in the centre of 
embryoid bodies (Risau et al., 1988; Vittet et al., 1996; Wang et al., 1992) it is also 
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possible that penetration of either one of the inhibitors into the embryoid bodies was 
insufficient to inhibit Flk-1 in differentiating endothelial cells. Furthermore, we 
cannot rule out the possibility that each inhibitor also inhibits additional kinases, 
which may also be involved in endothelial development. For example, at higher 
doses, KI-2 is known to inhibit PDGFβR, which recruits pericytes/vascular smooth 
muscle cells to the endothelium of nascent blood vessels in response to PDGF 
secreted by endothelial cells. Although the PDGFβR knockout mouse is perinatally 
lethal, it exhibits no defects in endothelial or major blood vessel formation 
(Hellstrom et al., 1999; Soriano, 1994) suggesting that inhibition of PDGFβR would 
not necessarily affect the outcome of the endothelial sprouting assay.  To further 
assess the effects of KI-1 and KI-2, characterisation of their ability to inhibit Flk-1 
signalling in long-term culture could be carried out in the D4T endothelial cell line 
using immunoblotting with an anti-phospho-Flk-1 antibody. Dose response studies 
with each of the inhibitors in the endothelial sprouting assay would also help to 
elucidate whether the differences seen in the ability of KI-1 and KI-2 to inhibit 
sprouting were due to differing potency’s of the inhibitors in the assay or off-target 
effects. 
 
Feraud et al., also demonstrated an 80% decrease in endothelial sprouting in the 
absence of extrinsic VEGF (Feraud et al., 2001) and Ng et al., demonstrated a 
requirement for VEGF in vessel formation but not endothelial specification (Ng et 
al., 2004). The results reported in this thesis demonstrate a significant decrease in 
sprouting upon removal of VEGF from the angiogenic cytokine cocktail but this 
decrease was not as great as that seen upon absence or inhibition of Flk-1. This is 
probably due to VEGF secretion from cells within the embryoid bodies 
(demonstrated by detection of VEGF mRNA in day 11 embryoid bodies) instigating 
an autocrine loop of VEGF-Flk-1 signalling.   
 
The characterisation of the reduction in sprouting in the sprouting endothelial assay 
afforded by use of the Flk-1-/- ES cell line and the Flk-1 inhibitor VEGFR2 kinase 
inhibitor-2 provided a base-line to allow the assay to be used to assess the 
importance of various signalling pathways downstream of Flk-1 in endothelial 
development.  
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4.5.2.2 Effect of PI3K and MAPK inhibition on endothelial sprouting 
from primary embryoid bodies 
Neither PI3K nor MAPK inhibition had any effect on the extent of endothelial 
sprouting from R1 embryoid bodies. Previous work using LY294002 in embryoid 
bodies has demonstrated its stability for at least 5 days (Bone and Welham, 2007) by 
which point any effect upon endothelial specification would have been apparent. As 
the PI3K pathway was not demonstrably activated down-stream of Flk-1 upon 
VEGF-stimulation it is perhaps not surprising that inhibition of PI3K signalling with 
5µM or 10µM LY294002 did not affect vasculogenesis or sprouting angiogenesis at 
this early developmental stage. PI3K signalling has been widely implicated in adult 
angiogenesis and is a key anti-angiogenic target being explored in cancer 
chemotherapy (Hennessy et al., 2005). One possible mechanism for the role of PI3Ks 
is through upregulation of VEGF expression (Jiang et al., 2000). This is supported by 
evidence from a microarray investigating the effect of inhibition of PI3K with 
LY294002 in self-renewing ES cells, in which LY294002 treatment caused 
significant down-regulation of VEGFa and c transcripts (M.J Welham, pers. comm.). 
As VEGF was added exogenously in the assay the effects of decreased VEGF 
expression would be masked. As removal of exogenous VEGF does not fully prevent 
sprouting within the assay (see section 4.5.2.1), addition of 5µM LY294002 to the 
assay in the absence of VEGF could be used to further probe the role of this pathway 
in endothelial development, as would molecular analysis of VEGF expression within 
the assay in the presence and absence of LY294002 using semi-quantitative or 
quantitative RT-PCR.  
 
Inhibition of MAPK signalling with 5µM U0126 also had no effect on the percentage 
of embryoid bodies that underwent sprouting within the assay. This suggests that the 
role of Flk-1 in endothelial differentiation is not mediated through its activation of 
MAPK, which correlates well with studies in knockout animals as neither the MEK-1 
or MEK-2 knockout animals demonstrate defects in embryonic vascularisation 
though this may be due to functional redundancy (Belanger et al., 2003; Giroux et 
al., 1999). However, as use of 10µM U0126 severely inhibited embryoid body 
formation (see section 4.5.3) only 5μM U0126 was used for this study, meaning it is 
possible that the MAPK pathway is required for endothelial development but that 
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residual MEK-1/2 activity meets this requirement. To further investigate the 
importance of MAPK signalling down-stream of Flk-1 in endothelial development a 
less blunt approach utilising site directed mutagenesis of tyrosine residues at amino 
acid positions 951,1175 or 1214, of Flk-1 in order to prevent Flk-1 mediated 
activation of the MAPK pathway could be used. Finally, activation of the MAPK 
pathway (though not necessarily down-stream of Flk-1), has also been implicated in 
the up-regulation of VEGF expression (Milanini et al., 1998). Again, performing the 
sprouting embryoid body assay in the absence of exogenous VEGF and investigating 
the effect of MEK-1/2 inhibition of VEGF expression would help to elucidate a 
potential VEGF-mediated role for the MAPK pathway in endothelial development.  
 
The finding that neither inhibition of the PI3K or the MAPK pathways had any effect 
on the ability of embryoid bodies in the endothelial sprouting assay to undergo 
sprouting was somewhat surprising, given published data on the role of PI3K in adult 
angiogenesis, and suggests key distinctions between angiogenesis in the adult versus 
early embryo. What other candidates could be involved in the transduction of Flk-1 
signalling in endothelial differentiation? The p38 MAPK pathway has been 
implicated in endothelial migration in adult angiogenesis and is reportedly activated 
down-stream of Flk-1 in adult endothelial cells (Yashima et al., 2001). However, in 
contrast, use of the pharmacological inhibitor of p38 SB202190 enhanced 
neovascularisation in chick chorioallantoic membrane (Matsumoto et al., 2002) 
making the potential role of p38 MAPK unclear. Signalling via phospholipase-C is 
another pathway that could be functionally involved in endothelial cell 
differentiation as the PLC knockout mouse, is embryonic lethal and like the Flk-1 
knockout mouse suffers vascular defects (Liao et al., 2001). It is also possible that 
the role of Flk-1 in early endothelial development is largely involved in migratory 
responses and that in the absence of Flk-1 the microenvironment of potential 
endothelial cells does not support their commitment and expansion. This is partially 
supported by studies studies in the Flk-1 knockout in which the role of Flk-1 in the 
formation of  appears to be largely migratory (Hiratsuka et al., 2005a; Schuh et al., 
1999; Shalaby et al., 1997; Shalaby et al., 1995). Further studies using ES cells 
expressing conditionally active Flk-1 and mutants of Flk-1 where key 
phosphorylation sites have been replaced, could help further characterise the Flk-1 
signalling pathways required in endothelial development. 
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4.5.3 Effect of MAPK inhibition on embryoid body 
development and Flk-1 expression 
During the endothelial sprouting assay it was noted that differentiation of ES cells in 
10µM U0126 severely inhibited embryoid body formation and 5µM U0126 
decreased both the efficiency of embryoid body formation and the size of the 
embryoid bodies which formed. Further study indicated a 50% decrease in efficiency 
of embryoid body formation and a 25% decrease in the diameter (equivalent to 55% 
decrease in volume and cellularity if embryoid bodies at day 4 are modelled as 
spherical) of embryoid bodies which formed in the presence of 5µM U0126 or 50µM 
PD098059. The 50% decrease in efficiency of embryoid body formation correlates 
well with findings from Burdon et al., which demonstrated increased self-renewal of 
ES cells and inhibition of differentiation in the hanging drop differentiation assay 
upon inhibition of MEK-1 with PD098059 from day 2 of differentiation (Burdon et 
al., 1999). The decrease in efficiency of embryoid body formation in the presence of 
5µM U0126 and the lack of differentiation when cells were cultured in 10µM U0126 
suggests an absolute requirement for MAPK in the initiation of differentiation. This 
could be further investigated by creating an ES cell line expressing a tet-inducible 
dominant negative MEK-1 mutant which would allow investigation of the stage(s) of 
differentiation at which MAPK inhibits differentiation (Mansour et al., 1994). 
Burdon et al., attributed the decreased efficiency of embryoid body formation to a 
purely differentiative defect. However, the reduced size of the embryoid bodies 
which did form in 5µM U0126 suggests that the defect may also be proliferative. 
Endothelial sprouting assays performed have confirmed the ability of embryoid 
bodies differentiated in the presence of 5µM U0126 to form endothelial sprouts (see 
section 4.5.2.2) and the lack of a significant difference in Flk-1 surface expression 
between embryoid bodies cultured in the presence and absence of inhibitors supports 
the notion that differentiation can  proceed as normal under these conditions. This 
would imply that the role of MAPK signalling is two-fold, promoting both 
differentiation and proliferation. To further investigate the role of the MAPK 
signalling pathway in controlling cell proliferation during differentiation, the 
cellularity of embryoid bodies cultured in the presence or absence of U0126 and 
PD98059 could be measured. This could substantiate whether the decrease in 
embryoid body size observed when ES cells differentiated in the presence of the two 
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inhibitors was caused by a decrease in cell number within the embryoid body. In 
addition, analysis of mRNA and protein expression of markers of pluripotency 
(including Oct-4, Nanog and Rex-1), and differentiation towards different lineages 
(including Brachyury, Scl, Pax6, and Nodal), using semi-quantitative or quantitative 
RT-PCR and immunoblotting, immunocytochemistry and flow cytometry 
respectively, could elucidate whether inhibition of MEK1/2 altered the kinetics or 
lineage bias of differentiation which could in itself explain the reduction in embryoid 
body size. 
 
4.5.4 Importance of Flk-1 in the differentiation of ES cells to 
form beating cardiomyocytes. 
The delay in initiation of the development of beating areas in Flk-1-/- embryoid 
bodies, when compared with R1 embryoid bodies, indicates that Flk-1 plays a role in 
promoting, but is not required for, cardiomyocyte differentiation. However, further 
studies using Flk-1 inhibitors or Flk-1 siRNA, or virally introduced Flk-1shRNA to 
inhibit or knock down Flk-1, are required to confirm the result is not due to a 
disparity between the two ES cell lines. The lack of a requirement for Flk-1 in 
cardiomyocyte differentiation appears at odds with other findings which have 
demonstrated an increase in cardiac markers upon VEGF application (Boheler et al., 
2002; Fujimoto and Yanagisawa, 1983; Sachinidis et al., 2002) and more recently a 
decrease in expression of the cardiac specific homeobox gene Nkx2.5 upon 
inhibition of Flk-1 with an α-Flk-1 antibody (Chen et al., 2006). However, Nkx2.5 
itself is not required for cardiomyocyte differentiation but for later morphogenesis in 
cardiac development (Lyons et al., 1995) so its down-regulation upon antibody 
blocking of Flk-1 is not necessarily concomitant with a decrease in cardiomyocyte 
differentiation. The requirement for Flk-1 itself may therefore be later in cardiac 
development. Chen et al., also found decreased cardiac marker expression upon 
MAPK inhibition (Chen et al., 2006). As Flk-1 activates the MAPK pathway it is 
possible that the delay in cardiomyocyte differentiation could be caused by a 
deficiency in MAPK signalling which could be overcome by increased activation of 
another signalling pathway such as FGFR1 (Mima et al., 1995). Expression analysis 
of cardiac genes such as Nkx2.5, myosin heavy chain, cardiac troponin I bFGF, 
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CD166 (ALCAM) and GATA-4 may help identify the mechanism behind the delay 
in cardiomyocyte differentiation.  
 
4.5.5 Conclusions 
An embryoid body-based endothelial sprouting assay was used to investigate the role 
of Flk-1 and its downstream mediators in a developmental model of vasculogenesis 
and angiogenesis. Use of Flk-1 null ES cells or the Flk-1 inhibitor VEGFR2 kinase 
inhibitor-2 caused a significant decrease in the number of embryoid bodies which 
formed sprouts, reducing the percentage of sprouting embryoid bodies to that seen in 
R1 embryoid bodies differentiated in the absence of angiogenic cytokines. Previous 
work has shown that in the absence of angiogenic cytokines no endothelial sprouts 
can form (Feraud et al., 2001) suggesting that Flk-1 is required for formation of 
endothelial sprouts. Inhibition of the MAPK pathway with 10μM U0126 during 
embryoid body development prevented embryoid body formation. Use of 5μM 
U0126 or 50μM PD98059 also demonstrated a significant decrease in the efficiency 
of embryoid body formation and the size of those embryoid bodies which formed, 
suggesting a requirement for the MAPK pathway for differentiation (and possibly 
proliferation of differentiating cells). The effect of MAPK signalling on endothelial 
sprouting was investigated using partial inhibition of MAPK signalling with 5μM 
U0126. No reduction in the ability of embryoid bodies to form sprouts, or the extent 
of sprouting from individual embryoid bodies was seen suggesting that the MAPK 
pathway is not involved in endothelial differentiation or migration and that activation 
of the MAPK pathway by Flk-1 is not the mechanism by which endothelial 
differentiation and migration are potentiated. Although activation of PI3K 
downstream of Flk-1 is important for adult angiogenesis (Hennessy et al., 2005) 
inhibition of PI3K with LY294002 had no effect on sprouting from embryoid bodies. 
Previous studies of Flk-1 signalling in embryoid body-derived cells (chapter 3) found 
no evidence of PI3K activation by VEGF in which model, supporting a diminished 
role for PI3K signalling in developmental vessel formation.  Finally, the ability of 
Flk-1-/- ES cells to differentiate to form beating cardiomyocyes with the same 
efficiency as as R1 parental ES cells (all be it with a delay in differentiation) suggests 
that despite a strong association between Flk-1 expression and cardiac differentiation 
Chapter 4 –  Results 
 172
(Boheler et al., 2002; Ema et al., 2006; Kattman et al., 2006; Kouskoff et al., 2005; 
Sachinidis et al., 2002)  Flk-1 is involved in but not required for in vitro 
cardiomyocyte differentiation.   
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5.1 Introduction 
Deletion of Flk-1-/- in the mouse results in embryonic lethality by E9.5 due to a lack 
of formation of both the vasculature and blood (Shalaby et al., 1995). Owing to this 
embryonic lethality, use of in vitro differentiation systems represents an attractive 
alternative approach for further investigation of the role of Flk-1 in early embryonic 
development. Previous work, using an embyroid body-based system of 
differentiation demonstrated activation of the MAPK and PLC signalling pathways 
upon VEGF stimulation of Flk-1 in embryoid body-derived cells (section 3.3). In 
chapter 4 of this thesis, functional assays utilising Flk-1-/- ES cells and inhibitors of 
Flk-1 and the PI3K and MAPK pathways have been used to begin to investigate the 
role of Flk-1 signalling in endothelial and cardiac development. Flk-1 expression is 
required for endothelial differentiation (section 4.5.2, (Shalaby et al., 1995) and is 
important but not necessary for the in vitro differentiation of cardiomyocytes (see 
section 4.5.3). Furthermore, Flk-1 expression may be important in haemopoietic 
differentiation. Haemopoietic precursors express Flk-1 but it is down-regulated upon 
lineage commitment (Kabrun et al., 1997). Cells of the haemopoietic lineage are able 
to differentiate in the absence of Flk-1, although with much lower efficiency and 
their differentiation appears to be very much microenvironment dependent (Hidaka 
et al., 1999; Schuh et al., 1999). For example, Flk-1-/-ES cells differentiated in vitro 
in OP-9 stromal cell co-culture can produce only mesodermal plaques and no 
committed haemopoietic colonies, whilst Flk-1-/- ES cells differentiated in an 
embryoid body-based system are able to differentiate to form all haemopoietic 
lineages, all be it at lower efficiency (Hidaka et al., 1999).  
 
In order to further investigate the consequences of varying the timing and duration of 
Flk-1 signalling on haemopoietic, endothelial and cardiomyocyte development Flk-1 
expression was re-constituted in Flk-1-/- ES cells using a Tet-regulated system. Site-
directed mutagenesis of tyrosines at amino acid positions 951, 1175, 1214 in the 
cytoplasmic tail of Flk-1 could then be used to investigate the importance of different 
Flk-1-mediated signalling pathways during the differentiation process. 
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5.2 Cloning strategy 
The aim of the cloning strategy was to produce an ES cell line which inducibly 
expressed Flk-1. To achieve this, the Tet-regulated expression system in which 
expression of the gene of interest is controlled by addition and subtraction of the 
antibiotic tetracycline (or the closely related doxycycline), was used (described in 
5.2.1). Previous use of this Tet-regulatable system in the laboratory had occasionally 
led to mosaic expression of the protein of interest (differing levels of induction 
between ES cells from the same population; Bone and Paling, unpublished 
observations). It was postulated that this may have been due to chromatin positional 
effects. Anasstassiadis et al., found some improvement in levels and predictability of 
expression by flanking the Tet-o construct with chicken-globin insulators 
(Anastassiadis et al., 2002). The pInshygro plasmid, containing four such insulators 
was therefore used to minimise the possibility of mosaic expression of the tet-
response plasmid.   
5.2.1 The Tetracycline regulated expression system 
The tetracycline-regulated expression system allows high level, regulated expression 
of a gene of interest. It was developed using the E.coli tetracycline repressor protein 
(TetR) which negatively regulates expression of genes within the tetracycline operon 
by binding to tet-operator sequences (Tet-o) in the absence of tetracycline (Tet). The 
mammalian expression system, developed by Gossen and Bujard, comprises two 
plasmids; a regulator plasmid encoding a version of the TetR protein and a response 
plasmid, in which expression of the gene of interest is regulated by a promoter 
containing Tet-o sequences (see Figure 5-1).  In the original Tet-off expression 
system the gene of interest was expressed down-stream of the Tet-operator when 
tetracycline was withdrawn from culture (Gossen and Bujard, 1992). Modification of 
four amino acids within the tet-repressor created the modified reverse Tet-repressor 
(rTetR) of the Tet-on expression system in which addition of doxycycline (a Tet 
derivative) induces expression of the gene of interest (Baron et al., 1995).  
 
The Tet-on expression system is illustrated in Figure 5-1. The host-cell line must be 
stably transfected first with the regulator plasmid and subsequently the response 
plasmid encoding the gene of interest. The regulator plasmid (in this study pCAGGs-
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irtTA-VP16-puro;(Anastassiadis et al., 2002) constitutively expresses the reverse 
tetracycline-transactivator (rtTA) fusion protein comprising the DNA binding 
domain of the Tetracycline repressor (TetR) fused to the C-terminal 127 amino acids 
of the transcriptional activation domain of virion protein 16 of herpes simplex virus 
(VP16), under the control of the CAGGs ubiquitously active promoter (chicken β-
actin promoter coupled to human CMV (cytomegalovirus) immediate early enhancer 
with rabbit β-globin gene sequences including a polyadenylation signal and an SV40 
(simian virus 40) origin of replication). The response plasmid (pInshygro-TetTK-
Flk-1pA) comprises the Tet-response element (TRE, which consists heptamerised 
tet-operators), and a downstream minimal herpes simplex thymidine kinase (TK) 
promoter for the gene of interest. In this study the TRE-TK-gene of interest construct 
is flanked by four chicken globin insulators.  
 
 
Figure 5-1Illustration of the Tet-on expression system used in the study. Addition of 
Doxycycline causes a conformational change in the Tet-transactivator allowing it to bind to 
the Tet-regulatory element (TRE). This brings the transcriptional activation domain of VP16 
into close proximity with the thymidine kinase (TK) promoter allowing transcription of the 
gene of interest.  
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The tetracycline-regulated expression system has several advantages over 
constitutive expression or other inducible systems; 
 
• Tight regulation of gene expression during the generation of stable 
transfectants with extremely low background or ‘leaky’ expression. This 
allows study of potentially cytotoxic gene products and in the case of ES cells 
gene products which may affect self-renewal. 
 
• On/off gene regulation. Unlike the Cre-lox and FRT expression systems in 
which gene expression is permanently active following homologous 
recombination the tet-regulated expression system enables rapid up and 
down-regulation of the target gene allowing temporal expression.  
 
• The prokaryotic regulatory proteins of the tet-regulated expression systems 
act very specifically on their target sequences with no pleiotropic effects 
(Harkin et al., 1999). 
 
• Levels of gene expression are comparable or greater than in a constitutive 
system  utilising the same promoter (Yin et al., 1996). 
 
• Both tetracycline or doxycycline at the concentrations required to regulate 
gene expression in cells are non-toxic and do not induce non-specific effects 
in contrast to other inducible systems which may require exposure to heat 
shock, heavy metal ions, steroid hormones, cytokines or radiation  (Saez et 
al., 1997).  
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5.2.2 Overview of Flk-1 cloning strategy 
An overview of the Flk-1 cloning strategy is illustrated in Figure 5-2. The cDNA 
sequence encoding full length murine Flk-1 was not available commercially and did 
not appear to have been previously cloned in its entirety. As ES cells differentiated 
for 3-6 days were known to express Flk-1 (see section 3.2) mRNA containing Flk-1 
message was isolated from day 5 primary embryoid bodies. This was then reverse 
transcribed using random primers and superscript reverse transcriptase. Flk-1 cDNA 
was amplified from the day 5 primary embryoid body cDNA pool using the proof 
reading polymerase Pfu with sequence specific primers which introduced 5’ and 3’ 
XbaI restriction sites. The amplified cDNA was digested with XbaI, gel purified and 
ligated into XbaI digested pcDNA3.1zeo constitutive expression vector. An EcoR1 
diagnostic digest was used to establish that Flk-1 was in the correct orientation 
within the pcDNA3.1zeo plasmid. The construct was then sequenced to confirm the 
orientation of Flk-1 and verify that the sequence of the cloned Flk-1 was identical to 
that previously published (GenBank accession number NM_010612) using 
Sequencher software from Gene Code Corporation. The pcDNA3.1zeo expression 
vector was used as an intermediary vector in the cloning of Flk-1 into the pKS-
TetTK-pA Tet-response vector. This allowed simpler screening and sequencing of 
cloned Flk-1 as pcDNA3.1zeo is well characterised. The pcDNA3.1zeo-Flk-1 
plasmid also allowed constitutive expression of Flk-1 in the Baf/3 pro-B cell line 
which was used to ensure that Flk-1 could be expressed at the cell surface without 
the need for an additional signal sequence.  
 
An XbaI digest of the pcDNA3.1zeo-Flk-1 construct released the Flk-1 fragment that 
was then subcloned into the SpeI-linearised pKS-tettk-pA tetracycline-response 
plasmid. Once again, diagnostic digests were used to establish the correct orientation 
of Flk-1 within the plasmid. The tet-tk-Flk-1-pA fragment was excised using blunt 
end digestion with PvuI and PvuII. The 5kb fragment was gel purified and blunt end 
ligated into SnaBI linearised pInshygro to create the pInshygro-TetTK-Flk-1-pA 
plasmid.  
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Figure 5-2 Schematic illustrating generation of pInshygro-tettk-Flk-1-pA construct. 
Flk-1 cDNA was obtained by RT-PCR from mRNA of day 5 embryoid bodies and amplified 
with sequence specific primers which added the XbaI restriction site. The Flk-1 fragment 
was first ligated into pcDNA3.1zeo then sub-cloned into the pKS-tettk-pA plasmid to add 
the necessary tet-response sequences. Finally the tet-tk-Flk-1-pA fragment was blunt end 
ligated in the pInshygro plasmid to add chromatin insulators and the hygromycin selection 
cassette. For plasmid maps see Appendix. 
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5.2.3 Generation, screening and selection of clones 
Initially Flk-1 in the pcDNA3.1zeo construct was transfected into the Baf/3 pro-B 
cell line by electroporation. Transfected cells were plated at 2x105, 1x105 and 
0.5x105 per well in 96 well plates with Zeocin selection. 37 of 96 in the 0.5x105 plate 
and 58 on both 1 and 2 x105 plates were Zeocin resistant. 20 clones were picked from 
the 0.5 x 105 plate and screened by flow cytometry for Flk-1 surface expression. The 
results are shown in Figure 5-3A. Only clone 9 showed appreciable surface 
expression of Flk-1 though some expression was also noted in clones 5 and 10. These 
findings indicate that the Flk-1 cDNA cloned can encode full-length Flk-1 protein. 
Screening of 3 of the clones apparently not expressing Flk-1 protein using RT-PCR 
(Figure 5-3B) demonstrated that all 3 expressed Flk-1 mRNA. This result suggests 
either the clones were expressing a low level of Flk-1 expression or the Baf/3 cells 
were deficient in an unknown chaperone protein, found in Flk-1-expressing cells, 
which is required for surface expression.  
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Figure 5-3 Screening Baf/3 clones stably transfected with linearised pcDNA3.1zeo for 
Flk-1 expression. A) Twenty clones were picked and screened for Flk-1 cell surface 
expression using flow cytometry. Cells were labelled with an anti-Flk-1 antibody or an equal 
concentration of isotype-matched control and a secondary FITC-labelled antibody. The 
numbers above the plots indicate the clone identity number. The Y axis represents cell 
number and the X axis represents fluorescent intensity. The purple trace indicates the isotype 
control population whilst the green trace indicates the anti-Flk-1 antibody stained population. 
B) mRNA was extracted from clones 1, 12 and 17. RT-PCR was followed by 30 cycles of 
PCR using primers specific for a 250bp fragment of Flk-1 (see Table 2-9).  
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To generate Flk-1-Tet-on ES cell lines, Flk-1-/- ES cells underwent two rounds of 
transfection to create the double stable Tet cell line (see section 2.5.1.2). The first 
step was to generate Flk-1 null ES cells expressing irtTA. This was achieved by 
electroporating linearised pCAGGs-irtTA-VP16-IRES-puro plasmid into Flk-1-/- ES 
cells and selecting positive clones with puromycin. 50 puromycin resistant clones 
were picked and expanded, 23 were frozen down and 9 were screened see section 
5.2.3.2). In order to screen puromycin resistant clones for the expression of 
functional irtTA and to compare inducible expression between clones, independent 
clones were transiently transfected with a pKS-Δp85-tettk-pA Tet-response plasmid 
which in the presence of doxycycline would express myc-epitope tagged dominant 
negative p85 (the regulatory subunit of class IA PI3Ks) (see sections 5.2.3.1 and 
5.2.3.2). The selected irtTA clones were then stably transfected with the pInshygro-
tettk-Flk-1-pA Tet-response construct. Following selection in hygromycin, clones 
were screened by flow cytometry for doxycycline inducible surface expression of 
Flk-1 (see section 5.2.3.3). 
 
5.2.3.1 Optimisation of transient transfection of R1 ES cells 
Prior to screening of pCAGGs-irtTA-VP16-IRES-puro clones, the conditions for 
transient tranfection in the Flk-1-/- ES cell line were optimised using the 
pAcΔPHAkt-GFP-N1 GFP expression vector which allowed expression of the 
transfected plasmid to be quanitifed using flow cytometry. The electroporation 
conditions used for stable transfection of the Flk-1-/- ES cell line led to wide-scale 
cell death and no discernable expression. It was therefore decided to utilise the 
lipofectamine lipid-based transfection system. The cell number and density, absolute 
amounts of both DNA and lipofectamine2000 used and the ratio of 
DNA:lipofectamine are important to maximise expression and minimise cell death. 
Cell toxicity and efficiency of transfection (assessed by GFP expression) were 
compared over a range of transfection conditions. The results are illustrated in Figure 
5-4. 
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Condition Cell number Amount of GFP 
plasmid 
Number of live 
cells (d3) 
50uF, 800V 1 x 106 8µg None (all dead d1)
500uF, 250V 10 x 106 
plated 1x106 
8µg 2.5 x 105 
500uF, 250V 1x106 8µg 3.5 x 105 
4ul lipofectamine 5x 105 4µg 2.7 x 106 
10ul lipofectamine 5 x 105 4µg 3.5 x 105 
20ul lipofectamine 5 x 105 4µg 0.75 x 105 
40ul lipofectamine 5 x 105 4µg None (all dead) 
 
 
Figure 5-4 Optimisation of transient tranfection conditions for the R1 Flk-1-/- ES cell 
line. Flk-1-/- ES cells were transiently transfected with a GFP-expressing plasmid using the 
conditions described in A. Following transfection the cells were plated onto a 10cm NUNC 
tissue culture dish. Three days after transfection the number of live cells and percentage GFP 
expression were measured. A illustrates the effect of different transfection conditions on the 
number of live cells after 3 days. B illustrates the percentage of cells expressing GFP and is 
indicative of transfection efficiency. The experiment was conducted once. 
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From Figure 5-4B it can be seen that only two of the tested transfection conditions 
resulted in significant GFP expression, use of 10 or 20µl lipofectmine2000 with 4µg 
plasmid DNA and 5 x 105 cells. The transfection efficiency’s for both conditions 
were comparable. However, nearly 5 times more live cells were retrieved from the 
plate in which 10µl lipofectamine2000 had been used therefore this condition was 
chosen to perform transient transfection of the pKS-Δp85-tettk-pA Tet-response 
plasmid expressing myc-tagged Δp85. 
 
5.2.3.2 Screening pCAGGs  irtTA clones 
To screen the CAGGs irtTA reverse-tet-transactivator clones for irtTA functionality 
they were transiently transfected with the pKS-Δp85-tettk-pA tet-response plasmid. 
Clones expressing functional irtTA, when induced by addition of doxycycline, 
expressed myc-tagged dominant negative p85 which was detected by 
immunoblotting with an anti-p85 antibody, shown in Figure 5-5.  
 
 
 
 
Figure 5-5 Immunoblot screening Flk-1-/- irtTA ES cell clones for functional irtTA.     
Flk-1-/- irtTA ES cell clones were transiently transfected with the pKS-Δp85-tettk-pA tet-
response plasmid and incubated for an initial 36 hours followed by an additional 24 hours in 
the presence (+) or absence (-) of 1µg/ml doxycyline to induce Δp85 expression prior to 
lysis. Whole cell lysates were immunoblotted and probed with an anti-p85 antibody which 
detected both the wild-type p85 protein and the slightly larger myc-tagged Δp85.  
 
Figure 5-5 demonstrates that all selected clones inducibly expressed the myc-tagged 
Δp85 in the presence but not the absence of doxycyline. The method used for 
screening makes comparisons of expression levels between clones difficult as they 
may largely depend on the efficiency of the individual transient transfections. 
However, clones 29,31 and 47 appear to express Δp85-myc protein levels equivalent 
to those of endogenous p85. Assuming transfection efficiency is around 20% (as seen 
in section 5.2.3.1 using the same conditions), this suggested that in combination with 
myc-Δp85 
p85 
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a stably transfected response plasmid these clones are likely to give good expression. 
Clone 29 and clone 47 were both tested for their ability to form embryoid bodies. EB 
formation occured at approximately the same efficiency as in the R1 parental ES cell 
line. Clone 29 was selected as the clone to be used for transfection with the 
pInshygro-TetTK-Flk-1-pA Tet-response plasmid. 
5.2.3.3 Screening of Flk-1-tet-ON clones 
The Flk-1-/- ES cell line expressing irtTA (clone 29) was stably transfected with the 
pInshygro-tettk-Flk-1pA construct. Following selection in Hygromycin 40 clones 
were picked and expanded. Following expansion 22 clones were frozen down and 
underwent initial screening. The simplest way to screen the clones would have been 
through lysing the doxycyline-induced cells and immunoblotting with a Flk-1 
specific antibody. Unfortunately, optimisation of Flk-1 immunoblotting with 4 
separate α-Flk-1 antibodies using the ECL western blotting detection system was 
unsuccessful, therefore the clones were initially screened using flow cytometry. Each 
clone was incubated +/- 1µg/ml doxycycline for 16 hours to induce expression and 
screened for doxycycline-induced Flk-1 surface expression by flow cytometry. 13 
clones showed no or only slight Flk-1 expression, clone 36 expressed Flk-1 both in 
the presence and absence of doxycycline and clones 5,10,15,29,32,33,37 and 39 
demonstrated varying degrees of doxycycline-induced Flk-1 expression (data not 
shown). Clones 5, 10, 15, 32 and 33 showed the greatest Flk-1 expression and were 
therefore subjected to a comparative study.  
 
As demonstrated by Figure 5-6B, all clones reproducibly expressed Flk-1 when 
induced by addition of doxycycline. Clones 15 and 33 were chosen for use in further 
characterisation and functional experiments as they expressed the highest dox-
induced levels of Flk-1 (Figure 5-6A and B), similar to levels seen in R1 embryoid 
bodies between days 4 and 5 (see section 3.2.2). 
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Figure 5-6 Flow cytometric analysis of Flk-1 expression in Flk-1-Tet-on clones. Flk-1-
Tet-on ES clones were incubated for 16 hours +/- 1µg/ml doxycycline to induce Flk-1 
expression. Cells were then labelled with either an anti-Flk-1 antibody or an equal 
concentration of isotype-matched control, and a secondary FITC-labelled antibody prior to 
flow cytometric analysis on a Becton Dickenson FACS Vantage flow cytometer. A) 
Histogram plots from one experiment showing comparative Flk-1 expression levels between 
clones. The numbers above the plots indicate the clone identification number. The Y axis 
represents cell number and the X axis represents fluorescent intensity. The purple and green 
traces represent the isotype control and anti-Flk-1 labelled populations respectively in cells 
incubated in the absence of dox. The blue and pink traces represent the isotype control and 
anti-Flk-1 antibody labelled cells incubated in the presence of dox. B) Percentage Flk-1 
expression (calculated using a 5% gate – see section 3.2.1) in Flk-1-Tet-on ES clones in 
which Flk-1 expression has been induced for 16 hours with 1µg/ml dox. Results shown 
represent pooled data from 3 individual experiments Error bars represent s.e.m. 
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5.3 Basic characterisation of clones 
Before the Flk-1-Tet-on ES clones could be used in any functional assays basic 
characterisation of the clones were required. These analyses included doxycycline 
dose optimisation for induction of Flk-1 expression and examination of the timing, 
duration and functionality of Flk-1 expression following induction both during self-
renewing and differentiating states.   
5.3.1 Dose-response of Flk-1 expression to varying 
concentrations of doxycycline 
Firstly, induction of Flk-1 expression by varying concentrations of doxycycline was 
investigated. Flk-1-Tet-on ES cells (clones 15 and 33) were incubated in a range of 
doxycycline concentrations for 16 hours prior to investigation of Flk-1 expression by 
flow cytometry and immunoblotting, which was optimised for anti-Flk-1 and anti-p-
Flk-1 antibodies using a new ECL-based advanced detection system with 
significantly enhanced sensitivity compared to systems previously available. The 
results illustrated by Figure 5-7A and B demonstrate a dose-response of induction of 
Flk-1 expression to doxycycline. Figure 5-7A indicates that induction is first seen at 
10ng/ml dox in clone 15 and 50ng/ml dox in clone 33. Flk-1 protein is visualised in 2 
bands of ~210 and 230 kDa, indicating that both partially and fully glycosylated 
forms of Flk-1 are expressed. Expression in both clones peaks between 100 and 
500ng/ml dox and this is born out by Figure5-7B, in which no increase is surface 
expression is seen between 500ng/ml and 2µg/ml. No Flk-1 expression is seen in 
clone 15 or clone 33 incubated in the absence of doxycycline confirming tight 
regulation of expression within the system (also illustrated by anti-Flk-1 
immunoblots in Figure 5-8). 
 
1µg/ml doxycycline was used in subsequent experiments as Flk-1 expression is 
maximal at this concentration and as doxycycline has a 24 hour half-life in culture 
starting with a higher concentration than is necessary may help to prolong 
expression. Additionally, no toxic effects have been reported in other cell systems at 
this concentration.  
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Figure 5-7 Ability of varying concentrations of doxycycline to induce Flk-1 expression 
in Flk-1-Tet-on clones. Flk-1-Tet-on ES clones were incubated for 16 hours +/- 0-2µg/ml 
doxycycline to induce Flk-1 expression. A) Following doxycycline induction cells were 
lysed and whole cell lysates immunoblotted with an anti-Flk-1 antibody. Blots were stripped 
and re-probed with an anti-SHP-2 antibody to check protein loading. B) Cells were labelled 
with either an anti-Flk-1 antibody or an equal concentration of isotype-matched control, and 
a secondary FITC-labelled antibody prior to flow cytometric analysis on a Becton Dickinson 
FACS Canto flow cytometer. The percentage of cells expressing Flk-1 was calculated using 
a 5% marker gate (see section 3.2.1). No Flk-1 expression was seen in the no doxycycline 
control. Results shown represent pooled data from 2 individual experiments. Error bars 
represent range. 
 
0 10
 
50
 
10
0 
50
0 
10
00
 
0 10
 
50
 
10
0 
50
0 
10
00
                     C15                                  C33 
Doxycycline (ng/ml) 
Flk-1 
SHP-2 α-SHP-2 
α-Flk-1 200 
Antibody   kDa 
A 
B 
Chapter 5 –  Results 
 189
5.3.2 VEGF-stimulation of Flk-1 in Flk-1-Tet-on ES cells 
Upon VEGF stimulation the Flk-1 receptor is auto-phosphorylated at a number of 
tyrosine residues including Y951 (Zachary, 2001).  VEGF-stimulation of day 5 
embryoid body-derived cells resulted in receptor phosphorylation that peaked at 5 
minutes and decreased to basal by 30 minutes (see section 3.3.1). To check that the 
Flk-1 protein expressed in the Flk-1-Tet-on ES cell clones was functional, cells were 
pre-induced with doxycycline, stimulated with 20ng/ml VEGF for between 0 and 30 
minutes and immunoblotted with an anti-phospho-Y951 Flk-1 antibody. 
 
Figure 5-8 demonstrates that VEGF stimulation of both clone 15 and clone 33 results 
in phosphorylation of the receptor over a time-course identical to that seen in VEGF-
stimulated day 5 embryoid body-derived cells when Flk-1 expression is pre-induced 
with 1µg/ml doxycycline. This indicates functionality of Flk-1 expressed in Flk-1-
Tet-on ES cells. No Flk-1 expression or phosphorylation is seen in either clone 
incubated with no dox confirming tight regulation in the system.  
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Figure 5-8 VEGF-stimulated Flk-1 phosphorylation in Flk-1-Tet-on ES clones.  
Immunoblot of whole cell lysates from Flk-1-Tet-on ES clones (15 and 33) pre-incubated in 
the presence or absence of 1µg/ml doxycycline for 24 hours prior to stimulation with 
20ng/ml VEGF over a 30 minute time course. Blots were probed with an anti-Flk-1 and anti-
phospho-Flk-1 antibodies then stripped and reprobed with the anti-SHP-2 antibody to control 
for equal protein loading. Blots shown are representative of 3 individual experiments for 
each clone.  
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5.3.3 Time-course of Flk-1 expression in Flk-1-Tet-on ES 
cell clones 
The intended use of the Flk-1-tet-ON ES cell line was in differentiation studies 
therefore the duration of Flk-1 expression following doxycycline induction was 
characterised in both self-renewing ES cells and models of differentiation. ES cells 
were incubated in the presence or absence of 1µg/ml doxycycline and Flk-1 surface 
expression was measured using flow cytometry.   
 
5.3.3.1 Duration of inducible Flk-1 expression in self-renewing ES 
cells 
Diffusion of small molecules such as doxycycline in the embryoid body model of 
differentiation may be difficult. As self-renewing ES cells grow as a monolayer they 
provide a more accessible means of characterising inducible Flk-1 expression with 
which expression during in vitro models of differentiation could be compared. 
Therefore, duration of Flk-1 expression following doxyxcyline induction was first 
characterised in Flk-1-Tet-on ES cells cultured in the presence of LIF. To maintain 
self-renewal ES cells need to be passaged regularly so this experiment was only 
conducted for 4 days following plating of cells in the presence of doxycycline. 
Figure 5-9 demonstrates that Flk-1 expression in Flk-1-Tet-on ES cells is maintained 
for at least 4 days following doxycycline induction.  
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Figure 5-9 Time course of Flk-1 expression in Flk-1Tet-on ES cells following induction 
with 1µg/ml doxycycline. Flk-1-Tet-on ES clones were incubated +/- 1µg/ml doxycycline. 
Doxycycline-induced Flk-1 expression was monitored by flow cytometry for 4 days. Cells 
were labelled with either an anti-Flk-1 antibody or an equal concentration of isotype-
matched control, and a secondary FITC-labelled antibody prior to flow cytometric analysis 
on a Becton Dickinson FACS Canto flow cytometer. The percentage of cells expressing Flk-
1 was calculated using a 5% marker gate (see section 3.2.1). Results shown represent pooled 
data from 2 individual experiments. Error bars represent range.     
                
5.3.3.2 Duration of inducible-Flk-1 expression during differentiation 
Following characterisation of the duration of Flk-1 expression in self-renewing Flk-
1-Tet-on ES cells the duration of Flk-1 expression following doxycycline induction 
needed to be characterised in in vitro models of differentiation. The first model in 
which the duration of Flk-1 expression was characterised was the formation of 
embryoid bodies in semi-solid medium. As illustrated by Figure 5-10 Flk-1 
expression was minimal by day 3 and insignificant by day 4 of differentiation (Flk-1 
expression less than 5-10% cannot be measured accurately using flow cytometry as 
small differences between isotype control and Flk-1 plots could easily be due to 
chance). It was thought that the decrease in Flk-1 expression may have been due to 
poor diffusion of doxycycline in the semi-solid medium therefore embryoid bodies 
were differentiated in liquid suspension. Similar results were seen in Flk-1 
expression in these embryoid bodies. Expression greatly declined by day 3 and was 
Chapter 5 –  Results 
 193
insignificant by day 4. This raised the possibility that diffusion of doxycycline into 
the embryoid bodies may have at least in part contributed to the decrease in 
expression. Addition of 1µg/ml doxycycline to suspension embryoid bodies cultured 
in its absence at day 2 did not appear to induce any Flk-1 expression in day 4 
suspension embryoid bodies nor did addition of additional doxycycline to day 2 
suspension embryoid bodies already cultured in 1µg/ml doxycycline maintain Flk-1 
expression to day 4 (Figure 5-10).  
 
Differentiation of Flk-1-Tet-on ES cells in adherent monolayer culture removed any 
doubt over the access of doxycycline to all cels cultured in the system. This was 
achieved inducing differentiation of Flk-1-Tet-on ES cells using LIF withdrawal. 
Flk-1 expression levels in this differentiation system were higher Flk-1 after 3 days 
but by 4 days no Flk-1 expression was observed suggesting that differentiation itself 
may have been the trigger of down-regulation of Flk-1 surface expression (Figure 5-
10). 
 
It was unclear whether expression of Flk-1 protein had decreased or whether it was 
possible that differentiation had caused increased internalisation of Flk-1. Gampel et 
al., reported increased Flk-1-cycling leading to increased Flk-1 expression in human 
endothelial cells upon VEGF-stimulation (Gampel et al., 2006) and culture of 
embryoid bodies in the presence of exogenous VEGF in this study increased Flk-1 
surface expression in embryoid body-derived cells (section 3-2-4). To investigate 
whether VEGF increased dox-induced Flk-1 expression in differentiating Flk-1-Tet-
on ES cell clones clones 15 and 33 were incubated in the presence and absence of 
both doxycycline and VEGF. Addition of VEGF at neither day 2 nor 3 had any effect 
on doxycycline-induced Flk-1 expression (data not shown).  
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Figure 5-10 Time-course of Flk-1 expression in Flk-1-Tet-on ES cells during 
differentiation in the presence of inductive doxycycline. Flk-1-Tet-on ES clones were 
differentiated in the presence of 1µg/ml doxycycline using 3 separate differentiation 
protocols; embryoid body formation in semi-solid or liquid medium and differentiation of ES 
cells by removal of LIF. Flk-1 expression was monitored by flow cytometry for 5 days. Cells 
were labelled with either an anti-Flk-1 antibody or an equal concentration of isotype matched 
control, and a secondary FITC labelled antibody prior to flow cytometric analysis on a 
Becton Dickinson FACS Canto flow cytometer. The percentage of cells expressing Flk-1 
was calculated using a 5% marker gate (see section 3.2.1). Results shown represent pooled 
data from 2 individual experiments (X indicates that analysis was not performed). Error bars 
represent range 
 
Clone 15 
Clone 33 
X 
X 
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Despite a perceived lack of Flk-1 expression in day 4 differentiating EBs whole cell 
lysates from the same cells did show Flk-1 protein expression (illustrated in Figure 5-
11). Unfortunately whole cell lysates from day 4 embryoid bodies were not run in 
parallel with those from cells from self-renewing ES cells or day 2 embryoid bodies 
on which Flk-1 surface expression was demonstrably higher. Therefore it is not 
possible to ascertain whether Flk-1 protein expression was decreased at day 4 or 
whether the receptor was internalised. 
 
 
 
 
 
 
 
 
 
Figure 5-11 Flk-1 expression in day 4 Flk-1tet-ON primary embryoid bodies. 
Immunoblots of whole cell lysates from Flk-1-tet-ON ES cells differentiated to form 
embryoid bodies either in the absence of 1µg/ml dox  for 4 days (no dox), the presence of 
dox for 4 days (+dox), the presence of dox for only days 3 and 4 (no dox/+dox) or the 
presence of dox for 4 days (+dox). Blots were probed with an anti-Flk-1 antibody then 
stripped and reprobed with an anti-SHP-2 antibody to check for equal loading.  
 
5.4 Functional characterisation of clones 
The basic characterisation of the Flk-1-Tet-on ES cells appeared to demonstrate that 
doxycycline-induced Flk-1 expression may not be maintained during differentiation 
of ES cells. However, it was decided to investigate whether even a short-term or low 
level increase in Flk-1 expression could alter cell fate.  
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5.4.1 Investigation of the effects of temporal changes in   
Flk-1 expression on cardiomyocyte differentiation of 
ES cells 
Flk-1 is implicated in the differentiation of cardiomyocytes (see section 4-4). In 
chapter 4 it was demonstrated that Flk-1-/- ES cells exhibited a delay in initiation of 
beating in the cardiomyocyte assay. As Flk-1 in R1 embryoid bodies is expressed 
from day 3 onwards the Flk-1-Tet-on ES cell lines were used to investigate whether 
this delay could be prevented by early induction of Flk-1 expression. 
 
The assay is performed in 3 phases (for more detail see section 2-2). Embryoid 
bodies are formed in hanging drops and after 2 days transferred into liquid media. 
Following a further 2 day incubation individual embryoid bodies are plated onto the 
gelatin-covered wells of a 96-well plate. To investigate whether up-regulation of Flk-
1 could rescue the delay in initiation of beating in Flk-1-/- ES cells, 1µg/ml 
doxycycline was added on day 3 to Flk-1-Tet-on clones. c29irtTA (Flk-1-/- ES cells 
stably transfected with the pCAGGs-irtTA-VP16-IRES-puro tet-regulator plasmid, 
the parental cell line of Flk-1-Tet-on ES cells) and R1 ES cells were included as 
controls. 
 
Both clone 15 and clone 33 of the Flk-1-Tet-on clones as well as c29irtTA cells, 
incubated in the presence of doxycycline exhibited greatly reduced numbers of 
beating cardiomyocytes. As the phenotype occurred in the c29irtTA cell line it was 
obviously not due to dox-induced Flk-1 expression. Further investigation into this 
phenotype revealed that it occurred only in c29irtTA upon exposure to doxycycline 
(Figure 5-12C) and and did not occur in response to doxycycline treatment in either 
R1 or Flk-1-/- ES cell lines (Figure 5-12A and B). 
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Figure 5-12 continued overleaf 
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Figure 5-12 Comparison of beating cardiomyocyte development between R1, Flk-1-/- 
c29irtTA ES cells cultured in an embryoid body-based model of cardiac differentiation 
in the presence and absence of doxycycline. ES cells were differentiated in hanging drops 
for 2 days and in suspension for a further 2 days prior to plating of individual embryoid 
bodies into gelatine coated wells of a 96-well plate. Doxycycline where used, was added at 
1µg/ml on day 3. 96 wells were scored for the appearance of beating foci daily from 6 to 9 
days after the initiation of the assay. A). R1 ES cells B) Flk-1-/- ES cells C) c29irtTA ES 
cells D) clone 15 and clone 33 of Flk-1-Tet-on ES cell line. Charts A-C represent pooled 
data from 3 individual experiments. Chart D represents data from one individual experiment. 
Error bars represent s.e.m. **p≤0.05 in the paired students t-test.  
 
There are several explanations for the effect of doxycycline on formation of beating 
cardiomyocytes by Flk-1 null ES cells tranfected with the irtTA transactivator 
(C29irtTA). The most likely cause is expression of the VP16 transcriptional 
activation domain which can interfere with expression of genes lacking VP16 
binding sites (Baron et al., 1997). However, toxicity of both rtTA (Bryja et al., 2003) 
and doxycycline (Moutier et al., 2003) have also been demonstrated in ES cells and 
murine fetuses respectively. As c29irtTA ES cells could differentiate to form 
cardiomyocytes in the absence of doxycycline it is unlikely that rtTA toxicity was 
occurring. 
D 
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5.4.1.1 DiOC6 staining  
To establish whether the inhibition of cardiomyocyte differentiation was due to 
toxicity of doxycycline in c29irtTA ES cells 5x105 cells were plated onto 10cm 
tissue culture dishes with 0,1 and 2μg/ml doxycycline for 3 days. After 3 days cells 
were stained with trypan blue and viable cells counted with a haemocytometer, 
2.4x106 cells viable cells were counted from dishes cultured with 0 or 1μg/ml 
doxycycline and 3.2x106 cells were counted from the dish cultured in 2μg/ml 
doxycycline. Very few trypan blue stained cells were observed in any of the cultures. 
DiOC6 (3,3′-dihexyloxacarbocyanine iodide) staining was used to investigate 
whether cells incubated in the presence of doxycycline were undergoing apoptosis. 
Reduced mitochondrial membrane potential is an early irreversible step in apoptosis 
that causes a decrease in uptake of the cationic DiOC6 and a corresponding decrease 
in FL1 fluorescence measured by flow cytometry. Figure 5-13 illustrates that 
addition of dox to c29irtTA ES cells did not lead to a decrease in DiOC6 staining. 
This combination of results suggests that at the doses used doxycycline was not toxic 
to the c29irtTA ES cells.  
 
 
 
 
 
 
 
 
 
Figure 5-13 DiOC6 staining of c29rtTA cells incubated for 3 days in the presence of 
absence of doxycycline. C29rtTA ES cells were incubated for 3 days in 0, 1 or 2μg/ml 
doxycycline prior to DiOC6 staining. Histogram plots show comparative DiOC6 staining 
measured by flow cytometry. The Y axis represents cell number and the X axis represents 
fluorescent intensity. The purple trace indicates cells incubated in the absence of dox, the 
green trace indicates cells incubated in 1μg/ml dox and the pink trace indicates cells 
incubated in the presence of 2μg/ml dox.  
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5.4.2 Haemopoietic plaque assay 
Mice that lack Flk-1 expression die by E9.5 due to failure of formation of 
haemopoietic and vascular systems (Shalaby et al., 1995). However, in vitro Flk-1-/- 
embryoid bodies re-plated into a haemopoietic colony assay are able to form all 
myeloid and erythroid lineages, all beit at reduced frequency. Conversely, Flk-1-/- ES 
cells differentiated in OP9 stromal cell co-culture can produce only mesodermal 
plaques and no committed haemopoietic colonies (Hidaka et al., 1999). This suggests 
that formation of haemopoietic progenitors is very much microenvironment 
dependent, a hypothesis which is supported by in vivo observations which indicate a 
requirement for Flk-1 in the migration and expansion of the BL-CFC/haemangioblast 
rather than its formation (Schuh et al., 1999). Due to the inability of Flk-1-/- ES cells 
to form haemopoietic colonies in OP9 co-culture this system was used to investigate 
the requirement for Flk-1 in facilitating haemopoietic differentiation using Flk-1-Tet-
on ES cells. 
 
Flk-1-Tet-on ES cells were plated onto semi-confluent OP9 stromal cells to promote 
the formation of mesodermal plaques. After 2.5 days 1μg/ml doxycycline was added 
to induce Flk-1 expression in c15 and c33 Flk-1-Tet-on ES cells. It was expected that 
this would up-regulate Flk-1 expression by day 3, the point at which Flk-1 
expression in R1 wild type ES cells is first detected in OP9 co-culture (Paling, pers. 
comm). Day 5 colonies were examined for formation of mesodermal plaques. 
Representative colonies from R1 wild type ES cells (panels A and B) and c15 Flk-1-
Tet-on ES cells (panels C and D) are illustrated in Figure 5-14. It was difficult to 
positively classify the colonies formed as either mesodermal or undifferentiated 
possibly because the mesodermal plaques had not had long enough to develop. 
However, it was noted that R1 colonies were generally larger than colonies formed 
by any of the Flk-1 null ES cells and that doxycycline treatment (Figure 5-14A and 
C) did not appear to affect colony appearance in any of the ES cell lines used.  
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Figure 5-14. Representative plaques from R1 and clone 15 Flk-1-Tet-on ES cells 
differentiated for 5 days in OP9 co-culture in the presence or absence of doxycycline. 
R1, c29irtTA and Flk-1-Tet-on ES cells were plated onto semi-confluent OP9 stromal cells 
in a 6 well plate to promote the formation of mesodermal plaques. After 2.5 days 1μg/ml 
doxycycline was added to half the wells of each cell line.  On day 5 plates were examined for 
formation of mesodermal plaques. Representative colonies from; A and B. R1 wild type ES 
cells, C and D. clone 15 Flk-1-Tet-on ES cells cultured in the presence (A and C) and 
absence (B and D) of doxycycline. Scale bar 1cm = 250μm. E. All colonies (+ and – 
doxycycline treatment) for each cell line were counted. The number of colonies formed by 
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doxycycline treated ES cells is expressed as a percentage of those formed by untreated cells. 
Chart represents pooled data from 3 individual experiments.  
 
Figure 5-14E demonstrates that doxycycline treatment had no effect on the total 
number of colonies which formed in any of the ES cell lines investigated. 
Furthermore though total colony numbers for the cell lines used varied there were no 
observed differences between the cell lines used. 
 
As it was difficult to accurately distinguish between undifferentiated and 
mesodermal colonies at day 5 and the co-culture protocol called for dissociation and 
re-plating of colonies at day 5, total colonies were counted (for results see Figure 5-
14E above) and RNA was isolated for genetic characterisation (Figure 5-15).  
 
Cells harvested from day 5 colonies were re-plated onto fresh OP9 cells and cultured 
with fresh doxycycline for a further 5-7 days. RNA was again extracted from day 12 
colonies and semi-quantitative RT-PCR was used to investigate expression of 
mesodermal and haemopoietic markers in R1 wild type, c29rtTA, and Flk-1-tet-ON 
colonies cultured in the presence and absence of doxycycline. The panel of markers 
used to investigate haemopoietic differentiation were: 
 
Brachyury – an early mesodermal marker 
c-kit – a receptor tyrosine kinase required for haemopoietic differentiation 
Scl – a basic helix-loop-helix transcription factor required for primitive haemopoiesis 
β-H1-globin – embryonic haemoglobin characteristic of embryonic erythropoiesis. 
β-major-globin – adult haemoglobin characteristic of embryonic, fetal and adult 
erythropoiesis. 
 
These markers were all used by Hidaka et al., to characterise R1 and Flk-1-/- ES cell 
differentiation in the OP-9 haemopoietic plaque assay (Hidaka et al., 1999). More 
detail can be found in section 1.3.1. 
 
Figure 5-15 illustrates mesodermal and haemopoietic marker expression in R1 wild 
type, Flk-1-/- and Flk-1-Tet-on ES cells cultured on an OP9 stromal cell layer to 
promote multi-lineage haemopoietic differentiation. The primers for Flk-1 itself were 
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designed against a portion of the gene downstream of the β-galactosidase insert 
therefore transcript can still be seen in Flk-1-/- ES cells which makes the data difficult 
to interpret. Future use of Flk-1 primers spanning the β-galactosidase insert site  such 
as those designed by Shalaby et al., would give a clearer picture of doxycycline 
inducible Flk-1 expression (Shalaby et al., 1997). However, greater levels of 
transcript are seen on both days in Flk-1-Tet-on clones incubated in the presence of 
doxycycline suggesting that Flk-1 expression was up-regulated on both day 5 and 
day 12 of the assay. In addition, immunoblotting of lysates from day 12 clone 15 and 
c33 Flk-1-Tet-on clones encouragingly indicates some induction of Flk-1 by 
doxycycline (Figure 5-15B).  
 
Brachyury expression was decreased in Flk-1-/- cultures compared to wild-type on 
day 5 suggesting that there may be a lower proportion of cells of the mesodermal 
lineage. This result contrasts with that seen by Hidaka et al., who reported no 
decrease in Brachyury expression on day 5.  However, by day 12 Brachyury 
expression in Flk-1 null cells had increased indicating that the colonies are more 
immature than those formed from wild type R1 ES cells in which Brachyury 
expression was down-regulated.  
 
Expression of the haemopoietic markers however, did follow the pattern previously 
reported. Flk-1-/- ES cells differentiated in OP9 co-culture expressed little or no Scl, 
β-H1-globin and β-major-globin. Expression of β-H1-globin appeared slightly higher 
in doxycycline treated c15 and c33 Flk-1-Tet-on cells which may indicate 
upregulation of haemopoiesis by induction of Flk-1 expression. However, the 
observed increase is very slight and would have to be further characterised before 
conclusions could be drawn.  
 
There was no clear pattern in expression of c-kit which was expressed at days 5 and 
10 in all ES cell lines and did not appear to be further induced by doxycycline 
treatment. In addition to definitive haemopoiesis, c-kit is required for commitment of 
ES cells to differentiate (Bashamboo et al., 2006). Therefore c-kit expression in Flk-1 
null ES cell colonies at days 5 and 10 in the haemopoietic plaque assay does not 
necessarily indicate differentiation of the haemopoietic lineage.  
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Figure 5-15 Expression of mesodermal and haemopoietic markers by wild type, Flk-1-/-, 
c29rtTA and Flk-1-Tet-on ES cells differentiated on an OP9 stromal cell layer. ES cells 
were differentiated on an OP9 stromal cell layer for 5 days to form mesodermal plaques. Day 
5 colonies were disaggregated and plated onto fresh OP9s to promote differentiation of 
haemopoietic colonies. Doxycycline, when added, was added at day 2.5 and re-added at day 
5 when cells were re-plated. A) RNA was extracted from ES-derived colonies at day 5 and 
day 12 and from over-confluent OP9 cells to control for the presence of contaminating OP9 
RNA. RNA was reverse transcribed to produce cDNA from which mesodermal and 
haemopoietic gene products were amplified using specific primers (see Table 2-9) to amplify 
mesodermal and haemopoietic gene products to determine cell fate. The expression of β-
actin was used as a control as its expression remains unchanged regardless of treatment. 
Right and left hand panels from day 5 mesodermal plaques were run on the same gels as 
right and left hand panels showing marker expression in day 12 colonies. B) Differentiated 
Flk-1-Tet-on ES cells cultured in the presence and absence of doxycycline were lysed at day 
12. Whole cell lysates were immunoblotted with an anti-Flk-1 antibody. Blots were stripped 
and re-probed with an anti-SHP-2 antibody to check for equal loading. 
 
 
 
 
 
 
 
 
 
 
 15       33 
-   +    -   +
 Flk-1 
 SHP-2  α-SHP-2 
 α-Flk-1 
 Antibody  Dox (1µg/ml) 
 Flk-1-tet-ON clone no. 
B 
Chapter 5 –  Results 
 206
5.5 Discussion 
Molecular cloning was used to produce ES cell lines which inducibly expressed the 
Flk-1 receptor. These cell lines were characterised and used to begin to investigate 
the importance and timing of Flk-1 signalling in cardiac and haemopoietic 
differentiation.  Results are summarised below: 
5.5.1 Summary 
• A Baf/3 cell line constitutively expressing Flk-1 under the control of the 
CMV promoter was generated. 
 
• Flk-1-Tet-on ES cell lines in which Flk-1 is expressed only in the presence of 
doxycycline were generated by stably transfecting Flk-1-/- ES cells with both 
the reverse tetracycline-transactivator and the Flk-1 gene under the control of 
the tetracycline response element. Flk-1 expression exhibited doxycycline 
dose-dependence and was maintained for at least 4 days following induction 
in ES cells. VEGF stimulation of doxycycline treated Flk-1-Tet-on ES cells 
elicited auto-phosphorylation of tyrosine 951 over a time period identical to 
that seen in Flk-1 expressing embryoid-body derived cells. 
 
• Flk-1 surface expression in differentiating Flk-1-Tet-on ES clones cultured in 
the presence of doxycycline was less robust and declined sharply between 
days 2 and 3 of differentiation.  
 
• Flk-1-/- ES cells stably transfected with the reverse tet-transactivator (clone 
29) exhibited a marked inhibition in differentiation to form beating 
cardiomyocytes when incubated in the presence of doxycycline. 
 
• Addition of doxycycline to Flk-1-Tet-on ES cells at day 2.5 of OP-9 co-
culture failed to rescue the defect in haemopoietic development exhibited by 
Flk-1-/- ES cells in this assay. 
 
Chapter 5 –  Results 
 207
5.5.2 Inducible Flk-1 expression in Flk-1-tet-ON ES clones 
undergoing differentiation. 
Flk-1 surface expression in Flk-1tet-ON ES cells was not maintained beyond 2 days 
in differentiating ES cells. Several differentiation assays were used to investigate 
duration of expression; embryoid bodies differentiated in either semi-solid or liquid 
medium and ES cells differentiated in monolayer by LIF removal. Flk-1 expression 
on day 3 was higher in both clones differentiated in monolayer by LIF removal but 
was still lower than on day 2 and was absent at day 4. Preliminary experiments in 
suspension embryoid bodies indicated that addition of dox at day 2 was unable to 
promote or maintain Flk-1 expression to day 4. Immunoblotting revealed that despite 
a lack of Flk-1 surface expression in day 4 embryoid bodies Flk-1 protein was still 
expressed. The decline in Flk-1 expression could be occurring for a number of 
reasons:  
 
• Degradation of doxycycline causing the doxycycline concentration 
available to fall below that required for maximal Flk-1 induction. 
The half-life of doxycycline is 24 hours. In the differentiation assays it was added at 
1µg/ml. Maximal inducible Flk-1 expression was attained with between 0.1 and 
0.5µg/ml doxycycline in Flk-1-tet-ON ES cells therefore doxycycline levels could 
fall below those needed to maintain expression by day 2. However, initial application 
of doxycycline in Flk-1-Tet-on ES cells maintained in a self-renewing state in the 
presence of LIF is sufficient to maintain expression for at least 4 days and 
preliminary experiments in which fresh dox was added after 2 days did not alleviate 
the decrease in expression suggesting that the degradation of dox in the system 
cannot fully explain the decline in Flk-1 surface expression after 2 days of 
differentiation. 
 
• Inability of doxycycline to penetrate embryoid bodies.  
As embryoid bodies increase in size it is possible that doxycycline is unable to 
penetrate to reach cells within the embryoid bodies. This may explain the difference 
between inducible Flk-1 expression in cells differentiated in monolayer cultures in 
the absence of LIF versus those differentiated in embryoid bodies. However, 
previous experience of the tet-system suggests that this is unlikely to pose a problem 
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as early as day 3 or 4 of embryoid body development. In previous work in which the 
Tet-off system was used to inducibly express SHP-1 no SHP-1 expression was seen 
in embryoid bodies as late as day 6 suggesting that tet was still able to reach cells 
within the embryoid bodies to repress SHP-1 expression (Paling and Welham, 2005). 
More over, inducible Flk-1 expression also declines in Flk-1-Tet-on ES cells 
differentiated by the removal of LIF, a system in which access of doxycyline to 
differentiating cells is unimpeded 
 
• Internalisation of Flk-1 
It is possible that overall cellular levels of Flk-1 protein do not decline but that 
instead Flk-1 is either internalised or fails to reach the cell membrane. 
Immunoblotting could be used to further investigate relative Flk-1 protein levels 
during differentiation to clarify whether there is a genuine decrease in total Flk-1 
protein levels. Gampel et al., in work performed using adult human endothelial cells, 
found that stimulation of cells with VEGF increased receptor cycling and thus 
increased Flk-1 expression at the surface (Gampel et al., 2006). Culture of embryoid 
bodies in the presence of both doxycycline and exogenous VEGF however, failed to 
increase Flk-1 surface expression in day 2 and day 3 suspension embryoid bodies 
over levels seen in EBs cultured in the presence of doxycycline alone. 
 
• Down-regulation of reverse-tet-transactivator expression upon 
differentiation. 
If the decrease in Flk-1 protein levels during differentiation is genuine it is likely due 
to the position of integration of either the reverse-tet-transactivator or the tet-
response element within the genome. The decrease in Flk-1 expression upon 
differentiation is seen in two independent clones in which the response plasmid 
underwent two separate recombination events. Additionally, the tet-response plasmid 
is insulated with chicken β-globin chromatin insulators thus it is more likely be due 
to the site of integration of the regulator plasmid that drives expression of irtTA, 
which is the same in both clones. It is possible that the chromosomal integration site 
of the reverse-tet-transactivator in c29rtTA occurred in close proximity to genes or 
cis-acting elements that are down-regulated or repressed during differentiation, 
causing a decrease in expression of the reverse-transactivator itself. This could be 
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investigated using semi-quantitative RT-PCR or qPCR to monitor expression of the 
rtTA transcript during differentiation.  
 
Further work is required to fully characterise the ability of Flk-1-Tet-on ES cells to 
maintain inducible Flk-1 expression during differentiation in a variety of systems. To 
confirm whether Flk-1 protein levels themselves decline during differentiation a 
time-course of Flk-1 protein expression in doxycycline induced Flk-1-Tet-on ES 
cells undergoing differentiation in both embryoid bodies and ES cells cultured in the 
absence of LIF would need to be performed. If, as seems likely, the decrease in Flk-1 
surface expression correlates with a decrease in Flk-1 protein expression, which 
cannot be rescued by further addition of dox the cause of this down-regulation would 
need to be further investigated. It is possible that stable transfection of tettk-Flk-1-pA 
into a different rtTA Flk-1-/- clone could create an inducible cell line which is able to 
maintain Flk-1 expression in both self-renewing and differentiating states. An 
alternative approach would be to use homologous recombination to integrate the 
regulator construct into the ROSA26 locus to enable maintenance of expression 
during differentiation (Masui et al., 2005; Zambrowicz et al., 1997).  
 
5.5.3 Inability of c29rtTA to differentiate to the 
cardiomyocyte lineage in the presence of doxycycline 
C29irtTA is a Flk-1-/- ES cell line stably transfected with the reverse-tet-
transactivator. It was used as the parental cell line from which the Flk-1-Tet-on ES 
cell lines expressing Flk-1 under control of the tet-response element were derived. 
During experiments characterising the ability of doxycycline-induced Flk-1 
expression in Flk-1-Tet-on ES clones to rescue the delay in cardiomyocyte 
differentiation seen in Flk-1-/- ES cells it was noted that addition of doxycycline 
caused a marked inhibition in the ability of the cells to form any beating 
cardiomyocytes. Further investigation revealed that doxycycline also inhibited 
cardiomyocyte formation in c29irtTA ES cells ruling out Flk-1 up-regulation as a 
cause of the phenotype. Previous studies in the lab have indicated that tetracycline 
itself can effect the expression of some genes involved in cardiac differentiation 
including Epb4.1 (Belinda Bateman, pers. comm.). However, addition of doxycycline 
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to R1 wild type ES cells or Flk-1-/- ES cells caused no inhibition in cardiomyocyte 
formation and the addition of doxycycline to c29irtTA self-renewing ES cells did not 
appear to decrease proliferation or induce apoptosis. This suggests that the 
doxycycline-induced inhibition of cardiomyocyte differentiation is mediated by 
binding of doxycycline to the reverse-tet-transactivator and not the presence of dox 
itself. There is no tetracycline response element in this cell line therefore any effects 
mediated by the reverse-tet-transactivator would be off-target. irtTA is a fusion 
between the bacterial TetR and the viral VP16 transactivation domain. ES cells are 
very sensitive to toxicity of proteins with strong activation domains such as VP16 
(Masui et al., 2005). VP16 could have affected cardiomyocyte differentiation by one 
of two mechanisms; transcriptional ‘squelching’ by the VP16 transactivation domain 
which occurs as a result of titration of components of the transcriptional machinery 
away from their respective intracellular pools interfering with transcription of non-
target genes (Gilbert et al., 1993; Gill and Ptashne, 1988) or interaction of 
doxycycline-bound irtTA with non-target sequences allowing the transactivational 
domain of VP16 to repress or activate selective genes and abolishing the ability of 
c29irtTA ES cells to differentiate towards the cardiomyocyte lineage. 
 
To further investigate this phenomenon the effect of doxycycline on the ability of 
other rtTA clones to differentiate to form cardiomyocytes could be investigated. This 
would help to elucidate whether the effect is mediated by the reverse-transactivator 
rather than doxycycline itself and clarify whether it is caused by the integration site 
of the reverse-tet-transactivator and is therefore unique to this clone. Whatever the 
mechanism of doxycycline-induced blockage of cardiomyocyte differentiation in 
c29irtTA ES cells the phenotype could enable study of genes important for 
cardiomyocyte differentiation. Initial characterisation of the point at which 
differentiation ceases could be carried out using semi-quantitative RT-PCR or q-PCR 
to investigate expression of markers of self-renewal (including Oct-4 and Nanog), 
mesodermal differentiation (Brachyury) and cardiomyocyte differentiation (Nkx2.5, 
Gata4, bFGF, cardiac troponin I and, Myhc (myosin heavy chain)). This could 
potentially be followed by chromatin-immunoprecipitation (ChIP) of genes bound to 
irtTA in cardiomyocyte cultures of c29irtTA ES cells cultured in the presence and 
absence of doxycycline using a polyclonal antibody which recognises the 
transactivation domain of VP16. 
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5.5.4 Ability of Flk-1-Tet-on ES cells to rescue the defect in 
haemopoietic differentiation of Flk-1-/- ES cells in the 
haemopoietic plaque assay  
Flk-1-/- ES cells are unable to differentiate to form haemopoietic plaques in OP9 co-
culture (Hidaka et al., 1999). The Flk-1-Tet-on ES cell lines were created to 
investigate the importance and timing of Flk-1 expression in systems such as this. 
Initially, 1µg/ml doxycycline was used to induce Flk-1 expression at day 3 of the 
assay to attempt rescue of haemopoietic differentiation. Analysis of expression of the 
haemopoietic markers Scl, β-H1-globin and β-major indicated that the rescue had 
been unsuccessful. Further investigation of Flk-1 protein expression in day 12 Flk-1-
Tet-on/OP9 co-cultures indicated some expression of Flk-1 at this time point in the 
dox-treated samples, though it is possible that the levels of induced Flk-1 expression 
may not have been high enough to rescue haemopoietic differentiation. A 
comparison of dox-induced Flk-1 protein levels with Flk-1 protein levels in wild type 
R1 cultures on day 5 and 12 could help give a more accurate picture of the levels of 
dox-induced Flk-1 expression. 
 
Another method of investigating the temporal requirement for Flk-1 signalling in 
haemopoietic differentiation in the haemopoietic plaque assay could be the use of 
small molecule Flk-1 inhibitors added at different time points. This approach is less 
flexible as it allows only for the inhibition of Flk-1 signalling and could not be used 
to investigate the effect of maintenance of signalling or early induction of signalling. 
This approach may be appropriate in investigating the temporal requirement of Flk-1 
in haemopoietic differentiation as Flk-1 signalling is generally accepted to act early 
in the migration and expansion of haemopoietic progenitors (Schuh et al., 1999). 
However, it would not be as useful in investigation of the temporal requirement of 
Flk-1 expression in the differentiation of endothelial progenitors in which expression 
is maintained and is important for endothelial function (Zachary, 2001). 
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5.5.5 Conclusions 
ES cell clones which upon addition of doxycycline inducibly express Flk-1 have 
been successfully created. Though initial characterisation of these lines was 
promising, surprisingly, their performance in differentiation assays was less so. This 
study has illustrated the importance of both robust characterisation of transfected cell 
lines and the inclusion of appropriate controls in such experiments. The main issues 
encountered in the use of the Flk-1-Tet-on ES cell lines created appear to relate to the 
integration of the reverse-tet-transactivator. Characterisation of cell lines expressing 
the (reverse)-tet-transactivator without a tet-response plasmid is difficult as no 
functional read out of tet-transactivator activity is available. A more straightforward 
way to circumvent potential issues with the site of integration of the (reverse)-tet-
transactivator may be to transfect the tet-response plasmid onto more than one clone 
containing the transactivator to minimise the likelihood of positional effects or to 
generate an ES cell line in which rtTA expression is targeted to the ROSA26 locus, 
which is known to be expressed in a stable manner in most mouse tissues. 
 
Though the issues encountered in the behaviour of the tet-system could not have 
been predicted at the outset of these studies,the cell lines created could still be used 
for short-term expression of Flk-1, for study of Flk-1 signalling at different stages of 
development and in the investigation of the effect of upregulating Flk-1 expression in 
self-renewing ES cells.  
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6.1  The role of Flk-1 signalling in an embryoid-
body model of development 
Signalling mediated by the receptor tyrosine kinase KDR (human Flk-1) in adult 
somatic cells has garnered much research as KDR mediates VEGF-induced 
angiogenesis, important in a number of pathological conditions. These include 
cancer, in which the angiogenic contribution of KDR signalling to the growth of 
solid tumours is a major target in cancer therapy (Tonini et al., 2003), diabetic 
retinopathy, a complication of type I and type II diabetes and the underlying cause of 
which is deregulated angiogenesis (Frank, 2004). Genetic knockout of Flk-1 in mice 
results in embryonic lethality by day E9.5 due to a lack of formation of the 
vasculature and blood (Shalaby et al., 1995; Shalaby et al., 1997) demonstrating that 
Flk-1 signalling also plays a key role in embryonic development. However, despite 
extensive knowledge of signalling via KDR in adult somatic cells (Zachary, 2001), 
little is known about the signalling pathways activated by Flk-1 during development 
and the importance of these signalling pathways during embryogenesis. In this study 
signalling mediated downstream of Flk-1 in an embryoid body model of 
development was characterised and the functional importance of these signals in the 
differentiation of haemopoietic, endothelial and cardiomyocyte lineages was 
investigated. A summary of the findings is provided in Figure 6-1.  
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Figure 6-1 Model of Flk-1 signalling and its functional involvement in embryonic stem 
cell differentiation towards committed cells of the mesodermal lineage. Stimulation of 
murine Flk-1 in embryoid body derived-cells potentiates activation of PKC and MAPK 
signalling but does not appear to activate PI3K signalling. Flk-1 signalling is required for 
differentiation of the endothelial lineage but this requirement is not mediated through 
activation of the MAPK pathway or PI3K pathways. Flk-1 null ES cells exhibit delayed 
differentiation towards the cardiomyocyte lineage implying Flk-1 involvement in its 
differentiation.   
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Functional characterisation of Flk-1 in in vitro models of endothelial and 
cardiomyocyte differentiation was performed using Flk-1 null ES cells and the Flk-1 
inhibitors, VEGFR2 kinase inhibitor-1 and VEGFR2 kinase inhibitor-2. An essential 
role for Flk-1 in vessel formation both in the adult (Shibuya and Claesson-Welsh, 
2006) and the embryo (Shalaby et al., 1995) have been previously demonstrated. 
Results from the sprouting embryoid body assay also demonstrate involvement of 
Flk-1 in endothelial differentiation indicating that this assay provides a good model 
system in which to investigate the role of signalling downstream of Flk-1 during 
endothelial differentiation. Further dissection of the sprouting embryoid body assay 
utilising inhibition of Flk-1 with VEGFR2 kinase inhibitor -1 and VEGFR2 kinase 
inhibitor-2 during either the endothelial specification phase or the angiogenic 
expansion phase demonstrated individual requirements for Flk-1 in both endothelial 
specification and angiogenic expansion.  
 
To investigate the signalling pathways activated downstream of Flk-1 populations of 
dissociated day 5 embryoid bodies, containing approximately 50% Flk-1-expressing 
cells, were stimulated with VEGF. Downstream signalling was characterised by 
immunoblotting of whole cell lysates. Transient activation of the MAPK and PLCγ 
signalling pathways was observed with phosphorylation levels of both PKC 
(classical and novel isoforms) and ERK1/2 peaking at 2 minutes VEGF stimulation 
and declining to basal levels by 10 minutes. This closely follows the pattern of 
VEGF-induced signalling seen in adult endothelial cells (Doanes et al., 1999; 
Takahashi and Shibuya, 1997; Yashima et al., 2001). In some adult endothelial cells 
activation of the MAPK pathway upon VEGF stimulation is thought to be mediated 
by PLCγ (Yashima et al., 2001). Inhibition of PKC with Calphostin C provoked no 
decrease in phosphorylation of ERK1/2, a downstream effector of MAPK signalling, 
suggesting that this is not the case in embryoid body-derived cells.  
 
Further characterisation of MAPK signalling during differentiation was carried out 
using the MEK inhibitors PD98059 and U0126 in embryoid body-based assays. 
Complete inhibition of MEK-1 and 2 with 10μM U0126 abolished the ability of ES 
cells to differentiate to form embryoid bodies. Incubation of cells with 5μM U0126 
or 50μM PD98059 led to decreased efficiency of embryoid body formation and a 
decrease in embryoid body size, suggesting a concentration dependent requirement 
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for MAPK signalling in commitment of ES cells to differentiation and in their 
subsequent proliferation. This data correlates well with experiments performed by 
Burdon et al., which demonstrated increased ES cell renewal upon inhibition of the 
MAPK pathway with PD98059 (Burdon et al., 1999). Though MAPK signalling is 
demonstrably important for differentiation it unlikely that activation of the pathway 
early in embryoid body formation is mediated by Flk-1 as Flk-1 expression is not 
detected until day 3 of differentiation.  
 
Partial inhibition of MAPK signalling using 5μM U0126 or 50μM PD98059 had no 
effect on endothelial sprouting from day 10 embryoid bodies suggesting that there is 
no requirement for MAPK signalling in the specification of endothelial cells or in 
their expansion. In genetic studies, MEK-2 knockout mice were viable (Belanger et 
al., 2003) and although MEK-1 knockout mice were embryonic lethal at day 10.5 
this was due to defective vascularisation in the labyrinth region of the placenta and 
no effect on embryonic vascularisation was noted (Giroux et al., 1999). The lack of 
effect on embryonic vascularisation in both MEK-1 and MEK-2 knockout mice 
supports the findings from the sprouting embryoid body assay. However, as no 
studies have been performed using MEK-1/MEK-2 double knockout mice the 
possibility of functional redundancy cannot be ruled out. Flk-1Y1173F/Y1173F embryos, 
which recapitulate the Flk-1-/- phenotype demonstrate little or no reduction in 
ERK1/2 phosphorylation at E8.5 detected by immunocytochemistry when compared 
to wild type or Flk-1+/- embryos (Sakurai et al., 2005). This suggests that MAPK 
activation at this embryonic stage (during which endothelial specification and 
vasculogenesis are occurring) is largely mediated through other receptors and 
provides further support for the results observed in the in vitro sprouting embryoid 
body assay.  
 
No evidence of activation of PI3K signalling upon VEGF  stimulation of embryoid 
body-derived cells was observed despite the importance of PI3K signalling 
downstream of Flk-1 in adult endothelial cells (Fujio and Walsh, 1999; Fulton et al., 
1999). Activation of PI3K was also investigated in VEGF-stimulated secondary blast 
cells and D4T embryoid body-derived endothelial cells but again no activation was 
detected. Since activation of the PI3K pathway downstream of Flk-1 in adult 
endothelial cells this pathway is very important for VEGF-induced angiogenesis 
Chapter 6 –  General discussion 
 218
(Shiojima and Walsh, 2002) the effect of inhibiting PI3K on endothelial sprouting 
was investigated. Inhibition of PI3K signalling with 5μM LY294002 had no effect on 
endothelial sprouting suggesting that PI3K is not required for vasculogenesis or 
angiogenesis in embryoid bodies. This supports the previous finding that PI3K 
signalling is not activated downstream of VEGF signalling in embryoid body-derived 
cells. Studies using knockout mice lacking both the p85α and β regulatory subunits 
(Brachmann et al., 2005) or either the p110β or p110δ catalytic subunits (Bi et al., 
2002; Clayton et al., 2002; Okkenhaug et al., 2002) displayed no defect in vessel 
formation, although knock-out of p110β was embryonic lethal before implantation 
masking any potential involvement in vasculogenesis.  However, embryonic lethality 
at day 10.5 in the p110α knockout mouse is caused by defects in vascularisation 
including “dilated vessels in the head, reduced branching morphogenesis in the 
endocardium, lack of hierarchical order of large and small branches in the yolk sac 
and impaired development of anterior cardinal veins” (Lelievre et al., 2005). These 
defects reportedly mimic several aspects of the Tie2-/- phenotype and deficiency in 
the p110α catalytic subunit also causes diminished Tie2 expression causing the 
authors to postulate that PI3K functions as an upstream regulator of Tie2 expression 
during mouse development (Lelievre et al., 2005). As the observed defects in 
vascularisation occur after the initiation of vasculogenesis this result supports my in 
vitro findings and points to a role for class IA PI3K in angiogenesis later in 
development which continues in the adult. The surprising finding that Flk-1 does not 
appear to activate PI3K signalling during early embryoid body development nor is 
PI3K involved in early endothelial differentiation and expansion suggests that Flk-1 
signalling in the adult and the embryo may not be as similar as is often assumed 
(Hong et al., 2006). 
 
Recent research has pointed to involvement of Flk-1 in cardiac differentiation 
(Boheler et al., 2002; Iida et al., 2005; Sachinidis et al., 2003b). Cardiogenic 
mesoderm is postulated to differentiate from a population within the embryoid body 
which lacks Flk-1 expression at day 3.25 but upregulates expression of Flk-1 by day 
4.25 (Kattman et al., 2006; Kouskoff et al., 2005). However, despite a strong 
association between Flk-1 expression and cardiac differentiation a functional 
requirement for Flk-1 in cardiogenesis had not been proven. A comparison of 
cardiomyocyte differentiation in R1 parental and Flk-1 null ES cells revealed a delay 
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in formation of beating cardiomyocyte foci in Flk-1 null ES cells when compared to 
R1 parental ES cells. This indicates that Flk-1 promotes, but is not required for, 
cardiomyocyte differentiation suggesting that any absolute requirement for Flk-1 
expression occurs at a different stage of cardiogenesis.  
 
In order to further investigate the role of Flk-1 in haemopoiesis, endothelial 
differentiation and cardiomyocyte differentiation an inducible Flk-1-Tet-on ES cell 
line was created on a Flk-1-/- parental background. This approach was designed to 
allow investigation of the temporal importance of Flk-1 signalling during 
differentiation. Additionally, mutations of tyrosines within the cytoplasmic tail of 
Flk-1 would have allowed characterisation of the phosphorylation sites required for 
activation of different signalling pathways and their importance during 
differentiation. However, a number of unexpected obstacles were encountered with 
this approach that could not have been predicted at the outset. First, surface 
expression of doxycycline-induced Flk-1 could not be sustained long-term upon 
induction of differentiation, significantly limiting the window during which analyses 
could be performed. Secondly, and very surprisingly, addition of doxycycline to Flk-
1-/- ES cells expressing TetR abolished cardiomyocyte differentiation. Addition of 
doxycycline had no effect on the ability of R1 wild type or Flk-1 null ES cells to 
form beating cardiomyocytes which implied that the dox-effect was mediated by 
rtTA. This made study of the temporal importance of Flk-1 during differentiation 
difficult but use of a similar approach could still yield valuable results (see section 
6.2.4 for further discussion). 
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6.2 Future directions 
 
During the course of this study several areas that warrent further research have 
arisen. These range from further characterisation of Flk-1 signalling in embryoid 
body-derived cells to new genetic approaches to study the temporal effects of Flk-1 
expression in models of early development.  
 
6.2.1 Flk-1-mediated signalling in in vitro models of 
development 
Investigation of Flk-1-mediated signalling in embryoid body-derived cells revealed 
activation of the MAPK and PLC signalling pathways upon VEGF stimulation and 
indicated that MAPK activation was not mediated through PKC. To confirm non-
involvement of PLCγ in VEGF-mediated MAPK activation further studies could be 
conducted using the PLC inhibitor U73122. Activation of Ras by VEGF could be 
investigated using Raf-1 pull-down followed by immunoblotting for Ras protein. 
siRNA or dominant negative Ras (Yamamoto et al., 1999) could then be used to 
investigate the Ras/Raf dependency of VEGF-induced MAPK signalling. Further 
characterisation of VEGF-stimulated signalling in embryoid body-derived cells, 
including characterisation of potential activation of p38 MAPK and the involvement 
of adapter proteins such as Shb (Holmqvist et al., 2004; Rolny et al., 2005) and 
VRAP (Wu et al., 2000b) in coupling Flk-1 to downstream signalling pathways, 
could be performed using  immunoprecipitation and siRNA-based approaches. 
Further genetic approaches for the study of Flk-1-mediated signalling are discussed 
in 6.2.4. 
 
6.2.2 Signalling pathways involved in Flk-1 mediated 
commitment and expansion of endothelial cells 
As neither PI3K nor MAPK signalling mediate the involvement of Flk-1 in 
endothelial differentiation the identity of the signalling pathway(s) involved is still of 
interest. Other downstream effectors of Flk-1 signalling in adult endothelial cells 
which may mediate endothelial differentiation and vasculogenesis include p38 
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MAPK (Lamalice et al., 2006; Yashima et al., 2001) and PLCγ1 (Takahashi et al., 
2001; Takahashi and Shibuya, 1997). The p38 MAPK pathway has been implicated 
in endothelial migration in adult angiogenesis (Yashima et al., 2001), but use of the 
pharmacological inhibitor of p38 MAPK, SB202190, enhanced neovascularisation in 
chick chorioallantoic membrane (Matsumoto et al., 2002). However, the PLCγ1 
knockout mouse is phenotypically similar to the Flk-1-/- mouse, dying at E10 (0.5-1 
day later than the Flk-1-/- mouse) due to vascular and erythroid defects (Liao et al., 
2001). This pathway therefore seems a good target for further investigation. Initial 
characterisation of PLCγ1 null ES cells (Shirane et al., 2001)in the embryoid body-
sprouting assay would validate involvement of PLCγ1 in endothelial differentiation 
and expansion. Inhibition of PLC with an inhibitor such as U73122 (Bleasedale et 
al., 1989) could then be used to provide further information concerning whether any 
PLC-mediated effect occurred during specification of endothelial cells or their 
expansion.  
 
6.2.3 Characterisation of the Flk-1-mediated delay in 
cardiomyocyte differentiation 
Flk-1 null ES cells are delayed in their ability to form beating foci of cardiomyocytes 
when compared with R1 wild type ES cells. Further characterisation of the role of 
Flk-1 in cardiomyocyte formation could initially involve use of Flk-1 inhibitors to 
validate the results gained from use of Flk-1 null ES cells and investigate when 
inhibition of Flk-1 is required to cause the delay in cardiomyocyte differentiation. 
The delay in initiation of beating in the Flk-1 null cardiomyocyte cultures may be 
caused by deficiency in activation of a signalling pathway(s) downstream of Flk-1, 
which can be overcome by upregulation of signalling through a related receptor, such 
as FGFR1 (Mima et al., 1995). Possible candidate signalling molecules which may 
be responsible for the delay in cardiomyocyte differentiation include; PLCγ1 
(Rottbauer et al., 2005), eNOS (Kanno et al., 2004) or p38 MAPK (Aouadi et al., 
2006). Use of inhibitors of these signalling pathways (for example with U73122, L-
NAME and PD169316 respectively) could enable validation of any involvement in 
the Flk-1 null phenotype. Further characterisation could involve including 
comparative analysis of expression of genes including Nkx2.5, Fgfr1, Gata4, bFGF, 
Chapter 6 –  General discussion 
 222
cardiac troponin I, Myhc (myosin heavy chain) and eNOS between Flk-1 null and R1 
ES cells during cardiomyocyte differentiation. This would allow investigation of any 
association between the delay in cardiomyocyte beating and a delay in upregulation 
of cardiomyocyte-related genes and would test whether the delay is in fact abrogated 
by increased bFGF or FGFR1 expression.    
 
6.2.4 Use of genetic approaches to study the roles of Flk-1 
signalling in haemopoietic, endothelial and 
cardiomyocyte differentiation 
A system in which Flk-1 expression could be regulated would allow more detailed 
investigation of the temporal requirements of Flk-1 in haemopoietic, endothelial and 
cardiomyocyte differentiation. In addition, site-directed mutagenesis of tyrosines 
within the cytoplasmic domain of the Flk-1 receptor could enable investigation of the 
signalling pathways activated by phosphorylation of specific tyrosine residues using 
VEGF stimulation of embryoid body-derived cells. Following characterisation of 
signalling, the relative importance of specific tyrosine residues, and the signalling 
pathways they activate, could be assessed in functional assays evaluating 
haemopoietic, endothelial and cardiomyocyte differentiation. Unusually for a 
receptor tyrosine kinase much of the role of Flk-1 appears to be mediated by tyrosine 
1173. The Flk-1Y1173F/Y1173F mouse exhibits an almost identical phenotype to the Flk-
1-/- mouse (Sakurai et al., 2005) and phosphorylation of the correspondsing tyrosine 
residue of KDR in adult endothelial cells has variously been reported to activate the 
PI3K pathway (Dayanir et al., 2001; Holmqvist et al., 2004) PLC signalling and 
MAPK signalling (Sakurai et al., 2005; Takahashi et al., 2001). During the course of 
this study I generated a Flk-1construct in which tyrosine 1175 was mutated to 
phenylalanine. This mutated Flk-1 could be expressed constitutively or in an 
optimised Tet-regulatable expression system in Flk-1 null ES cells to investigate 
whether VEGF is still able to activate previously characterised Flk-1-mediated 
signalling pathways, including MAPK and PLC signalling. Other tyrosine residues of 
interest include tyrosine 1212, reported to be required for MAPK and PLC signalling 
(in contrast to findings by Takahashi et al.,) (Meyer et al., 2002; Takahashi et al., 
2001) and tyrosine 951, which reportedly couples to the adaptor protein Shb which 
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mediates activation of PI3K and endothelial migration in adult endothelial cells 
(Holmqvist et al., 2004). 
 
Random integration of the reverse-tet-transactivator in the clone used for creation of 
the Flk-1 Tet-on ES cell line may have been responsible for the lack of sustained 
expression of doxycycline-induced Flk-1 upon differentiation. To prevent this, future 
studies could be conducted by targeting the tet-transactivator to the ROSA26 locus 
using homologous recombination (Masui et al., 2005; Zambrowicz et al., 1997). An 
alternative approach, utilising ES cells in which Flk-1 expression can be inducibly 
knocked down using an inducible shRNA system (Gupta et al., 2004; Hiraoka-Kanie 
et al., 2006) would allow investigation of the temporal importance of Flk-1 
expression but could not be used to investigate the signalling pathways activated 
through different tyrosine residues in the receptor. Use of a recently described dual 
knockdown-rescue approach (Ivanova et al., 2006) would allow rescue of Flk-1 
knockdown by Flk-1 with mutated tyrosine residues, thus facilitating investigation of 
the signalling mediated by, and functional importance of tyrosine residues within the 
cytoplasmic tail of Flk-1. 
 
These studies have provide new insight into how signalling mediated by Flk-1 is 
coupled to functional responses in models of embryonic development and raised 
further questions that could be addressed in future studies. 
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Descriptions of plasmids used in this study are given in Table 2-9 which is 
reproduced below. This Appendix contains additional plasmid information and 
plasmid maps 
 
Table 2-9 Plasmids used in this study 
Plasmid Derivation Use 
pcDNA3.1Zeo 
(Invitrogen) 
Mammalian expression 
plasmid containing the CMV 
early immediate promoter and 
Ampicillin and Zeocin 
resistance genes. 
Tractable vector used for 
initial cloning of Flk-1. 
pcDNA3.1Zeo-Ms 
Flk-1 
The Murine Flk-1 sequence 
ligated into pcDNA3.1zeo 
using the XbaI restriction site 
Used to check viability of 
cloned Flk-1 sequence in 
BaF/3 cell line and for 
sequencing. 
pCAGGS-irtTA-
VP16-IRES-puro 
(Anastassiadis et 
al., 2002) 
Reverse Tetracycline 
transactivator with puromycin 
resistance gene. 
Enables regulated expression 
by addition of doxycycline of 
genes expressed in the tet 
response plasmid. 
pKS-TetTK-pA 
(Anastassiadis et 
al., 2002) 
Bluescript vector modified to 
encode tet operators, a 
thymidine kinase (TK) 
promoter and polyA tail.  
Used for insertion of Flk-1 
sequence into TetTK-pA. 
pKS-TetTK-flk-1-
pA 
Flk-1ligated into pKS-TetTK-
pA using the SpeI restriction 
site 
Used to insert TetTK-Flk-1-pA 
sequence into Inshygro vector. 
pKS-Δp85-TetTK-
pA 
Myc tagged p85 subunit 
lacking the binding site for 
the catalytically active p110 
component of PI3K ligated 
into pKS-TetTK-pA. 
To determine the presence of 
functional tetracycline 
transactivator in stably 
transfected R1 ES cells using 
transient tranfection.  
pAcΔPHAkt-GFP-
N1 
pACGFP-N1 vector 
(Clontech) expressing GFP 
tagged Akt PH domain non-
lipid binding mutant 
Optimising transient 
transfection of  R1 ES cells 
using flow cytometry to detect 
GFP expression 
pInshygro 
(Anastassiadis et 
al., 2002) 
Expression vector containing 
4 chicken β-globin chromatin 
insulators flanking the 
multiple cloning site and a 
hygromycin resistance gene. 
Insulators thought to block 
inappropriate action of 
regulatory elements reducing 
likelihood of mosaic 
expression. Hygromycin 
resistance enables selection. 
pInshygro-TetTK- 
Flk-1-pA 
TetTKFlk-1-pA blunt end 
ligated into the multiple 
cloning site of the SnaB1 
digested Inshygro plasmid 
Construct linearised and 
transfected into Flk-1-/- R1 ES 
cells stably expressing 
CAGGS-irtTA-VP16-IRES-
puro 
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8.1  pcDNA3.1Zeo 
Plasmid obtained from Invitrogen.  
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8.1.1 pcDNA3.1Zeo-Flk-1 
 
The pcDNA3.1Zeo plasmid was linearised with XbaI a non-cutter in the Flk-1 
sequence. Flk-1 cDNA was amplified with primers designed to introduce 5’ and 3’ 
Xba1 restriction sites. Following Xba1 digestion the Flk-1 sequence was ligated into 
pcDNA3.1Zeo creating the plasmid illustrated below. 
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8.2 CAGGs-irtTA-VP16-IRES-puro 
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8.3 pKS-tettk-pA 
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8.3.1 pKS-tettk-Flk-1-pA 
 
Flk-1 was digested out of the pcDNA3.1Zeo-Flk-1 plasmid using Xba1.The pKS-
tettk-pA plasmid was linearised using Spe1 creating compatible ‘sticky ends’ for 
ligation of Xba1 digested Flk-1 to create the following plasmid. 
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8.3.2 pKS-tettk-myc-deltap85-pA 
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8.4 pAcΔPHAkt-GFP-N1 
 
In this study GFP expression by this plasmid was exploited to allow for efficient 
screening of transiently tranfected cells using flow cytometry in order to optimise 
transient transfection conditions in R1 ES cells.  
 
The plasmid does however also contain the PH domain of Akt mutated to prevent 
lipid binding. This construct was flanked with BamH1 sites and ligated into the 
pEGFP-C1 plasmid following digestion with BamH1 which cuts in the multiple 
cloning site (MCS) 
 
 
 
deltaPH Akt BamH1 BamH1 
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8.5 pInshygro 
 
The 1.2kb elements are chicken β-globin chromatin insulators. 
 
 
 
 
 
 
 
 
 
 
 
 
BamH1, Sal1, Pac1, SnaB1, Asc!, Swa1, Xho1, BamH1/BglII 
MCS 
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8.5.1 pInshygro-tettk-Flk-1-pA 
 
To create the pInshygro-tettk-Flk-1-pA plasmid tettk-Flk-1-pA was digested out of 
the pKS-tettk-Flk-1-pA plasmid using PvuII.  The tettk-Flk-1-pA was blunt end 
ligated into SnaB1 linearised pInshygro between the flanking insulators creating the 
plasmid illustrated below. 
 
 
 
  
 
pInshygro-tettk-Flk-1-pA 
